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Abstract 
Tumour stem cells (TSCs) are hypothesised to be a rare population of tumour 
cells which possess stem cell-like properties and are resistant to conventional 
therapy. Although cell surface markers have been widely used to characterise TSCs, 
previous literature suggests that no specific marker has been found for ovarian 
TSCs. We aimed to identify and characterise novel antibodies specific to ovarian 
epithelial TSCs, particularly towards populations with Hoechst efflux (Side 
Population, SP) and aldehyde dehydrogenase activity which are associated with a 
stem cell phenotype and drug resistance.  
Putative TSC subpopulations from ovarian tumour cell lines isolated by 
fluorescence activated cell sorting (FACS) using differential Hoechst dye uptake and 
Aldefluor activity assays displayed stem cell-like characteristics, including the 
upregulation of stem cell markers, increased anchorage-independent growth and 
increased invasive properties. A panel of monoclonal antibodies (mAbs) was then 
generated by injecting Aldefluor-positive ovarian tumour IGROV1 cells into female 
BALB/c mice. 34 antibodies were found to be specific to Aldefluor-positive cells and 2 
of these enriched for SP cells. The 2 mAbs demonstrated cross-reactivity on human 
embryonic stem cells but no cross-reactivity to normal ovarian cell lines. 
Subpopulations of ovarian cell lines positive for the mAbs displayed stem cell-like 
characteristics, including upregulation of stem cell markers - CD133, ABCB1 and 
ALDH1A1. Sorted mAb populations were injected into non-obese diabetic/severe 
combined (NOD/SCID) mice and differential in vivo tumour formation was observed. 
Finally, the target antigen which both mAbs recognised was identified by mass 
spectrometry to be clathrin heavy chain (CHC1).  
We conclude that rare subpopulations with tumour-sustaining capability and 
stem cell-like characteristics can be identified in ovarian cancer using the 2 novel 
antibodies generated. Both mAbs target CHC1 on tumour-sustaining populations 
which are enriched for multiple stem cell markers and are therefore potential novel 
diagnostic markers and/or therapeutic agents. 
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1.1. Overview 
Although patient prognosis has improved considerably for many solid 
cancer types such as breast cancer, the survival rate of women with ovarian 
cancer has remained poor since the introduction of platinum-based treatment 
over 30 years ago (1, 2). This high mortality rate is due primarily to the 
development of acquired drug resistance in tumours which were initially 
chemosensitive and to a lack of markers available for diagnosing early stage 
disease (3).  
Notably, in the past 10 years, drug resistance has been attributed to 
the presence of tumour stem cells (TSCs) in numerous tumours, including 
ovarian cancer (4, 5). This controversial TSC hypothesis emphasizes the 
heterogeneity in cancers and the need to specifically target TSCs which are 
highly resistant to conventional chemotherapeutics.  
Specific stem cell markers have since been identified and 
characterised, particularly in studies involving the haematopoietic system (6, 
7). However, previous literature suggests that no specific marker has been 
found for ovarian TSCs, although during the course of these studies, markers 
of TSCs derived from other tissues have been evaluated in ovarian cancer (8-
10).   
The present study aimed to discover novel markers by identifying and 
characterizing antibodies which specifically recognise ovarian TSCs. The 
discovery of novel markers specific for ovarian TSCs may also lead to early 
diagnosis of the disease where effective screening methods are not available 
and continue to be elusive, as well as novel treatment strategies. The 
treatment of ovarian cancer as a stem cell disease could potentially improve 
treatment approaches and may be essential if more durable responses to 
therapy are to be achieved. This would in turn result in a reduction in mortality 
from ovarian cancer. 
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1.2. Epithelial ovarian cancer (EOC) 
1.2.1. Clinical presentation 
In the past, ovarian cancer was generally accepted as a “silent killer” 
as patients were thought to be asymptomatic until the disease had progressed 
to an advanced stage. However, recent data have reproducibly demonstrated 
that the vast majority of patients with ovarian cancer have symptoms for at 
least several months before their diagnosis (11-13). In early stage disease, 
patients may experience increased urinary frequency or constipation due to 
tumour growth. There may also be occasional lower abdominal distension, 
pressure and pain. In advanced disease, symptoms include abdominal 
distension, bloating, constipation, nausea, anorexia or early satiety. Upon 
physical examination, a pelvic mass can often be palpated. Abdominal 
distention and pleural effusions due to the presence of ascites is another 
common finding. Furthermore, enlarged lymph nodes, emaciation, leg edema 
and skin metastases are often observed (14, 15). 
1.2.2. Epidemiology  
Ovarian cancer is the sixth most commonly diagnosed cancer among 
women in the world, accounting for nearly 4% of all female cancers. On a 
worldwide basis, an estimated 204,000 new cases are diagnosed and 
125,000 women die of ovarian cancer annually. Ovarian cancer also 
represents the second leading gynaecologic cancer, following cancer of the 
uterine corpus (16). The lifetime risk of ovarian cancer is estimated at 1 in 70 
and the lifetime risk of dying from ovarian cancer at 1 in 95 (17, 18).  
It has also been reported that the incidence of ovarian cancer is 
highest in Europe and Northern America and lowest in Asia and Africa (17, 
18). Moreover, the incidence of ovarian cancer is age-related and is generally 
a disease of postmenopausal women. The median age of diagnosis is 63 
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years and the incidence begins to increase after age 40, reaching a peak 
between 80 and 84 years of age (19). Mortality is high because women 
typically present with late-stage disease (75-80%) when the overall 5-year 
relative survival rate is 45% (20). Although 5-year survival rates have 
improved moderately over the last two decades, there has been no 
corresponding improvement in the cure rates (21, 22). 5-year survival is also 
markedly decreased in patients older than 75 years as compared to the 
youngest patients below 45 years. Furthermore, the relapse rate following 
treatment of early stage ovarian cancer ranges between 10-40% while more 
than 60% of patients with advanced disease will eventually progress. Out of 
these patients, only 10-30% attain long-term survival, with a median 
progression-free survival (PFS) of 18 months.  
1.2.3. Risk factors 
Several risk factors have been correlated with ovarian cancer, including 
dietary factors (23, 24), obesity (25, 26), talcum powder use (27, 28) and 
certain fertility drugs (29, 30).  Furthermore, a poor reproductive history and 
duration of reproductive capacity has also been strongly correlated to the risk 
of ovarian cancer (31, 32). Factors associated with a decreased risk of 
ovarian cancer include the use of oral contraceptives, breastfeeding, bilateral 
tubal ligation or hysterectomy and prophylactic oophorectomy (33, 34).  
1.2.4. Types of ovarian cancer 
Epithelial ovarian cancer (EOC) accounts for 90-95% of ovarian 
malignancies. The most common histologic subtype is serous ovarian 
carcinoma (35), and most of these (>50%) are classified as high-grade serous 
ovarian carcinoma (HGSOC) based on a common molecular p53 signature 
and high mitotic index (36). These highly aggressive HGSOCs (Type II 
tumours) are also characterised by mutations in the DNA-damage repair 
genes BRCA1 and BRCA2.  Type I tumours such as clear cell, endometrioid, 
31 
 
 
low-grade serous, and mucinous ovarian carcinomas, however, typically 
present as indolent low-grade neoplasms with somatic mutations in genes 
such as KRAS, BRAF, ERBB2, PTEN, CTNNB1, and PIK3CA (37).  
Non-epithelial malignancies such as sex cord stromal tumours, germ 
cell tumours, sarcomas and lymphomas account for the rest of all ovarian 
cancers (17, 38). Sex cord stromal tumours are rare neoplasms, develop from 
stromal cells or the connective tissue within the ovaries that generate 
reproductive hormones, which account for approximately 3-5% of ovarian 
malignancies. This type of tumour is more commonly diagnosed in adult 
women. Germ cell tumours represent 5% of all ovarian neoplasms and 80% of 
preadolescent malignant ovarian tumours.  
1.2.5. Aetiology 
EOC has generally been thought to arise from ovarian surface 
epithelium (OSE), the modified pelvic mesothelium which covers the ovary. 
This single layer of flat-to-cuboidal epithelial cells possesses few 
distinguishing features (39) and two theories were proposed early on in the 
1970s to explain the role of OSE in EOC development.  
The first was the ‘incessant ovulation’ theory by Fathalla and 
colleagues where a possible link between chronic ovulation and the 
production of malignant neoplasms on the ovarian surface was suggested 
(40). This hypothesis proposed that ovulation traumatizes the ovarian surface 
as rupturing of the ovulating follicle damages the OSE, and immediate repair 
is required. This process of continuous damage and OSE proliferation to 
repair the wound therefore increases the chance of errors occurring during 
replication.  
Subsequently, several publications included data which supported this 
hypothesis. For example, rapid cell division in the ovarian lining during the 24 
hr proceeding ovulation was found to increase chromosomal aberrations (41). 
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Another report involved the neoplastic transformation of rat ovarian epithelial 
cells grown in cell culture which resulted in a loss of contact inhibition. After 
transplanting late passage cells into mice, tumours and chromosomal 
deformities were observed (42). Moreover, as mentioned earlier, the use of 
routine oral contraceptive has been found to decrease the risk of developing 
EOC (43) while this risk increased with an increasing number of lifetime 
ovulatory events (44-46). 
The second theory is the “gonadotrophin” hypothesis suggested by 
Stadel and colleagues (47). This hypothesis postulates that elevated levels of 
gonadotrophins result in increased proliferation and subsequent malignant 
transformation of the OSE. This model is in line with the protective effects of 
parity and oral contraceptive use (48, 49). Furthermore, studies have shown 
that receptors for gonadotrophins are present in the epithelial cells and the 
ovarian surface is responsive to these hormones (50).  
However, the mechanism of this hypothesis is unknown. In addition, a 
study analysing the association between serum levels of wild-type luteinizing 
hormone (LH) and ovarian cancer risk discovered that neither wild-type LH 
levels nor variant LH status was associated with increased risk of EOC (51).  
Although Type I tumours have been thought to develop from OSE cells 
because they are typically associated with cortical inclusion cysts or low-
grade precursor lesions in the ovarian cortex, Type II tumours are not linked 
to ovarian precursor lesions and in recent years, genetic and pathological 
evidence suggests that a large proportion of Type II HGSOCs may instead 
arise from the distal fallopian tube epithelium, specifically, the fallopian tube 
secretory epithelial cell (FTSEC) (37, 52). 
This hypothesis is supported by numerous studies showing that women 
with inherited BRCA1/2 mutations contained putative serous carcinoma 
precursor lesions in the fimbriated end of their fallopian tubes (35, 53, 54). 
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Kindelberger and colleagues also reported the simultaneous presence of 
serous tubal intraepithelial carcinomas (TICs) in >50% of patients at high risk 
for ovarian cancer or who were afflicted with sporadic ovarian cancer (55). 
Moreover, the same group discovered that serous TICs shared deregulations 
of oncogenic pathways as well as alterations in p53 and in DNA repair genes 
with later stage pelvic serous carcinomas. In contrast, characteristic mutations 
in p53 are rarely observed in OSE cells. 
In line with this concept, Wright and colleagues demonstrated that 
fimbrial epithelial cells from the fallopian tube may replace OSE in primates 
(56). Furthermore, Karst and colleagues showed that nonviral, clinically 
relevant genetic alterations were successful in transforming normal human 
FTSECs into tumours which were grossly, histologically, and 
immunophenotypically consistent with HGSOC, thus providing evidence that 
FTSECs may indeed be a cell of origin for HGSOC (57).  
Further studies determining the importance of the fallopian tube in the 
origin of HGSOC may therefore increase our understanding in regards to its 
molecular biology, thereby improving screening and prevention of this 
disease.  
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1.2.6. Ovarian cancer staging  
Presently, staging requires an extensive surgical assessment by an 
experienced gynaecological oncologist, where a laparotomy is performed to 
explore the entire upper abdomen. Clinical evaluation and imaging studies 
including liver function tests and chest X-rays are also performed as findings 
may affect final staging.  
Recent studies reported that 28-37% of tumours were diagnosed as 
stage I, 8% stage II, 44-47% stage III and 11-18% stage IV (22, 58). As 
survival is, to a large extent, predetermined by the stage at diagnosis, it is 
believed that improving the diagnosis at early stages would reduce the 
mortality. 5-year overall survival rates were reported at 84-93% for stage I, 65-
71% in stage II, 33-47% in stage III and 19% in stage IV (15, 18). One of the 
reasons for poor survival in EOC is that two-thirds of all cases are diagnosed 
when the cancer is disseminated in the peritoneal cavity or spread to other 
organs (22). Ovarian cancer staging is presented in Table 1.1 adopted from 
the report by Heintz and colleagues (58). 
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FIGO stage
            I         Growth limited to the ovaries
            Ia Growth limited to one ovary; no ascites present containing malignant cells.
No tumour on the external surface; capsule intact
            Ib Growth limited to both ovaries; no ascites present containing malignant cells.
No tumour on the external surface; capsules intact
            Ica Tumour either Stage Ia or Ib, but with tumour on surface of one or both ovaries, or with
capsule ruptures, or with ascites present containing malignant cells, or with positive 
peritoneal washings
            II Growth involving one or both ovaries with pelvic extension
            IIa Extension and/or metastases to the uterus and/or tubes
            IIb Extension to other pelvic tissues
            IIca Tumour either Stage IIa or IIb, but with tumour on surface of one or both ovaries, or 
capsule(s) ruptured, or with ascites present containing malignant cells, or with
positive perioneal washings
            III Tumour involving one or both ovaries with histologically confirmed peritoneal implants
outside the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver
metastases equals Stage III. Tumour is limited to the true pelvis, but with histologically
proven malignant extension to small bowel or omentum
            IIIa Tumour grossly limited to the true pelvis, with negative nodes, but with histologically
confirmed microscopic seeding of abdominal peritoneal surfaces, or histologic proven
extension to small bowel or mesentery
            IIIb Tumour of one or both ovaries with histologically confirmed implants, peritoneal 
metastasis of abdominal peritoneal surfaces, none exceeding 2 cm in diameter;
nodes are negative
            IIIc Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes
            IV Growth involving one or both ovaries with distant metastases. If pleural effusion is
present, there must be positive cytology to allot a case to Stage IV. Parenchymal liver 
metastasis equals Stage IV.
a In order to evaluate the impact on prognosis of the different criteria for allotting cases 
to Stage Ic or Iic, it would be of value to know if rupture of the capsule was spontaneous,
or caused by the surgeon; and if the source of malignant cells detected was peritoneal
washings, or ascites.  
Table 1.1. Ovarian cancer staging. 
Table taken from Heintz et al. 2006.  
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Figure 1.1. Cell types contributing to ovarian cancers. 
a, the stromal cells, germ cells and OSE cells account for 3-5%, 5% and 90-
95% of ovarian cancer cases respectively. Furthermore, of the three primary 
functional somatic cell types of the ovary, there is evidence supporting 
stem/progenitor cell biology in the OSE and the theca cells. However, there is 
no specific evidence for stem cell activity associated with granulosa cells. 
Figure adapted from Chang et al. 2008 (59). b, ovarian cancer may also arise 
from the fallopian tube. Here, we show a diagram of a fimbrial plica, 
illustrating the stepwise progression of normal fallopian tube epithelium to 
invasive serous carcinoma. Figure adapted from Karst & Drapkin, 2010 (35). 
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1.2.7. Patterns of spread  
Tumours have the ability to penetrate the ovarian capsule and directly 
invade contiguous organs such as the uterus, fallopian tube, bladder, rectum, 
or the pelvic peritoneum. The tumour cells may also spread via the lymphatics 
involving the pelvic and para-aortic lymph nodes. Lymph node metastases 
occur in as many as 20% of early stage cancers and the majority of 
advanced-stage cancers (60, 61). Finally, ovarian cancer cells may penetrate 
the capsule of the ovary and escape into the peritoneal cavity. This latter form 
of spread is the most damaging as tumour cells are disseminated throughout 
the peritoneal cavity.  
Several molecules have been implicated in ovarian cancer peritoneal 
dissemination. These include the vascular endothelial growth factor (VEGF) 
and VEGF receptors, integrins, hyaluronan receptor (CD44) and other 
adhesion molecules playing a role in spheroid formation, attachment to the 
peritoneal wall and pro-survival signaling pathways (62, 63). More recently, 
Brugge and colleagues discovered that mechanical forces were involved in 
aiding ovarian cancer cells get through the mesothelium, the top layer of the 
peritoneum (64). They further identified three molecules which were involved 
in the invasion process- integrin, talin, and myosin, proteins known to play a 
role in cell movement.  
1.2.8. Drug resistance in EOC 
1.2.8.1. Platinum-sensitive and -resistant disease 
Patients with a platinum-free interval of at least 6 months following 
treatment are referred to as ‘platinum-sensitive’, i.e. they are more likely to 
respond to subsequent treatment with platinum based chemotherapy than 
patients with platinum-free interval of less than 6 months. Several trials have 
reported that this group has a higher chance of responding either to a 
rechallenge with platinum-based treatment or to other agents especially if the 
38 
 
 
interval exceeds 2 years. Results from randomized phase III trials supported 
the superiority of combination platinum-based regimens compared to single- 
agent platinum-based therapy alone (65, 66). However, a number of clinicians 
believe that single-agent platinum therapy should be considered the standard 
of care for platinum-sensitive relapsing disease in view of the only modest 
survival advantages but worse toxicity of combination versus single-agent 
therapy. Unfortunately, there is insufficient data at present to compare two-
drug combinations with the same treatment administered as sequential single-
agents, which may minimize treatment-related toxicity. 
Conversely, patients with relapsed disease within 6 months from the 
end of first-line platinum treatment are referred to as ‘platinum-resistant’. 
Many drugs have been evaluated in this setting but response rates have been 
modest, ranging from 6 to 30% (67-69). The most commonly used second- 
line agents are pegylated liposomal doxorubicin (PLD), topotecan, and 
gemcitabine, with PLD being the most commonly utilized agent for initial 
management of platinum resistant recurrence. Etoposide, vinorelbine, 
oxaliplatin, and capecitabine have also shown some activity. However, toxicity 
profiles for these drugs differ, which is an important factor to be considered in 
the selection of agents. Furthermore, duration of treatment remains a matter 
of controversy and therapy may be continued until disease progression, 
unacceptable toxicity, or achievement of complete clinical response. 
1.2.8.2. Mechanisms of drug resistance 
Drug resistance has been attributed to mechanisms such as decreased 
active transport, increased efﬂux, rapid detoxiﬁcation of platinum through 
glutathione conjugation, accelerated removal of platinum-DNA adducts, 
enhanced DNA repair, mismatch repair deficiency, overactivation of pro-
survival pathways, defective apoptotic signaling, and p53 dysfunction.  
Several studies have sought to identify gene and protein expression 
changes related to chemoresistance in ovarian cancer. For example, 
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Spentzos and colleagues developed a 93-gene signature predictive of 
response to platinum-based chemotherapy (70) while Helleman and 
colleagues identified a set of 9 genes predictive of intrinsic platinum 
resistance in frozen clinical samples (71). Cheng and colleagues also 
compared global gene expression levels between isogenically matched, 
platinum-sensitive and -resistant ovarian cancer cell line pairs where various 
dysregulated genes were identified (72).  
In this section, we give a few specific examples of genes and proteins 
which have been found to play a role in drug resistance in ovarian cancer, as 
described by previous literature. 
1.2.8.2.1. MLH1  
The human homologue of the yeast mismatch repair gene MLH1 (73), 
hMLH1, has a central role in strand specific DNA mismatch repair. Brown and 
colleagues observed an increased frequency of loss of expression of hMLH1 
in post-chemotherapy tumours compared to pre-chemotherapy samples. The 
authors also reported that nine out of ten cisplatin resistant derivatives from 
the ovarian carcinoma cell line, A2780, showed complete loss of hMLH1 
protein expression (74).  
 
Data from a subsequent publication by Strathdee and colleagues 
revealed that the cisplatin sensitive parental A2780 cell line displayed 
methylation of the promoter of only one hMLH1 allele while the resistant cell 
lines all exhibited hyper-methylation of the promoters of both hMLH1 alleles. 
Furthermore, treatment of two of the resistant cell lines with 5-azacytidine, a 
known inhibitor of methylation, resulted in re-expression of hMLH1 and 
increased sensitivity to cisplatin in the 5-azacytidine treated cells (75).  
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1.2.8.2.2. ERCC1 
Resistance to platinum in ovarian cancer has also been linked to the 
expression of ERCC1, a gene involved in nucleotide excision repair and DNA 
repair capacity (76). One study observed a 3-fold higher expression of 
ERCC1 mRNA correlated with cisplatin resistance in ovarian cancer cell lines 
(77). Another found that high levels of ERCC1 were associated with an 
increased rate of nucleotide excision repair and reduced sensitivity to cisplatin 
(78). Selvakumaran and colleagues further reported that in the highly resistant 
OVCAR10 cancer cell line, decreased expression of ERCC1 by antisense 
oligonucleotide restored sensitivity to cisplatin both in vitro and in vivo. 
Similarly, a publication by Liu and colleagues showed that sensitization to 
cisplatin could be achieved in ovarian cancer cell lines when ERCC1 was 
depleted with small interference RNA (79). 
1.2.8.2.3. Annexin A3 
In 2010, Yan and colleagues reported an increase in annexin A3 
protein expression in platinum-resistant ovarian cell lines (80). The expression 
of antisense annexin A3 resulted in its downregulation and rendered the 
resistant cells more sensitive to platinum. Separate immunostaining studies 
revealed that cancers from platinum-resistant patients also possessed higher 
levels of annexin A3 than those from platinum-sensitive patients. Further in 
vivo experiments were carried out where the growth of tumours from 
inoculated SKOV3 ovarian cancer cells was inhibited by the administration of 
platinum, whereas tumours from annexin A3-expressing cells were resistant 
to platinum treatment. Interestingly, the authors observed that intracellular 
platinum concentration and platinum-DNA binding were significantly lower in 
annexin A3-overexpressing cells than those in parental cells. Therefore, they 
concluded that increased expression of annexin A3 may prevent the uptake or 
accumulation of platinum in cells, thereby providing a mechanism of platinum 
resistance in ovarian cancer.  
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1.2.8.2.4. IGF-1R 
In another study where cisplatin-resistant cells were generated by 
treating A2780 ovarian cancer cells with weekly cycles of cisplatin over a 
period of 6 months, the researchers discovered that enhanced IGF-1R 
expression and autocrine IGF-1 were associated with hyperactivation of the 
IGF-1R and phosphatidylinositol-3-OH kinase (PI3K) pathways in cisplatin-
resistant cells (81). Furthermore, there was a correlation of increasing IGF-1R 
mRNA expression levels with the emergence of resistance to cisplatin. 
Cytogenetic and array comparative genomic hybridisation analyses also 
revealed selection and de novo formation of chromosomal alterations during 
resistance development. Interestingly, an analysis of gene expression profiles 
of 80 primary ovarian carcinomas identified the regulatory subunit PIK3R2 of 
PI3-kinase as a significant negative prognosis factor for ovarian cancer.  
1.2.8.2.5. HDAC4 and STAT1 
Finally, Stronach and colleagues performed transcriptional analysis of 
a matched cell line series from three patients with high-grade serous ovarian 
cancer before and after development of clinical platinum resistance to define 
molecular determinants of evolved resistance (82). Their resulting data 
identified 217 genes which were differentially expressed in resistant cell lines. 
Moreover, significantly enhanced apoptotic response to platinum treatment in 
resistant cells was observed following knockdown of 4 genes, including 
histone deacetylase (HDAC) 4 and STAT1. Interestingly, following platinum 
exposure in resistant cells, STAT1 phosphorylation/nuclear translocation was 
observed whereas silencing of HDAC4 increased acetyl-STAT1 levels, 
prevented platinum-induced STAT1 activation and restored cisplatin 
sensitivity. Finally, the authors reported a significant increase in the HDAC4 
protein expression in 7 of 16 acquired platinum-resistant biopsies compared 
with their matched platinum-sensitive biopsies. They therefore concluded that 
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clinical selection of HDAC4-overexpressing tumor cells upon exposure to 
chemotherapy promotes STAT1 deacetylation and cancer cell survival.  
1.2.9. Current treatments for ovarian cancer 
1.2.9.1.  Early stage (I- IIa) 
Patients with early stage disease are usually treated with surgery 
followed by subsequent chemotherapy. However, a worse prognosis has 
been associated with patients with stage Ic disease, clear cell histology, high-
grade tumours, and suboptimal surgical staging (83, 84). These patients may 
therefore benefit with further adjuvant chemotherapy. Two trials investigated 
the effectiveness of adjuvant chemotherapy: the International Collaborative 
Ovarian Neoplasm (ICON-1) and the Adjuvant Treatment in Ovarian 
Neoplasm (ACTION) trials. Although adjuvant chemotherapy was associated 
with statistically significantly improved recurrence-free survival in patients with 
early-stage ovarian cancer, there has been criticism of the ICON-1 trial in 
relation to the adequacy of surgical staging and it has been suggested that 
benefit may only be applicable to suboptimally staged patients (84, 85). 
Another trial (GOG-157) compared six cycles of adjuvant 
carboplatin/paclitaxel compared to the typical three cycles which patients 
currently receive, in a cohort of 107 early-stage patients (86). Although there 
was no significant difference in recurrence or 5-year survival, there was a 
non-significant trend for a reduction in the cumulative risk of recurrence 
associated with six cycles of therapy. Moreover, in a retrospective subset 
analysis, Chan and colleagues presented data which suggested that six 
cycles of adjuvant chemotherapy may decrease disease recurrence in women 
with serous cancers (87). 
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1.2.9.2. Advanced stage (IIb-IV) ovarian cancer 
As mentioned above, the standard treatment for advanced ovarian 
cancer is initial or interval optimal surgical debulking followed by 
carboplatin/paclitaxel chemotherapy every 3 weeks for 6 cycles. This 
combination is based on the GOG-111 and EORTC-NCIC OV-10 studies 
where carboplatin/paclitaxel was found to be superior to 
cisplatin/cyclophosphamide (88, 89). Moreover, the AGO and GOG 158 trials 
showed equivalent efficacy of carboplatin/paclitaxel and cisplatin/paclitaxel 
but reduced toxicity was observed with the carboplatin/paclitaxel arm.  
The use of intra-peritoneal chemotherapy has also been evaluated in 
the treatment of advanced ovarian cancer. Results from three randomized 
trials revealed that improved PFS as well as improved overall survival was 
observed (90-92). Unfortunately, substantial toxicity issues such as catheter- 
related problems, fatigue, hematological, gastrointestinal, and neurological 
events with intra-peritoneal chemotherapy have led to this treatment modality 
not being accepted into general practice.  
Multiple phase III trials have also investigated the addition of a third 
cytotoxic agent – data obtained from more than 10,000 women showed that 
the addition of a third cytotoxic agent associated with increased toxicity but 
did not improve long-term clinical outcomes (93-95). 
1.2.9.3. Hormonal therapy for ovarian cancer  
Endocrine therapies have provided effective palliation with relatively 
little toxicity in other hormone-sensitive or hormone-dependent cancers. 
These include breast, prostate, uterine and kidney cancer. In particular, the 
drug Tamoxifen, an antagonist of the estrogen receptor (ER), has been useful 
in the clinical management of women with breast cancer and is associated 
with significant reduction in tumour recurrences and mortality in the adjuvant 
setting (96).  
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Similarly, in ovarian cancer where endocrine factors are strongly 
implicated in tumourigenesis, various trials involving anti-hormonal therapy 
have been performed. In experimental models of ovarian cancer, Bowman 
and colleagues demonstrated that moderate-high expression of ER was 
associated with a growth response to estrogen (97), and these models are 
growth-inhibited by antiestrogen strategies both in vitro and in vivo (98). In 
addition, a number of proteins were estrogen regulated, and these include the 
progesterone receptor, the EGF receptor, and heat shock protein 27 (99).  
Subsequently, the same group performed a phase II study evaluating 
letrozole, an aromatase inhibitor, in women with oestrogen receptor-positive 
relapsed ovarian cancer, and to identify markers that predict endocrine-
sensitive disease (69). Aromatase is the catalyst for the final rate-limiting step 
in estrogen biosynthesis while aromatase inhibitors such as letrozole have 
been reported to produce reversible, nonsteroidal inhibition of peripheral and 
intratumoural aromatase and suppress circulating estradiol levels by ~95% in 
postmenopausal women (100).  
This study revealed that, of the 44 enrolled participants, 17% and 26% 
of them achieved clinical response and disease stabilization respectively. 
Moreover, none of the participants ceased treatment due to toxicity, with 18 
participants reporting no toxicity. Furthermore, patient response was 
correlated with ERα levels and a number of other protein markers, such as 
low HER2 expression, were identified as possible predictors of response to 
letrozole.  
Although this class of agents is now established as second-line 
treatment of postmenopausal hormone-dependent breast cancer, the clinical 
effectiveness of letrozole in this patient group requires further assessment in 
the form of a large controlled trial. More research is also required before any 
definitive conclusions can be drawn regarding markers for predicting 
response.  
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1.2.9.4. Molecularly targeted therapies 
1.2.9.4.1. Small molecules that target the VEGFR receptor 
The vascular endothelial growth factor (VEGF) is overexpressed in 
ovarian tumours and is associated with a poor prognosis. Several tyrosine 
kinase inhibitors (TKIs) which target the VEGFRs directly are presently being 
investigated in clinical trials. One example is Cediranib (AZD2171), an orally-
administered, highly potent inhibitor of VEGFR1, VEGFR2, VEGFR3, platelet 
derived growth factor (PDGFRβ) and c-kit.  
In a phase II study by Matulonis and colleagues, cediranib was 
administered as a daily oral dose to patients with recurrent EOC, peritoneal or 
fallopian tube cancer (101). Results showed that cediranib demonstrated a 
significant clinical benefit rate where 5 patients had partial responses with an 
overall response rate of 18.5%. Moreover, 3 patients had stable disease 
lasting 30, 27+ and 24 weeks. In view of these results, a randomized placebo-
controlled 3-stage trial (ICON-6) was carried out to evaluate Cediranib in 
patients with platinum-sensitive relapsed ovarian cancer, in combination with 
carboplatin and paclitaxel. Initial findings were published recently by Raja and 
colleagues where Cediranib was found to be sufficiently well tolerated when 
administered together with platinum-based chemotherapy during stage I 
(102). The trial has presently progressed to stage II and results are awaited. 
1.2.9.4.2. Aurora kinase inhibitors 
Aurora kinases (A,B,C) are essential for the regulation of chromosome 
segregation and cytokinesis during mitosis (103, 104). Aberrant expression 
activation of these kinases plays a role in tumourigenesis and progression in a 
wide range of human tumours, including ovarian cancer. For example, Aurora-
A has been reported to be overexpressed in 83% of human epithelial ovarian 
carcinomas and predicts poor clinical outcome (105, 106). Furthermore, DNA 
amplification of the chromosomal region 20q12-q13 20 amplicon 
46 
 
 
corresponding to the Aurora-A gene location was observed in 13 out of 24 
sporadic and in all 4 hereditary ovarian tumours which were investigated in a 
study carried out by Tanner and colleagues (107). 
A 2007 study by Manfredi and colleagues showed that the small 
molecule inhibitor of Aurora-A, MLN8054, induced tumour cell senescence 
both in vitro and in vivo where treatment of human tumour cells grown in 
culture with MLN8054 showed a number of morphologic and biochemical 
changes associated with senescence (108). A year later, Lin and colleagues 
investigated the effects of MK-0457, another small molecule pan-aurora 
kinase inhibitor, in ovarian cancer cell models (109). Their data showed that 
aurora kinase inhibition alone significantly reduced tumour burden in 
chemosensitive and chemoresistant ovarian cancer cell lines. Moreover, 
combination treatment with docetaxel resulted in significantly improved 
reduction in tumour growth and increased tumour cell apoptosis compared to 
docetaxel alone.  
 Finally, data has shown that overexpression of Aurora-A can confer 
resistance to the taxane paclitaxel. Therefore, Scharer and colleagues 
performed a study to determine whether chemical inhibition of the aurora 
kinase family using the small molecule, VE-465, could synergize with 
paclitaxel to induce apoptosis in paclitaxel-resistant and -sensitive ovarian 
cancer cells (110). Results showed that at low doses, VE-465 synergized with 
paclitaxel to induce 4.5-fold greater apoptosis than paclitaxel alone in 
paclitaxel-sensitive 1A9 cells. Higher doses were required to induce apoptosis 
in paclitaxel-resistant PTX10 cells. The authors therefore suggested that 
patients whose tumours exhibit high Aurora-A expression may benefit from a 
combination therapy of taxanes and Aurora-A inhibition.  
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1.2.9.4.3. Hedgehog pathway inhibitors 
The hedgehog (Hh) signalling pathway is a key regulator of embryonic 
development, and its deregulation is associated with various birth defects. Hh 
signaling has also been recognised to be involved in tissue repair, 
proliferation, angiogenesis, as well as tumour growth, therefore suggesting 
that Hh antagonists might constitute a novel class of cancer treatment. 
In 2008, Bhattacharya and colleagues investigated the role of Hh 
signaling in ovarian cancer where the authors assessed the expression of 
different components of hedghehog pathway in primary tumour samples and 
cell lines (111). Moreover, the specific hedgehog pathway blocker, 
cyclopamine, was used to study the effect on clonal growth and proliferation 
of ovarian cancer cell both in vitro and in vivo. Data obtained from their study 
revealed that several Hh pathway components were upregulated in primary 
ovarian tumours and cell lines. However, the downregulation of a direct 
transcriptional target of the Hh pathway, PATCHED1 (PTCH1), was observed. 
Cyclopamine inhibited the proliferation and clonal growth of ovarian tumour 
cells in vitro and arrested ovarian tumour growth in vivo. Moreover, similar 
results could be achieved with the overexpression of PTCH1. 
A year later, Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) reported that 
IPI-926, a semi-synthetic derivative of cyclopamine, demonstrated significant 
inhibition of tumour growth in a primary ovarian cancer model. IPI-926 is 
currently being evaluated in a Phase 1 trial in patients with advanced and/or 
metastatic solid tumours. 
1.2.9.4.4.  PI3K/Akt/mTOR pathway inhibitors 
The PI3K pathway is a signal transduction cascade which is involved in 
a variety of important physiological functions, including cell cycle, cell survival, 
protein synthesis and growth, metabolism, and motility. Abnormal activation of 
the PI3K pathway leads to an increased activity resulting in tumour onset, 
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maintenance, progression and invasion. Furthermore, the PI3K pathway has 
been reported to be one of the most deregulated signaling pathways in many 
tumours, including ovarian ones (112). Therefore, it is considered an attractive 
target in ovarian cancer therapy. 
In a 2004 publication, Altomare and colleagues showed that elevated 
AKT expression was observed in 21 of 31 (68%) ovarian carcinomas (113). 
Moreover, pretreatment of SKOV3 ovarian cancer cells, which exhibit 
constitutive AKT activity under low serum conditions, with the PI3K inhibitor 
LY294002, augmented cisplatin-induced apoptosis. In addition, inhibition of 
mTOR activity with rapamycin resulted in G1 arrest in SKOV3 cells. 
Moreover, in 2007, an in vivo study using xenografts of SKOV3 cells 
revealed that the mTOR pathway inhibitor, RAD001, inhibited tumour growth, 
angiogenesis, and production of ascites (114). Collectively, these findings 
indicate that inhibitors of the PI3K pathway could possibly represent 
potentially important therapeutic and/or chemopreventive targets in ovarian 
cancer. 
1.2.9.4.5. Epigenetic therapies  
Epigenetics is defined as a heritable change in gene expression 
without alteration of the DNA sequence itself and includes DNA methylation, 
histone modification, nucleosome repositioning, and micro-RNAs (miRNAs) 
dysregulation (115). In ovarian cancer, it has been shown that epigenetic 
changes are associated with tumourigenesis and disease progression, as well 
as for acquired drug resistance following chemotherapy (115, 116). 
Furthermore, DNA hypermethylation studies have shown that ovarian tumours 
contained a large number of hypermethylated loci (117).  Such disease stage-
specific methylated loci had earlier been suggested to represent possible 
methylation signatures for classification and possible targets for therapy (118, 
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119), and together with other (120) studies demonstrated that CpG island 
methylation was cumulative with ovarian cancer progression. 
At present, two epigenetic therapies to have entered clinical trials are 
deoxyribonucleic acid methyltransferases (DNMT) and histone deacetylase 
(HDAC) inhibitors (121, 122). DNMTs mediate DNA methylation and their 
inhibitors act by covalently and irreversibly binding to the DNMT enzyme 
active site, resulting in genomic hypomethylation (123). Although 
monotherapy of these agents has shown effectiveness against 
haematological malignancies, their activity against solid tumours has been 
disappointing (123, 124). A phase I/II trial of one DNMT inhibitor, decitabine, 
together with carboplatin, is currently being conducted to investigate the 
effectiveness of combination therapy. This trial is based on the hypothesis 
that low-dose decitabine allows the resensitization of platinum-resistant 
ovarian tumours to carboplatin. Data obtained from the phase I component of 
this study demonstrated safety of the combined regimen and biological activity 
in vivo (125).  
Histone deacetylation is another transcriptional silencing mechanism in 
ovarian cancer, and HDAC inhibitors (HDACIs) can relieve epigenetic gene 
repression and exert anticancer effects by inhibiting the deacetylation of 
nonhistone proteins (126). Unfortunately, similar to DNMT inhibitors, poor 
single-agent activity of HDACIs such as vorinostat and belinostat has been 
demonstrated. In a single-agent ovarian cancer trial of the HDACI vorinostat, 
only 1 of 27 patients experienced a partial response (127), suggesting that 
HDACIs may also be more effective when used in combination with other 
agents (122, 128). In support of this hypothesis, one preclinical study showed 
that a combination of decitabine with belinostat elicited greater platinum 
resensitization of resistant ovarian cancer xenografts than decitabine alone 
(129).  
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1.2.9.5. Immunological strategies  
1.2.9.5.1. Antibody-based therapy 
More than 90% of EOCs differentially express high levels of antigens 
that render them susceptible to therapeutic approaches which target these 
antigens. Relevant antigens include mutated tumour suppressor genes, such 
as p53 and BRCA-1, overexpressed tumour antigens such as CA125, tumour-
associated glycoprotein-72 (TAG-72), mucin-1 (MUC1), MFR (membrane 
folate receptor), PEM (polymorphic epithelial mucin), folate- binding protein 
and carbohydrate antigens, as well as overexpressed growth factor receptors 
erbB2, EGFR and VEGF. Detailed examples of antibodies used in ovarian 
cancer therapy against some of these antigens can be found in Chapter 4. 
1.2.9.5.2. Radioimmunoconjugates   
The conjugation of isotopes to mAbs has been investigated in order to 
enhance the therapeutic index of antibody based therapies in ovarian cancer. 
Due to the high local energy transfer of B-emitters, these are the optimal 
candidates for radioimmunotherapy. Furthermore, when 
radioimmunoconjugates are administered intraperitoneally, radionuclides with 
short half lives are preferable as they deliver less radiation to the bone 
marrow. At present, radioisotopes available for radioimmunotherapy include 
99mTc, 186Re, 188Re, 90Y, 131I and 177Lu, all of which can be conjugated using a 
bifunctional chelate or direct sulfhydryl reaction. Preliminary studies have 
suggested response rates to radioconjugated antibodies are better in ovarian 
cancer patients with small volume disease (130, 131). Examples of these 
antibodies are given in Chapter 4. 
1.2.9.5.3. Toxins and drug-conjugated antibodies 
There has also been interest in conjugating chemotoxins to antibodies 
to obtain more specific tumour targeting and higher dosing than that achieved 
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by systemic administration of unconjugated drugs. Toxicity in antigen negative 
normal tissues is avoided as these targeted toxins require internalisation by 
the target cell to effect apoptosis or cell death. For example,  in the treatment 
of patients with advanced-stage indolent histology non-Hodgkin’s lymphomas, 
a phase II clinical trial was carried out to evaluate the antitumour effects of a 
combination chemotherapy program based on ProMACE (prednisone, 
methotrexate, doxorubicin, cyclophosphamide, etoposide) followed by a B 
cell-specific immunotoxin (132). Results showed that although this 
combination did not produce durable complete remissions in the majority of 
patients, the remissions appeared quite durable (> 4 years) in about 40% of 
the complete responders.  
In ovarian cancer therapy, a phase I trial involving OVB3-PE, an 
immunotoxin composed of a murine monoclonal antibody reactive with human 
ovarian cancer and conjugated to Pseudomonas exotoxin, was performed in 
23 patients with refractory ovarian cancer. Data obtained revealed that no 
clinical antitumour responses were observed. Moreover, dose levels used in 
this trial was accompanied by dose-limiting toxic encephalopathy. The authors 
suggested that neurologic toxicity was likely to be due to cross-reactivity of 
OVB3 to normal human brain tissue, which was not appreciated during 
preclinical screening (133). 
Another phase I study investigated the immunotoxin, LMB−1, which is 
composed of monoclonal antibody B3 chemically linked to PE38, a genetically 
engineered form of PE (134). B3 recognises a carbohydrate antigen (LeY) 
present on many human solid tumours. In this trial, 38 patients with solid 
tumours who failed conventional therapy and whose tumours expressed the 
LeY antigen were evaluated. Results showed that antitumour activity was 
observed in 5 patients, stable disease in 18 patients and progressive disease 
in 15 patients. This included a complete remission in one breast cancer 
patient and a greater than 75% reduction and resolution of all clinical 
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symptoms lasting for more than six months in a colon cancer patient. 
Unfortunately, none of the patients with ovarian cancer exhibited clinical 
responses. Moreover, vascular leak syndrome manifested by 
hypoalbuminemia, fluid retention, hypotension and, in one case, pulmonary 
edema, was reported. 
1.2.9.6.  Surgical resection for relapsed ovarian cancer 
Although cytoreductive surgery for patients with newly diagnosed 
ovarian cancer is generally accepted, the role of secondary cytoreductive 
surgery in the setting of recurrent disease is unresolved. Data from several 
retrospective studies suggested the role of secondary cytoreductive surgery 
for select patients where an important prognostic factor was the disease-free 
interval (DFI), defined as the interval from the completion of platinum-based 
chemotherapy to the diagnosis of recurrence, or the 'platinum-free' interval.  
Most studies demonstrated a survival benefit for patients who had 
complete resection and whose DFI was greater than 12 months (135-138). 
For example, in the study by Chi and colleagues where 157 patients who 
underwent secondary cytoreduction were analysed, the authors 
recommended that secondary cytoreduction should be offered to all patients 
with platinum-sensitive disease and a single site of recurrent disease 
regardless of DFI, as well as to all patients with a DFI of more than 30 months 
regardless of number of sites of disease (137). Furthermore, in their opinion, 
patients with carcinomatosis and a DFI of less than 12 months should not be 
considered for secondary cytoreduction.  
Another example is a multicenter study on secondary cytoreductive 
surgery (AGO-DESKTOP OVAR trial) performed in 2006, which consisted of 
an exploratory study based on data from a retrospective analysis of hospital 
records. 267 patients were included in this trial and complete resection was 
associated with significantly longer survival compared with surgery leaving 
any postoperative residuals (45.2 vs 19.7months; p<0.0001). The AGO-
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DESKTOP OVAR trial determined that no residual disease post-primary 
surgery, early stage at diagnosis, no ascites, and good performance status at 
recurrence predicted optimal resection almost 80% of the time (136). Results 
from phase III trials (EORTC 55963; AGO-DESKTOP III) evaluating the 
impact of surgical management in combination with chemotherapy in relapsed 
ovarian cancer on survival will provide further insight into this therapy. 
1.2.10. Novel therapeutic strategies 
Despite recent advances, long-term survival rates for EOC are poor, 
with many patients developing resistance to treatment, as discussed earlier. 
Hence more effective therapeutic modalities are required. The development of 
novel therapeutic strategies which inhibit, restore or modulate key molecules 
and pathways, whose deregulation results in the appearance of the malignant 
phenotype and adverse clinical outcomes, may improve mortality rates. In 
addition, the development of novel methods which target specific antigens on 
ovarian cancer cells may also be useful. One particularly interesting approach 
which has gained impetus in the past 10 years is the identification and 
eradication of ovarian tumour stem cells (TSCs). We explore the TSC 
hypothesis in our next section and investigate the relevance of TSCs in 
ovarian cancer.  
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1.3. Tumour stem cells (TSCs) in EOC 
1.3.1. The TSC hypothesis 
At the gross level, tumours are characterised into distinct subtypes by 
histology, the expression of specific markers, as well as gene expression 
profiling. These subtypes possibly reflect distinct cells of origin at the time of 
tumour initiation. Furthermore, light microscopy studies have shown that solid 
tumours are histologically heterogeneous and include tumour cells, stroma, 
inflammatory infiltrates, and vascular structures within a variety of biochemical 
signals (139, 140). This feature of heterogeneity within tumours was first 
reported in pioneering studies involving spontaneous mouse leukaemias and 
lymphomas where the frequency of tumour-propagating cells ranged from 1% 
to the majority of cells (141, 142). Tumour cells derived from lung, ovary and 
brain tumours also displayed differences in growth as observed in colony-
forming assays in vitro (143).  
At least two models have been put forward to account for the 
heterogeneity and inherent differences in tumour-regenerating capacity of 
cancer cells: the clonal evolution ‘stochastic’ (144, 145) and TSC models 
(146) (Figure 1.1).  According to the stochastic model, all cancer cells within 
the same tumour tissue possess the ability to generate new tumours by 
simple proliferation of transformed cells (147). The intra-tumour heterogeneity 
is explained by a clonal diversity of the transformed cells in the repertoire of 
genetic mutations.  
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Figure 1.2. The stochastic model vs. the TSC model.  
a, stochastic model where all cells within a tumour have the potential to 
proliferate extensively. b, TSC model where most tumour cells have only 
limited proliferative potential whereas a subset of cancer cells consistently 
proliferate extensively in clonogenic assays and can form new tumours on 
transplantation. Figure adapted from Reya et al. 2001 (148). 
However, the alternative “hierarchical/stem cell” concept proposes that 
tumours are driven and sustained in their malignant growth by a minority 
subpopulation of tumour cells with “stem-like” properties. Regardless of the 
environment or mutational status of the cells, only a rare, phenotypically 
distinct subset of TSCs has the potential to self-renew, proliferate excessively, 
and differentiate aberrantly into a heterogeneous progeny of cancer cells 
culminating in the intra-tumour heterogeneity (148-151). 
At present, the consensus definition of a TSC is a cell within a tumour 
which possesses the capacity to self-renew and to cause the heterogeneous 
lineages of cancer cells comprising the tumour (139). The term, TSCs, 
therefore reflects their 'stem-like' properties and ability to continually sustain 
tumourigenesis.   
Besides the ability to self-renew, TSCs share other important 
properties with normal tissue stem cells. For example, it is thought that both 
TSCs and normal stem cells undergo asymmetric as well as symmetric cell 
divisions to proliferate and differentiate (140). Furthermore, normal stem cells 
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are relatively quiescent, resistant to drugs and toxins through the expression 
of several ATP-binding cassette (ABC) transporters, possess active DNA-
repair capacity, and are resistant to apoptosis. Similarly, while their self-
renewal properties allow for the maintenance and expansion of cancer cell 
populations, TSCs are quiescent and rarely proliferate. The quiescent nature 
of these TSCs thereby renders them resistant to the toxicity of conventional 
anti-cancer drugs which target rapidly dividing cells.   
Indeed, the presence of residual TSCs may explain the recurrence of 
the cancer relapse in many patients even after complete tumour resection and 
systemic treatment involving chemotherapy and/or radiotherapy (4). 
Therefore, it is critical to develop more effective cancer therapies to eradicate 
TSCs rather than rapidly dividing cells in the cancer. This in turn may abolish 
the cancer as the remaining cells in the cancer growth have limited 
proliferative capability. Thus, the concept of TSCs may lead to new areas of 
research in carcinogenesis and future treatment options. 
1.3.2. Early evidence supporting the TSC hypothesis 
The concept that a distinct population of cells may be the cellular origin 
of cancer arose almost 150 years ago when similarities were detected 
between embryonic tissue and cancer with respect to their increased capacity 
for proliferation and differentiation. It was thus hypothesised that resting 
embryonic stem cells residing in adult tissue may acquire the ability to give 
rise to cancer upon activation (152). Functional cell proliferation studies in the 
1940s-60s further demonstrated this concept of cellular heterogeneity. For 
example, Clermont and Leblond showed that proliferating cells in the testis 
took up a pulse of label. By tracking the label, they noted differentiation of 
these cells to mature cells. Moreover, these cells were also observed to 
maintain themselves (153).  
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In the 1960s and 1970s, several haematologists carried out pioneering 
cytokinetic studies first in cell lines and murine models of the acute leukemias 
and then by in vivo examination of leukemia blast proliferation kinetics in 
human AML and acute lymphoblastic leukemia (ALL) patients (154-156). 
Results obtained showed that only a small fraction (∼ 5%) of leukemic blasts 
was rapidly cycling in vivo. A larger, fast cycling subset and a smaller, slow 
cycling fraction were also observed in patients. Notably, it was inferred that 
the slow cycling fraction represented a leukemic stem cell (LSC) population 
which was actually generating the fast cycling fraction as these LSCs had 
similar cytokinetic properties to those observed for normal hematopoietic stem 
cells (HSCs) (157). 
At the same time, numerous studies showed that there were distinct 
subpopulations of cells not only in leukemia, but also in many types of solid 
tumours (158-162). Thus, it was speculated that cancer was initiated from 
transformed stem cells and developed as a heterogeneity tissue, containing 
TSC subpopulations and differentiated cancer cell subpopulations. Although 
these early studies were critical in the development of the stem cell model for 
cancer, they were limited by a lack of isolation methods which allowed 
examination of the different cell populations within a tumour.  
It was only in 1972 that the characterization of leukaemia and other 
TSCs was greatly facilitated when Herzenberg and colleagues developed 
high-speed multi-parameter flow cytometers (163). These automated 
machines allowed the identification and/or purification of distinct cell 
populations, based on the ability of fluorescently labelled antibodies to bind 
cell-surface antigens. Another crucial event occurred in the 1990s when 
conclusive tests for self-renewal were separately developed by Weissman 
and Dick which allowed normal human stem cells to grow in mice (139).  
Thereafter, using flow cytometry and this new mouse model, Dick 
began in 1994 to publish a series of seminal reports identifying cancer stem 
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cells in leukemia. In 1997, he was part of a team which isolated two groups of 
leukemia cells from leukemia patients with specific surface markers CD34 and 
CD38, and found that only cells with the surface phenotype CD34+CD38- 
possessed the ability to engraft in mice and produce large numbers of colony-
forming progenitors (164). Thus they concluded that CD34+CD38- 
subpopulations were the initiating cells of leukemia. This was the first 
experimental evidence of TSCs. In 2004, another pivotal study by Hope and 
colleagues demonstrated that AML originated from a cellular hierarchy, with 
only the most primitive of cells being able to initiate and sustain the leukemia 
(165). Both studies suggest that malignant tumours are comprised of TSCs, 
which are consistently enriched for the ability to proliferate and transfer 
disease, as well as more differentiated cancer cells, which have limited 
proliferative potential. 
Improvements in analysis of subpopulations of cells with advanced 
technologies have led to cancer being increasingly viewed as a stem-cell 
disorder where continued growth of tumours depends on self-renewing TSCs. 
The identification of TSCs in leukaemia, as well as in many other solid 
tumours, also provide evidence for the broad applicability of the TSC model.  
1.3.3. Possible origins of TSCs 
It had earlier been hypothesised from clinical observations and genetic 
studies of a variety of cancers that six genetic mutations were required to 
convert a normal somatic cell into a cancer cell (166). These mutations 
included self-sufficiency for growth signals, insensitivity to antigrowth signals, 
evasion of apoptosis, limitless ability to replicate, sustained angiogenesis, and 
tissue invasion and metastasis. 
Similarly, there are several lines of evidence showing that TSCs can 
arise from transformed malignant normal stem or progenitor cells (167-170). 
For example, it has been discovered that soft-tissue sarcoma cells and bone 
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marrow-derived mesenchymal progenitor cells share a common phenotype 
(171, 172). Moreover, by transfecting the progenitor cells with a construct 
encoding an oncogenic fusion protein, these cells can be converted into 
Ewing’s sarcoma cells (173). In another study, a chimeric synovial sarcoma 
fusion protein SYT–SSX was misexpressed in a conditional transgenic mouse 
model to show that synovial sarcomas originate from myogenic precursors 
(174). Finally, Houghton and colleagues showed convincingly that epithelial 
tumours such as gastric cancer could arise from progenitor cells of the bone 
marrow (175).  
An alternative model of tumour initiation may be the fusion of stem cells 
with cells that have undergone a variety of mutational events related to cancer 
development (176). Such fused cells possibly express stem cell features and 
show large chromosomal aberrations and aneuploidy. In addition, they could 
also possess unique cell-survival programmes that are shared by normal stem 
cells and that might drive tumour progression. Therefore, a stem cell fused to 
a somatic cell that has received a number of defined mutational hits might 
explain the occurrence of the chromosomal derangements that can occur 
during early tumour development (177). 
Malignant transformation may also occur through deregulation of 
proliferation and differentiation pathways which appear to be shared by stem 
cells of all organs. For example, the role of the Notch pathway in controlling 
stem cell proliferation has been demonstrated for several cell types including 
haematopoietic, neural and mammary stem cells (178). However, 
components of the Notch pathway have also been reported to act as 
oncogenes in mammary and other tumours (179). Similarly, the polycomb 
group transcriptional repressor, Bmi-1, is involved in regulation of neural stem 
cells (180) but has been discovered as a common oncogene activated in 
lymphoma (181) and in TSCs of pediatric brain tumours (182).  
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Finally, normal stem cells reside in a physiologically distinct and 
specialized microenvironment, or niche, which supports the cells. The niche 
also generates extrinsic factors such as development regulatory signal 
molecules including HH, Wnts, BMPs, FGFs and Notch, which control stem 
cell number, proliferation, and fate determination. Under normal physiological 
conditions, the stem cell niche provides an environment that predominantly 
inhibits both proliferation and differentiation. However, in tumours, TSCs may 
become self-sufficient to undergo uncontrolled proliferation and/or the niche is 
converted into an environment with dominant signals favouring cell 
proliferation and growth (183).  
1.3.4. Established TSC isolation and characterisation 
techniques  
In the last ten years, increasing evidence supporting the TSC 
hypothesis has gained impetus due to advances in stem cell biology and the 
development of new animal models to measure self-renewal and more directly 
test the validity of this hypothesis. While there are no established protocols for 
isolating pure populations of TSCs, the general aim of many studies has been 
to enrich for cell populations that display features which are characteristic of 
normal stem cells. The tumourigenicity of the isolated cell populations is then 
confirmed by assessing the tumour-forming potential of these cells in 
appropriate mice models. 
1.3.4.1. Cell surface markers  
Based on phenotypic expression of cell surface proteins, malignancies 
arising from a ‘TSC compartment’ have been reported to include melanoma 
as well as solid tumours such as cancers of the skin, head/neck, lung, bone, 
colon, pancreatic, breast, prostate and ovary (5, 184-191) (Table 1.2). 
However, it should be noted that identification of TSCs is complicated and 
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Table 1.2 only serves to provide examples of cell surface markers associated 
with TSCs. 
For example, populations of CD44+ stem-like prostate cancer cells 
have been identified, and these cells expressed higher mRNA levels of 
several ‘stemness’ genes, such as Smoothened and Oct-3/4, when compared 
to CD44– cells. Moreover, these CD44+ prostate cancer cells were able to 
generate CD44– cells in vitro and in vivo and appeared to undergo 
asymmetrical division in clonal analysis (191, 192). In pancreatic 
malignancies, tumours that formed from CD44+CD24+ESA+ subpopulation 
cells were indistinguishable from the human tumours in which they originated. 
These observations indicate that the tumour-initiating cells were stem cell-like 
in their ability to self-renew and give rise to a heterogeneous cell population 
(193).  
In vivo studies have also been performed where TSCs of the mammary 
gland were identified based on the CD44+CD24- cell surface phenotype. 
These cells were isolated from primary tumours or pleural effusions from 
breast cancer patients and injected into the mammary fat pad of 
immunocompromised mice to measure the tumour-forming ability of the cells 
(190). As few as one hundred of these cells were sufficient to cause tumour 
formation in the mice. However, injections of tens of thousands of cancer cells 
that did not express the CD44+CD24- phenotype failed to cause tumour 
formation. Interestingly, the expression of Notch 3, which plays a role in stem 
cell self-renewal, cell fate, apoptosis, and proliferation, has been found to be 
upregulated in CD44+ populations of both normal and malignant breast cells. 
This upregulation of Notch receptors and the presence of ligands is often 
correlated with a more aggressive phenotype (194-196), thus supporting the 
idea that TSCs are the aggressive cancer cells within a tumour.  
More recently, two separate groups reported that a glioblastoma cell 
population which could differentiate into endothelial cells and form blood 
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vessels in vitro was enriched in tumour stem-like cells expressing CD133 
(197, 198). Their data suggests that TSCs have the ability to give rise to the 
endothelial cells that line the tumour vasculature, thereby mediating tumour 
growth and metastasis.  
Over the past 5 years, several studies have also focused on the 
isolation and characterisation of TSCs in ovarian cancer. For example, in 
2009, Alvero and colleagues reported that isolated CD44+ cells from ascites 
or solid ovarian tumours were highly resistant to chemotherapy with paclitaxel 
and carboplatin, while CD44- cells from the same patient were responsive to 
chemotherapy (199). In the same year, Baba and colleagues detected the 
CD133 antigen on ovarian cancer cell lines, in primary cancers and on 
purified epithelial cells from ascitic fluid of ovarian cancer patients (9). While 
CD133+ ovarian cancer cells generated both CD133+ and CD133− daughter 
cells, CD133− cells were found to divide symmetrically. Moreover, CD133+ 
cells exhibited enhanced resistance to platinum-based therapy and formed 
more aggressive tumour xenografts at a lower inoculum when compared to 
their CD133− progeny. As CD133 expression was further discovered to be 
directly regulated by epigenetic modifications, the authors suggested that 
these CD133+ TSCs may serve as chemotherapeutic targets for reducing 
disease recurrence.  
Similarly, Ferrandina and colleagues investigated the expression of 
both the CD133-1 and CD133-2 epitopes in primary ovarian tumours (8). In 
their publication, the authors reported that CD133+ cells gave rise to a 
significantly larger number of colonies when compared to that in the CD133- 
population. Moreover, CD133+ cells showed an enhanced proliferative 
potential compared to CD133- cells. Therefore, both CD133-1 and CD133-2 
could be useful in order to select and enrich the population of CD133+ ovarian 
tumour cells which are characterised by a higher clonogenic efficiency and 
proliferative potential.  
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Finally, in 2011, Steffensen and colleagues investigated the 
association between the number of CD44+ TSCs in ovarian cancer tumours 
and PFS (200). 17.1% of the samples revealed a high percentage of CD44+ 
TSCs. Interestingly, the number of TSCs was significantly higher in patients 
with early-stage ovarian cancer (FIGO I/II). Moreover, this was associated 
with significantly shorter PFS. Therefore, the authors suggested that 
quantification of the number of CD44+ TSCs in EOC could be used as a 
predictor of disease and could be applied for treatment selection in early-
stage ovarian cancer. 
 
 
 
 
 
 
 
 
 
 
 
Tumour Specific 
marker/markers 
References 
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Acute myeloid leukaemia CD34+CD38- (164) 
Breast  CD44+CD24-ESA+ (190) 
Brain  CD133+ (201) 
Colon  CD133+ (188) 
Head and neck  CD44+ (202) 
Prostate  CD44+ (191, 192) 
Multiple myeloma CD138- (203) 
Metastatic melanoma CD20+ (204) 
Ovarian  CD44+, CD133+ (205, 206) 
Pancreatic  CD24+CD44+ESA+ (193) 
Lung adenocarcinoma Sca1+CD45-Pecam-
CD34+ 
(186) 
Colorectal  EpCAMhigh 
CD44+CD166+ 
(207) 
Bone sarcoma Stro1+CD105+CD44+ (187) 
 Table 1.2. Examples of cell surface markers associated with TSC    
populations. 
 
In conclusion, these studies support the role of surface molecules as 
prognosis markers and cells which express these markers contribute to drug 
resistance during conventional therapy. Furthermore, isolated TSC 
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populations have shown stem-like characteristics such as self renewal 
capabilities, higher clonogenic efficiency and increased proliferative potential. 
Unfortunately, none of these reported markers is expressed exclusively by 
TSCs. For example, brain TSCs were isolated with the CD133 marker (201). 
However, this marker is also present on normal brain stem cells (208). In fact, 
the majority of cells that express these TSC markers are non-stem cells (209). 
In addition, markers used to identify TSCs from one organ or tumour type may 
not be useful for identifying TSCs in other tissues. For instance, CD44 may be 
useful for the identification of TSCs in breast and prostate cancers but it is not 
consistently expressed by brain TSCs. Therefore, besides this approach 
involving the specific phenotypic expression of markers, functional differences 
that identify stem cells from non-stem cells have also been applied to the 
search for TSCs. 
1.3.4.2. Hoechst dye method 
Stem cells are known to efficiently pump out DNA-binding dyes such as 
Hoechst 33342 via an ATP-binding cassette (ABC) membrane pump-
dependent mechanism, whereas more differentiated cells retain the dye. By 
exploiting this principle, the side population (SP) assay was developed by 
Margaret Goodell to identify the presence of putative stem cells and to isolate 
these cells from other cells in the haematopoietic system based on the 
exclusion of Hoechst dye (210). When analysed by flow cytometry, putative 
stem cells appeared as a low-fluorescence "tail" of cells relative to the much 
larger bulk of Hoechst-bright cells. This "tail" is now known as the SP which 
disappears upon addition of export pump inhibitors such as verapamil. 
Presently, SP cells have been identified in established cancer cell lines 
including rat C6 glioma, U87MG human glioblastoma, MCF-7 human breast 
carcinoma, HuH7 human hepatoma, and HeLa human adenocarcinoma cell 
lines (211-214). There are also numerous reports of SPs in other tissue types 
and their respective tumours such as the mammary gland, skeletal muscle, 
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prostate, ovary, lung, liver, skin, testis, heart, epidermis and gastrointestinal 
tissues (211, 215-223).  
For example, in 2001, Wulf and colleagues detected a malignant SP 
cell subset in more than 80% of the acute myeloid leukemia patients they 
studied. As the cells also expelled lipophilic antileukemic drugs, these cells 
might be candidate leukemic stem cells capable of contributing to relapse 
(224). Increased expression of the drug transporter, ABCB1, in SP cells has 
also been suggested as a potential cause of drug resistance in refractory and 
relapsed neuroblastoma (225-227). Therefore, independent of whether SP 
cells are truly a TSC population, their high expression of drug efflux 
transporter genes and their associated high capacity to efflux lipophilic drugs 
may have a significant influence on treatment outcome. 
Furthermore, Wu and colleagues discovered a SP population with 
tumour-initiating capacity within a broad range of benign and malignant 
mesenchymal tumours, where the benign, locally invasive, low-grade tumours 
had a low SP population whereas high-grade malignant tumours had high SP 
populations (228). Therefore, the proportion of SP cells could be used as a 
prognostic factor and therapeutically targeting this subpopulation of cells could 
be used to improve patient outcome.  
Using the same method, Szotek and colleagues first identified and 
characterised SP cells from two distinct genetically engineered mouse ovarian 
cancer cell lines (218). The authors reported that these SP cells formed 
measurable tumours sooner and at fewer inoculated numbers than compared 
to the non-SP (NSP) cells. Moreover, SP cells exhibited resistance to 
conventional chemotherapeutic agents while the NSP cells did not. It was also 
observed that Müllerian Inhibiting Substance, the protein responsible for the 
regression of the Müllerian duct during development, was able to inhibit the 
growth of these SP cells in vitro. Finally, SPs could also be identified in 
human ovarian cancer cell lines as well as patient primary ascites cells.  
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More recently, Hu and colleagues isolated SP cells from ascites 
derived from ovarian cancer patients and from mice inoculated with human 
ovarian cancer cell lines (229). These SP cells expressed stem cell-related 
genes such as ABCG2/BCRP1, Oct4, stellar, and nanog. Interestingly, 
ABCG2/BCRP1 expression was higher in SP than in NSP cells. Also, mice 
inoculated with SP cells yielded more tumours than did mice inoculated with 
NSP cells. Further cell culture data supported this finding where increased cell 
proliferation was observed in SP cells when compared with NSP cells. Finally, 
SP cells were more resistant to chemotherapy when compared with NSP 
cells, both in vivo and in vitro.  
Although the SP phenotype is largely considered as a stem cell 
biochemical marker (150), as with cell surface markers, possession of a SP 
phenotype is not a universal property of stem cells, and in some tissues, the 
SP fraction may not contain the stem cells. For example, experiments that 
identified normal breast stem cells by their ability to generate mammary 
glands in cleared fat pads showed that the majority of these cells are not 
included within the SP fraction (230). It is also important to note that possible 
toxicity of the dye to cells that do not exclude it should also be considered as a 
caveat to interpreting functional assays of SP cells.  
1.3.4.3. Aldehyde dehydrogenase activity 
An alternative method of detecting TSCs through aldehyde 
dehydrogenase (ALDH) activity as assessed by the fluorescent Aldefluor 
assay has gained recognition in the past few years. ALDH is a detoxifying 
enzyme responsible for the oxidation of a variety of intracellular aldehydes 
and has been suggested to be involved in stem cell differentiation through 
metabolism of retinal to retinoic acid (231). It is expressed at high levels in 
haematopoietic stem cells (HSCs), conferring resistance to certain alkylating 
agents such as cyclophosphamide and 4-hydroxyperoxycyclophosphamide. 
Fluorescent substrates for ALDH such as BODIPY-aminoacetaldehyde 
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(BAAA) have been developed and shown to be successful in the isolation of 
mouse and human HSCs (232).  
The Aldefluor activity assay was first published by Ginestier and 
colleagues in 2004 where a subpopulation of cells that displayed stem cell 
properties in normal human breast tissue and breast carcinomas was isolated 
(233). The use of Aldefluor has now been extended to various other solid 
tumours such as in the lung, colorectal liver and ovary (207, 234, 235).  
Ginestier and colleagues utilized in vitro and in vivo experimental 
systems to show that normal and cancer human mammary epithelial cells with 
increased ALDH have stem/progenitor properties. In a series of 577 breast 
carcinomas, expression of ALDH detected by immunostaining also correlated 
with poor prognosis (233). More recently, a majority of breast cancer cell lines 
has been shown to contain an Aldefluor-positive population with a distinct 
molecular profile that displays TSC properties (236). In a separate study, 
immunohistochemical analysis of 303 clinical specimens from three 
independent cohorts of lung cancer patients and controls showed that 
expression of ALDH was positively correlated with the stage and grade of lung 
tumours and related to a poor prognosis for the patients with early-stage lung 
cancer (234).  
A couple of years ago, Deng and colleagues reported that the 
expression levels and patterns of ALDH in epithelial cancers were remarkably 
distinct, and they correlated with their corresponding normal tissues. 
Furthermore, ALDH protein expression levels as measured by 
immunohistochemical staining were found to be positively correlated with 
ALDH enzymatic activity measured by the Aldefluor assay. Interestingly, 
tumour cells with high levels of ALDH expression exhibited TSC properties 
and were resistant to chemotherapy. Moreover, high ALDH expression was 
significantly associated with poor clinical outcomes in serous ovarian cancer 
patients (237).  
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In the same year, a publication by Landen and colleagues further 
supported this data where the percentage of ALDH-positive cells correlated 
negatively with PFS in patient samples. The authors also observed 
significantly higher ALDH expression and activity in taxane- and platinum- 
resistant cell lines. Moreover, an approximately 50-fold higher tumourigenicity 
was reported in A2780cp20 ALDH-positive cells when compared to ALDH-
negative cells. In addition, although tumours derived from ALDH-positive cells 
gave rise to both ALDH-positive and ALDH-negative populations, ALDH- 
negative cells could not generate ALDH-positive cells. Subsequent ALDH1A1 
silencing using nanoliposomal siRNA sensitised both taxane- and platinum-
resistant cell lines to chemotherapy, significantly reducing tumour growth in 
mice compared with chemotherapy alone (238).  
The above findings present the Aldefluor activity assay as an important 
new tool to facilitate the clinical application of stem cell concepts, and provide 
a potential prognostic factor and therapeutic target for treatment. The 
procedure is simple with a high level of reproducibility. In addition, substrates 
for ALDH such as BAAA should not enter the nucleus or bind DNA. 
Consequently, the isolation of primitive cells by BAAA staining may be safer 
and less toxic than methods such as SP analysis which are based on staining 
with dyes that bind to nucleic acids or require ultraviolet excitation. 
Furthermore, Aldefluor as a cell viability dye makes it more reliable than 
surface marker selection-based methods that do not discriminate between 
viable and nonviable cells (239). In fact, only viable cells with functional 
enzymatic activity and an intact membrane can retain the Aldefluor reaction 
product, whereas apoptotic and necrotic cells with leaky membranes are not 
detected. However, this method is relatively new and has not been validated 
as robustly as the Hoechst dye method. Therefore, more studies regarding its 
use in isolation of TSCs would be required in future.  
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1.3.4.4. Tumour sphere formation assay 
Finally, another approach for TSC enrichment is the tumour sphere 
assay which investigates the ability of the cells to grow as multicellular 
spheroids under non-differentiating and non-adherent conditions, a 
characteristic believed to be indicative of self-renewal. In a typical tumour 
sphere assay, cells from primary tumours or cancer cell lines are dissociated 
into a single cell suspension and cultured in a serum-free growth factor-rich 
medium containing primarily epidermal growth factor (EGF) and fibroblast 
growth factor (FGF). Resulting multicellular spheroids of enriched TSCs can 
thereafter undergo serial dissociation and passaging to further enrich for stem 
cell- like cells. This method was first implemented by Reynolds and Weiss 
years ago to isolate neural stem cells (240). Since then, it has been adapted 
to purify putative TSC populations in brain, breast, colorectal, pancreatic, 
prostate, as well as ovarian cancer (201, 241-247). 
For example, in 2008, Zhang and colleagues sought to identify and 
characterise a self-renewing subpopulation of human ovarian cancer-initiating 
cells (OCICs) which were fully capable of serial propagation of their original 
tumour phenotype in animals (10). First, ovarian serous adenocarcinomas 
were disaggregated and subjected to growth conditions selective for self-
renewing, nonadherent spheroids. Subsequent xenoengraftment of as few as 
100 dissociated spheroid cells allowed full recapitulation of the original tumour 
while unselected cells remained non-tumourigenic.  These cells also 
demonstrated enhanced chemoresistance to ovarian cancer 
chemotherapeutics including cisplatin or paclitaxel. Furthermore, upregulation 
of stem cell markers such as Bmi1, stem cell factor, Notch-1, nanog, nestin, 
ABCG2, and Oct4 was observed when compared with parental tumour cells 
or OCICs under differentiating conditions. Finally, immunostaining of the 
spheroids showed significant upregulation of CD44 and the stem cell factor 
receptor CD117. Similar to sphere-forming OCICs, it was observed that full 
recapitulation of the original tumour could be achieved with injections of as 
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few as 100 CD44+/CD117+ cells while CD44-/CD117- cells remained non-
tumourigenic.  
1.3.5. Targeting TSC populations  
The TSC concept is appealing as the long-lived nature of stem cells 
subjects these cells to the accumulation of multiple mutations that are 
required for carcinogenesis. It is conceivable that according to the TSC 
model, therapeutic approaches that do not eradicate these target tumour 
progenitors, which are believed to express normal stem cell phenotypes, such 
as a low mitotic index, enhanced DNA repair, and expression of drug efflux 
transporters such as ABCB1 and ABCG2 (4, 151, 248) are likely to achieve 
little success. Although temporary regression of gross tumour lesions may be 
induced with current therapies, failure to eradicate TSCs may contribute 
directly to relapse and metastatic dissemination (148). This might explain why 
several experimental therapeutic approaches have shown poor clinical results 
despite extensive preclinical validation in vitro.  
1.3.5.1. Self-renewal signaling pathways 
One approach to inhibit TSCs is to target pathways essential for the 
growth and maintenance of normal stem cells. For instance, stem cell 
regulators such as the Sonic hedgehog (SHH) and Wnt pathways are also 
commonly hyper activated in tumours and are required to sustain tumour 
growth (249). Therefore, this pathway represents an attractive target for 
cancer therapy. As described earlier, the steroid-like compound, cyclopamine 
(250), has been found to inhibit the growth of ovarian cancer cells with 
activated Hedgehog (HH) signaling (251).  
Furthermore, UV-induced basal cell carcinomas in P53-/- mice were 
inhibited by low levels of cyclopamine given in the drinking water (252). 
Analysis of HH/PATCHED (PTCH) genes showed that the expression of SHH, 
suppressor of fused homolog (SUFU), PTCH, and the GLI-Kruppel family 
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members, GLI2 and GLI3, were significantly downregulated by cyclopamine 
treatment. Therefore, expression of the mRNA or protein of these genes could 
be useful for evaluating the effectiveness of targeted therapy in human 
cancers. 
1.3.5.2. TSC niche 
The identification of factors within the tumour microenvironment which 
regulate self-renewal may also lead to the identification of potential 
therapeutic targets. For example, Sneddon and colleagues compared gene 
expression profiles of squamous cell carcinoma (SCC)-derived stromal cells 
versus stromal cells from nontumour skin (253). They subsequently identified 
two bone morphogenetic protein (BMP) antagonists, GREMLIN1 and 
FOLLISTATIN, which were differentially expressed in the tumour-derived 
stroma. GREMLIN1 had earlier been found to be expressed only by stromal 
cells in diverse human carcinomas, but not in corresponding normal tissues. 
In this study, the authors reported that GREMLIN1 was able to prevent 
inhibition of SCC growth by BMP in vitro. Thus inhibiting GREMLIN1 may 
serve to prevent growth of tumours.  
In addition, Prince and colleagues demonstrated that the TSC- 
containing population in well and moderately differentiated HNSCC was 
physically located adjacent to stroma, further indicating that there may be 
important interactions between the TSC and the stroma in carcinomas (202). 
Supporting data also came from Calabrese and colleagues who found that 
CD133+Nestin+ cells which contained the TSC fraction were associated with 
vasculature (254). Another publication showed that endothelial cells supplied 
secreted factors which maintained the brain TSCs in vitro in a self-renewing 
and undifferentiated state. Finally, increasing the number of endothelial cells 
or blood vessels in xenografts expanded the TSC population and accelerated 
their growth, while antiangiogenic therapies depleted the TSCs from the 
xenografts and arrested tumour growth.  
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Thus the concept of the role of a TSC niche and the potential of 
inhibiting its interactions with TSC populations appears to be an approach 
with a great deal of therapeutic potential, both for disease treatment and for 
chemoprevention (255). Furthermore, the identification of the TSC niche 
should allow the development of in vitro assay systems that mimic the in vivo 
environment, providing more rapid results than the currently cumbersome and 
time-consuming in vivo assays, as well as allowing manipulations that are 
currently not feasible with in vivo systems.  
1.3.5.3. Sensitizing chemoresistant TSCs to cytotoxic therapies 
In a glioma study, the population of cells enriched for glioma TSCs was 
dramatically increased by irradiation. This showed that irradiated TSCs 
possessed survival advantages relative to the non-TSC population.  
Radioresistant tumours also displayed an increased percentage of the TSC 
population when compared to the parent cell population. Furthermore, 
radiation had little effect on the ability of TSCs to regrow tumours. Therefore, 
it has been speculated that the TSC-enriched cell population might avoid 
radiation-induced cell death through activation of DNA damage repair 
mechanisms (256). As most cytotoxic therapies used for cancer therapy 
damage DNA or disrupt mitosis to induce cell death in highly proliferative 
tumour cells, the apparent resistance of TSCs to radiation-induced DNA 
damage toxicity suggests that TSCs also play a role in mediating 
chemotherapy resistance in tumours.  
Indeed, a separate group later reported that TSCs from gliomas 
displayed marked resistance to several chemotherapeutic agents such as 
carboplatin and paclitaxel relative to the non-TSC population (257). A year 
later, Hermann and colleagues reported the discovery of a stem cell-like 
subpopulation of pancreatic cancer cells which exhibited strong resistance to 
the drug, gemcitabine, both in vitro and in vivo (189). Recent data also 
suggested that preferential Akt activity may confer chemotherapy resistance 
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to hepatocellular carcinoma TSCs (258). However, colon TSCs, which were 
shown to have baseline resistance to cell death induced by fluorouracil or 
oxaliplatin treatment, could be chemotherapy sensitised by an interleukin-4 
blocking antibody (259). As mentioned earlier, Landon and colleagues 
successfully silenced ALDH using nanoliposomal siRNA in order to sensitise 
both taxane- and platinum-resistant cell lines to chemotherapy. This 
significantly reduced tumour growth in mice compared with chemotherapy 
alone (238). Therefore, these findings suggest that chemoresistant 
phenotypes of TSCs can be manipulated in efforts to sensitise TSCs to 
cytotoxic chemotherapies.  
 
 
 
 
 
 
 
 
 
 
1.3.6. Conclusion 
Based on the TSC concept, traditional treatments may not be effective 
in this cell population and novel therapies need to be developed, focusing on 
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their ability to eradicate the TSC subpopulation by targeting TSC-specific 
characteristics for novel and more effective antitumour treatments. In view of 
this need, we sought to generate novel mAbs which specifically targeted 
ovarian TSC subpopulations.  
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1.4. Aims of the project 
Hypothesis 1: TSCs in ovarian cancer possess stem cell-like properties 
- To identify rare subpopulation of cells in ovarian cancer cell lines using 
functional assays 
- To characterise these cell subpopulations through a series of in vitro 
and in vivo experiments 
Hypothesis 2: Specific mAbs can be generated to target novel surface  
markers on ovarian TSCs  
- To generate mAbs against isolated ovarian TSC subpopulations 
- Identification of novel mAbs which fulfill selection criteria  
- To further characterise mAbs by performing in vitro and in vivo 
experiments 
- Identification of novel target antigen(s) on ovarian TSCs which mAbs 
target 
Hypothesis 3: Ovarian TSC mAbs confer cytotoxic/cytostatic properties   
                       towards ovarian TSCs  
- To perform cytotoxicity and clonogenic assays of TSC and non-TSC 
Hypothesis 4: Novel target antigens may be useful as prognostic  
                            markers in EOC 
- analysis of novel target antigens in gene expression profiling and 
immunohistochemistry studies of ovarian cancer
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Materials and 
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2.1. Nucleic acid analysis 
2.1.1. Nucleic acid concentration measurement 
DNA and RNA concentration was quantified and the purity assessed with 
NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies, USA). 
2.1.2. DNA sequencing 
Sequencing reactions were outsourced to the commercial company, 1st Base, 
after adjusting concentration and volume of DNA sample as instructed.  
2.1.3. Quantitative real time-PCR analysis (RT-qPCR) 
Briefly, cDNA obtained as later described (section 2.3.8.1) was added to a 
mixture of 2x Taqman master mix, 20x Taqman gene expression assay and 
RNase free water in each well of a 96-well plate (Table 2.1).  Thereafter, 
reactions were run in 96-well plate formats using the TaqMan system on an 
ABI-7000 Real Time polymerase chain reaction (PCR) machine (Applied 
Biosystems, USA). The samples were thermocycled using the following 
programme: 95ºC for 10 seconds, 40 cycles; 95ºC for 3 seconds and 56ºC for 
20 seconds, which was followed by an acquisition step after each cycle. A 
dissociation step (95ºC for 15 seconds, 56ºC for 15 seconds, 95ºC for 15 
seconds) was added to generate the melt curve. The results were further 
analysed using the Step One PCR software (Applied Biosystems, USA). The 
expressions of the abovementioned genes were normalised using the 
endogenous genes, 18S and GAPDH. Gene assay IDs used for RT-qPCR are 
provided in Appendix 1.  
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Reagent Volume 
cDNA 1 μL 
2x Taqman master mix 10 μL 
20x Taqman gene expression assay 1 μL 
RNase free water 8 μL 
Table 2.1. Components of RT-qPCR reaction mix. 
2.1.4. Gene expression array 
The Human genome HGU133 Plus 2.0 array (Affymetrix, #900470), an 
oligonucleotide-probe based gene array chip containing ~50,000 transcripts 
which provides a comprehensive coverage of the whole human genome, were 
used in our microarray studies.  
2.1.5. RNA isolation and hybridisation to oligonucleotide 
arrays 
Total RNA was isolated using the Qiagen RNeasy kit (Qiagen, #74106) 
according to the manufacturer’s instructions. RNA integrity was first assessed 
by loading 1 μL aliquot of total RNA onto an RNA Labchip (Agilent 
Technologies, #5065-4476) and analysed on an Agilent 2100 Bioanalyser 
(Agilent Technologies, UK). The RNA integrity number (RIN) is a standardised 
numerical representation of RNA integrity, where 10 represents the most 
intact RNA on a scale of 1 to 10. In our experiments, RINs obtained for all 
RNA samples varied between 9.0 and 10.0 (RIN values above 8 are typically 
accepted for microarray applications). The traces were also assessed visually 
and accepted when two well-defined peaks corresponding to the 18S and 28S 
ribosomal RNAs were present. The OD 260 nm /OD 280 nm ratios of the 
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pooled RNA samples as measured by a NanoDrop® ND-1000 
Spectrophotometer varied between 2.05 and 2.10 (typical values 
recommended for microarray experiments are 1.9-2.1). 
The 3’IVT Express Kit (Affymetrix, #901228) was then used to prepare the 
sample for hybridisation onto gene expression arrays according to the 
manufacturer’s protocol. Briefly, reverse transcription of total RNA was 
performed to synthesize first-strand cDNA. This cDNA was then converted 
into a double-stranded DNA template for transcription. In vitro transcription 
synthesized aRNA and incorporated a biotin-conjugated nucleotide. The 
aRNA was then purified and fragmented for hybridisation using the GeneChip 
Hybridisation, Wash, and Stain Kit (Affymetrix #900720). Biotinylated cRNA 
was first hybridised to the gene chip array at 45°C for 16 hrs. The chip was 
then washed and stained with phycoerytherin (PE)-streptavidin. Finally, the 
chips were scanned with the Gene Chip Scanner 3000 (Affymetrix, USA) and 
raw expression data obtained was normalised by the RMA method (260).  
2.1.6. Microarray data analysis 
Expression values of multiple probes targeting the same gene were averaged, 
resulting in a total of 20323 unique genes to assess the differential expression 
using the Rank Product package in R Bioconductor statistical software (261). 
The Rank Product test is a nonparametric test, which is particularly applicable 
for small sample sizes and deviation from assumed underlying probability 
distributions in microarray analyses (262). Genes were considered to be 
regulated between two subsets if the rank product showed a false discovery 
rate (FDR) below 5%. Genes above this threshold were considered to be not 
regulated.  
Gene set analysis (GSA) was performed with the R software using the GSA 
package (263, 264). Paired comparison was carried out between two 
populations with the average signals of the probes mapped to one gene. The 
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gene sets tested in GSA are listed in Appendix 2. The enrichment of gene 
sets was determined at a FDR of <5%.  
Gene ontology studies were performed using the web-based programme, 
DAVID. Lists of genes (earlier identified by the Rank Product test as being 
upregulated or downregulated) were uploaded onto this website where the 
functional term of the candidate genes was compared to the functional term of 
all the genes on the microarray. The enrichment of functional terms was 
defined at FDR<5%.  
2.2. Protein analysis 
2.2.1. SDS-PAGE and Western blotting 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and 
Western blotting were performed by the methods of Laemmli (265) and 
Towbin (266) respectively. Briefly, eluates from IP were separated by SDS- 
PAGE (NuPAGE 4–12% gradient gel; Invitrogen, #NP0322BOX) under 
reducing conditions followed by either Western blotting or silver staining. For 
Western blotting, resolved proteins were transferred onto polyvinylidene 
fluoride membrane (PVDF; Millipore, #IPVH07850) at 110 volts for 90 min. 
Thereafter, the membrane was blocked with 5% skimmed milk dissolved in 
0.1% Tween-20/PBS. The membrane was then immunoblotted overnight at 
4°C with in-house mAb culture supernatant or commercial mAbs to human 
CHC1 (BD Bioscience, #610500; Thermo Scientific, #MA1-065; Lifespan, 
#LS-C22244) followed by horseradish peroxidase (HRP)-conjugated goat 
anti-mouse antibodies (1:10,000 dilution; DAKO #044701). Binding of HRP-
conjugated secondary antibodies was visualised by Immobilon Western 
Chemiluminescent HRP Substrate (Millipore, #WBKLS0100).  
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2.2.2. Silver staining 
Silver staining was performed using SilverQuest silver staining kit (Invitrogen, 
#LC6070) according to the manufacturer’s protocol and the protein band 
corresponding to the band on the Western Blot was manually excised for 
subsequent mass spectrometry (MS) analysis.  
2.2.3. In-gel digestion and mass spectrometry (MS) analysis 
Protein bands were treated before MS analysis. Briefly, the bands were 
soaked overnight at 4°C in washing solution (2.5 mM ammonium bicarbonate 
in 50% acetonitrile) followed by a 20 min incubation at 37°C after a change of 
wash solution. They were then dried, reduced with dithiothreitol and alkylated 
with iodoacetamide before trypsin digestion. The extracted peptides were 
analysed using QSTAR quadrupole-time of flight tandem MS (ABI/MDS-Sciex, 
Canada). Proteins were identified by searching raw files against the human 
subset of UniProt database (EBI) using the Mascot search engine (Matrix 
Science, USA). Only protein identity with a minimal of 95% probability match 
and 2 matched peptide fragments were considered.  
2.2.4. Immunoprecipitation (IP)  
First, IGROV1 membrane protein extracts were obtained using the ProteoJET 
Membrane Protein Extraction Kit (Fermentas, #K0321) according to the 
manufacturer’s instructions. IP of the antigen was then carried out using the 
automated Phynexus MEA system (Phynexus, USA). Briefly, rabbit  antibody 
conjugated with biotin (Open Biosystems, #SAB5695) was captured onto a 
Streptavidin Phytip column (5 μL of resin beads). The column was 
functionalized with either in-house mAb or the commercially-available CHC1 
antibody (BD Bioscience, #610500). Clarified membrane protein extracts were 
then passed through the column. After washing away unbound proteins with 
wash buffer I (10 mM NaH2PO4/140 mM NaCl pH 7.4), bound proteins were 
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eluted at low pH with Elution Buffer (200 mM NaH2PO4/140 mM NaCl pH 2.5) 
and neutralised immediately with 1 M Tris-Cl pH 9.0.  
2.3. Cell culture and cell line-based assays 
2.3.1. Basic maintenance of cell lines 
The ovarian cancer cell lines, IGROV1, HEYA8, PEA1, and the normal 
immortalised ovarian cell lines, OSEC2 and IOSE21, were all maintained in 
RPMI 1640 medium containing 10% fetal bovine serum (FBS). IGROV1 (267), 
PEA1 (268) and OSEC2 (269) were obtained from Ovarian Cancer Action, 
Imperial College, London, UK while IOSE21 and HEYA8 were obtained from 
Professor Frances Balkwill, Institute of Cancer, Centre for Cancer and 
Inflammation, Barts and The London School of Medicine and Dentistry, 
London, UK, and Professor Jean Paul Thiery, Institute of Molecular and Cell 
Biology, A*STAR, Singapore, respectively. The normal immortalised breast 
cell line, U19-BrSE, was obtained from Dr. Arthur McKenzie, Imperial College, 
London, UK, and maintained in DMEM-F12 plus medium supplemented with 
10% FBS, 1% penicillin/streptomycin, 1% glutamine, 2.5 mL of 1 mg/mL 
insulin, 0.5 mL of 1 mg/mL hydrocortisone, 10 µL of 1 mg/mL EGF, and 10 µL 
of 1 mg/mL cholera toxin.  
The human embryonic stem cell line, HES-3, was obtained from ES Cell 
International (ESI, Singapore) and cultured on matrigel coated organ culture 
dishes supplemented with conditioned medium from mouse feeders (270). To 
induce hESC differentiation in vitro, HES-3 cells were harvested as clumps 
and cultured as embryoid bodies (EB) for 7 days in EB-medium (80% KO-
DMEM, 20% FBS, 25 µg/mL penicillin, 25 µg/mL streptomycin, 2 mM L- 
glutamine, 0.1mM NEAA, and 0.1 mM 2-mercaptoethanol) on nonadherent 
suspension culture dishes (Corning Life Sciences, #3261) (271).  
 
84 
 
 
The human embryonic kidney cell line (HEK293) and lung fibroblast cell line 
(IMR-90) were obtained from the American Type Culture Collection (ATCC; 
Rockville, USA) and maintained in Dulbecco's modified eagle medium 
(DMEM; Invitrogen, #41965-062) supplemented with 10% FBS, 1% 
penicillin/streptomycin and 2 mmol/L L-glutamine.  
All cell lines were cultured at 37°C in a 5% CO2 incubator apart from the 
OSEC2 cell line which was kept at 33°C. The cell lines, IGROV1, PEA1, 
OSEC2 and IOSE21, were shown to be identical to those received based on 
DNA methylation pattern analysed within one month of use and the 
methylation patterns showed close similarity between samples from the same 
patient. Otherwise, no other authentication was carried out.  
2.3.2. Identifying ovarian TSCs 
For SP studies, cells (106 cells/mL) from the IGROV1 ovarian cancer cell line 
were incubated in DMEM containing 2% FBS, 10 mM HEPES (Gibco, 
#11344-041), and Hoechst 33342 (5 µg/mL; Invitrogen, #H3570) at 37ºC for 
60 min. As a control, cells were incubated as described above with the 
addition of 50 µmol/L verapamil. Cells were pelleted by centrifugation, 
resuspended in phosphate-buffered saline (PBS), and maintained at 4ºC until 
analysis/sorting. The Aldefluor kit (StemCell Technologies, #01700) was used 
to identify TSC populations with a high ALDH enzymatic activity according to 
the manufacturer’s instructions.  
2.3.3. Double staining procedure with Hoechst 33342           
dye      and      Aldefluor 
Double staining with the Hoechst 33342 dye and Aldefluor reagent was 
performed according to a protocol described by Pearce and Bonnet (272). 
Hoechst labeling was performed first, followed by the Aldefluor assay. Once 
stained, cells were maintained at 4ºC until analysis (within 1 hr). 
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Compensation was carried out by analysing singly stained samples using the 
Flowjo software.  
2.3.4. Analysis and isolation of ovarian TSCs by fluorescence- 
activated cell sorting (FACS) 
All flow cytometric experiments were conducted on either the FACScalibur or 
FACSAria fluorescence-activated cell sorter (Becton Dickinson) and analysed 
using the Flowjo software (Tree Star, Inc.). The Hoechst 33342 dye was 
excited at 350 nm, and its fluorescence was measured at two wavelengths 
using a 450 BP 20 and a 675 EFLP optical filter (Omega Optical, Brattleboro, 
VT). SP and NSP cells were then gated according to the control sample.  
Fluorescence was excited at 488 nm and emission was detected using a 
standard fluorescein isothiocyanate (FITC) 530/30-nm band-pass filter for 
experiments involving the Aldefluor activity assay. High ALDH (Aldefluor- 
positive) and low ALDH (Aldefluor-negative) cells were gated according to the 
negative control containing DEAB.  
For antibody-labeling experiments, cells were trypsinised and harvested as 
single cell suspensions, resuspended at 2 x 105 cells per 10 µL volume in 1% 
bovine serum albumin (BSA)/PBS and incubated for 30 min with each mAb 
clone (150 µL culture supernatant or 5 µg purified mAb in 200 µL 1% 
BSA/PBS) or a mAb to human CHC1 (BD Transduction Laboratories, 
#610500). Cells were then washed with cold 1% BSA/PBS, and further 
incubated for 15 min with a 1:500 dilution of goat α-mouse antibody FITC- 
conjugated (DAKO, #F0479). After incubation, the cells were again washed 
and resuspended in 1% BSA/PBS and 1.25 mg/mL propidium iodide (PI) for 
analysis/sorting. As a negative control, cells were stained with secondary 
FITC-conjugated antibody only. A list of antibodies used and their relevant 
details are provided in Appendix 4. 
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2.3.5. Screening of novel mAbs  
For primary screening, IGROV1 Aldefluor-positive cells were sorted by FACS 
as described earlier. After resuspending in 1% BSA/PBS, 5 x 104 cells were 
plated into each well of 96-well plates and incubated with 100 µL of 
supernatant from each of the 1109 mAb clones for 30 min at 4oC to prevent 
internalisation of surface antigens. 96-well plates were centrifuged at 400g for 
5 min and supernatant was discarded. Cells were then washed again with 1% 
BSA/PBS and incubated with FITC secondary antibody (DAKO, #F0429) at 
4oC for 15 min. After a final wash, cells were resuspended in 1% BSA/PBS 
and analysed on a flow cytometer. Secondary screening was carried out 
similarly on the following whole cell lines – IGROV1, PEA1, HEK293, IMR90 
and hESC.  
2.3.6. Establishment of hybridoma lines  
Once candidate hybridomas were identified, they were expanded and cells 
were frozen. When the growing hybridomas were 25% to 50% confluent in the 
96-well plate (master well), they were transferred to wells in a 24-well plate.  
Confluent cultures from wells in 24-well plates were centrifuged at 400g at 
room temperature. Thereafter, medium was removed and each cell pellet was 
resuspended in 500 µL of cold FBS/10% dimethyl sulfoxide (DMSO). The 
mixture was then transferred to cryotubes and stored at –150oC.  
2.3.7. Hybridoma adaptation 
As a previous study had shown that growing hybridomas in protein-free media 
facilitates downstream purification and increases purification yield of IgM 
(273), the hybridomas were adapted to in-house medium, PF-CDM. 
Adaptation of both mAb168 and mAb774 was done in 125 mL-shake flasks 
(Corning, #4442-125). The amount of Medium E was reduced and substituted 
by PF-CDM with each passage. The cells were seeded at 3 x 105 cells per mL 
and passaged at mid-log phase. 15 mL of the remaining culture medium was 
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centrifuged, and the antibody supernatant was collected and stored at 4°C for 
analysis. 
2.3.8. Cloning of mouse mAb heavy chain variable (VH) 
regions 
2.3.8.1.  Converting RNA to cDNA 
A RNA-primer mix was first prepared by adding 2 μg of RNA and 1 μg of 
oligodT primer to RNase-free water, to a final volume of 16 μL. The RNA-
primer mix was incubated for 5 min at 70°C and cooled on ice to remove the 
RNA secondary structure. Thereafter, the mix was added to a reaction 
cocktail including M/MLV reaction buffer, M/MLV Reverse Transcriptase, 
dNTP and RNase Inhibitor to make up a final volume of 30 μL (Table 2.2).  
Reagent Volume 
M/MLV rxn buffer 10 μL 
M/MLV RT 1 μL 
dNTP (10mM) 2 μL 
RNase Inhibitor 1 μL 
RNA-primer mix 16 μL 
Table 2.2. Components of RNA reverse transcription reaction mix. 
The samples were then incubated for 5 min at 25°C and an hour at 42°C, 
followed by 15 min at 70°C to inactivate the M/MLV Reverse Transcriptase. 
For each RNA sample, a control reaction was run in identical conditions 
without adding the M/MLV Reverse Transcriptase.  
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2.3.8.2.  Amplification of cDNA 
The presence of cDNA in the reverse transcription (RT) reaction product and 
the absence of residual genomic DNA in the control reactions were confirmed 
by performing a PCR amplification using primers for the mouse heavy chain 
variable (VH) region. The cDNA was added into a PCR mix including 5x buffer, 
MgCl2, dNTP mix, primers and Taq polymerase (Table 2.3). The PCR 
programme used was as follows: 95ºC for 2 min, 30 cycles: 95ºC for 1 min, 
52ºC for 1 min, 72ºC for 1 min; followed by the final elongation step: 72ºC for 
5 min. The sequences of primers used for PCR are provided in Appendix 3. 
 
Reagent Volume 
5x buffer 10 μL 
MgCl2 3 μL 
dNTP (10mM) 1 μL 
VH1 Forward and 
Reverse Primers 
2.5 μL each 
Taq polymerase 1 μL 
cDNA template 5 μL 
Water 20 μL 
Table 2.3. Components of PCR reaction mix. 
2.3.8.3.  Separation of bands via agarose electrophoresis 
The PCR products were separated on 1% agarose/TAE gel with 0.5 μg/mL 
ethidium bromide and visualised in UV light.  
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2.3.8.4.  Gel extraction 
Gel extraction was performed using the commercially available QIAquick gel 
extraction kit (Qiagen, #28704). Briefly, excised gels were weighed before 
adding 3 volumes of Buffer QG to 1 volume of gel. Gels were then incubated 
at 50°C for 10 min to dissolve the gels. After adding 1 gel volume of 
isopropanol, gels were applied a QIAquick spin column and centrifuged for 1 
min. Another 0.5 mL of Buffer QG was added after flow-through was 
discarded. The column was then centrifuged again for 1 min. Thereafter, 0.75 
mL of Buffer PE was added to the column to wash. Finally, DNA was eluted 
by adding 30 μL of DNase-free water, followed by centrifugation for 1 min. A 
gel was run as described earlier to check integrity of sample. Finally, 
concentration of the DNA was measured. 
2.3.8.5.  Ligation 
Ligation was performed by adding the DNA insert into a mixture consisting of 
ligase buffer, T4 DNA ligase, pGEM-T vector and water (Table 2.4). The 
reaction mix was then incubated at room temperature for 1 hr.  
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Reagent Volume 
Ligase buffer (2x) 5 μL 
T4 DNA ligase 1 μL 
pGEM-T vector 1 μL 
DNA insert 2 μL 
Water 1 μL 
Table 2.4. Components of ligation reaction mix. 
2.3.8.6.  Heat shock transformation 
The ligation mix was added to 50 μL of competent E.coli and incubated on ice 
for 1 hr. Thereafter, the mixture underwent heat shock at 42°C for 2 min. After 
the mixture was cooled on ice for 2 min, 300μL of SOC media was added to 
the mixure and incubated at 38°C for 1 hr, shaking at 400rpm. Finally, 150 μL 
of mixture was then spread on prewarmed LB plates and incubated at 37°C 
overnight. 
2.3.8.7.  Colony PCR 
Each colony was transferred into a PCR tube containing buffer, MgCl2, 
dioxynucleotide triphosphates (dNTP), primers, Taq polymerase, and water 
(Table 2.5). 1.5 μL of bacteria suspension was then transferred onto 
prewarmed LB-ampicillin plates. After incubation at 37ºC overnight, colony 
PCR was performed by using the following programme: 95ºC for 2 min, 30 
cycles: 95ºC for 1 min, 52ºC for 1 min, 72ºC for 1 min; followed by the final 
elongation step: 72ºC for 5 min. The sequences of primers used for colony 
PCR are provided in Appendix 3. 
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Reagent Volume 
5x buffer 5 μL 
MgCl2 2 μL 
dNTP (10mM) 1 μL 
M13/pUC Forward and 
Reverse Primers 
2.5 μL 
each 
Taq polymerase 1 μL 
Bacteria suspension 5 μL 
Water 6 μL 
Table 2.5. Components of colony PCR reaction mix. 
2.3.8.8. Plasmid isolation 
Transformed colonies were first transferred from LB agar plates to the tubes 
containing LB broth:ampicillin (1000:1). Tubes were then incubated at 37ºC 
overnight, shaking at 250rpm. Thereafter, plasmid isolation was performed 
using the Promega Wizard Plus SV Minipreps DNA purification system 
(Promega #A1330). Briefly, the bacteria culture was transferred to a 15 mL 
tube and spun at maximum speed for 10 min. The cell pellet was then 
resuspended with 250 μL of Cell Suspension Buffer and transferred to a 1.5 
mL tube. After adding 250 μL of Cell Lysis Buffer and 10 μL of Alkaline 
Protease Solution, the tube was left to stand at room temperature for 5 min. 
350 μL of Neutralization Buffer was then added and the lysate was 
centrifuged at top speed for 10 min at room temperature. The cleared lysate 
was decanted into Spin Columns and centrifuged at top speed for 1 min at 
room temperature. Flow through was then discarded and the column was re-
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inserted. Thereafter, 750 μL of Wash Solution was added and the column was 
centrifuged at top speed for 1 min.  
2.3.9. Immunofluorescence (IF) studies on cell lines 
0.2 x 106 IGROV1 cells and hESCs were grown in adherent 6 well plates for 
approximately 48 hrs. The cells were then washed with pre-warmed RPMI 
1640 medium (Invitrogen, UK) and fixed in 4% paraformaldehyde for 30 min 
at room temperature. Following 3x5 min washes with PBS, the cells were 
incubated with mAb culture supernatant overnight at 4oC. Binding of the 
antibody to cell surfaces was then visualised using goat α–mouse antibody 
conjugated with PE (1:500 dilution; DAKO, #R0480). Mounting media 
contained DAPI (Vector laboratories; #H-1200) to counterstain cell nuclei. For 
Oct4 staining in hESC, the same procedure was performed using a mouse 
mAb to Oct4 (Santa Cruz, #sc-8628) at a 1:20 dilution and an additional 
permeabilization step using Triton-X for the detection of intracellular antigens.  
2.3.10. Cell proliferation studies  
Spheroid assays involved gating and sorting (2500 cells/well) detected 
subpopulations into separate wells in non-adherent 6-well plates (Sigma-
Aldrich; #CLS3471) containing DMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin and 2 mmol/L L-Glutamine. Cells were incubated for 18 
days in a 37oC incubator and then transferred to adherent 6-well plates 
(Sigma-Aldrich; #CLS3516). Media was changed 24 hr after plating onto 
adherent plates and cells were allowed to grow for up to 12 days. Thereafter, 
colonies were fixed for 15 min in 3.8% formaldehyde and stained in 1% w/v 
Rhodamine B (Sigma-Aldrich; #R6626). Finally, stained cells were washed 
with several changes of tap water and air dried overnight at room 
temperature. The size and number of colonies formed were determined using 
a IX70 Olympus microscope (Olympus, USA) and a commercially available 
image-analysis software package, Image-Pro (Media Cybernetics, USA).  
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2.3.11. Invasion assay 
Detected subpopulations were separated by sorting as described earlier. 
Each subpopulation was then subjected to an invasion assay (Chemicon, 
#ECM550) according to the manufacturer’s instructions. Briefly, 300 μL of pre- 
warmed serum free RPMI were added to the interior of the inserts for 1 hr at 
room temperature to rehydrate the extracellular matrix layer. Thereafter, the 
media was removed and a cell suspension containing 0.2 x 106 cells was 
added to the inserts while 500 μL of media containing 10% FBS was added to 
the lower chamber. After a 24 hr incubation period, cotton- tipped swabs were 
used to gently remove non-invading cells as well as the ECMatrix gel from the 
interior of the inserts. 500 μL of staining solution was then added to the 
unoccupied wells of the plate and invasive cells on lower surfaces of the 
membranes were stained by dipping inserts in the staining solution for 20 min. 
After dipping the inserts in a beaker of water several times to rinse, inserts 
were left to air dry. Finally, quantification was performed by dissolving stained 
cells in 10% acetic acid (200 μL/well) and transferring 100 μL of the 
dye/solute mixture to a 96-well plate for colorimetric reading at OD 560nm. 
2.3.12. Clonogenic assay 
IGROV1 cells were plated at a density of 8 x 104 cells per each 25 cm2 tissue 
culture flask. Cells were then allowed to grow for 2 days so that they were in 
the exponential phase of growth for antibody addition. Thereafter, mAb774 
was added at 2-fold dilutions. For example, 4mL of mAb774 was added to 
4mL growth medium. 4mL of this solution was then transferred to the next 
tube which contained 4mL growth medium. The final concentrations of 
mAb774 in each flask were 0.2mg/mL, 0.1mg/mL, 0.05mg/mL and 
0.025mg/mL. Buffer which mAb774 was diluted in was used as a control. After 
an incubation period of 24 hr, cells were trypsinized and diluted to a density of 
10 000 cells/mL. 1 mL of cell suspension was then transferred to each Petri 
dish. Thereafter, 4 mL of growth medium was added to each Petri dish. After 
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an incubation period of 5 days, medium was removed and cells were washed 
with PBS. Colonies were then fixed for 15 min in 3.8% formaldehyde and 
stained in 1% w/v Rhodamine B (Sigma-Aldrich; #R6626). Finally, stained 
cells were washed with several changes of tap water and air dried overnight 
at room temperature. The size and number of colonies formed were 
determined using a IX70 Olympus microscope (Olympus, USA) and a 
commercially available image- analysis software package, Image-Pro (Media 
Cybernetics, USA).  
2.3.13. Cytotoxicity assay 
IGROV1 cells were plated at a density of 1 x 103 per well in 96-well plates. 
Cells were then allowed to grow for 2 days so that they were in the 
exponential phase of growth for antibody addition. Thereafter, mAb774 was 
added at 2-fold dilutions. For example, 200 µL of mAb774 was added to 200 
µL growth medium. 200 µL of this solution was then transferred to the next 
tube which contained 200 µL growth medium. The final concentrations of 
mAb774 in each well were 0.2mg/mL, 0.1mg/mL, 0.05mg/mL and 
0.025mg/mL. Buffer which mAb774 was diluted in was used as a control. 
Plates were then incubated at 37oC for either 24 hr, 48 hr or 72 hr. Cell 
viability at each timepoint was determined using the commercially available 
Alamar Blue assay (Invitrogen, #DAL1025), according to the manufacturer’s 
instructions. Control wells contained only cells plated at the same density.  
2.4. Patient sample analysis 
2.4.1. Preparation of ascites 
Patient ascites were centrifuged using the following settings – Acceleration: 9; 
Decceleration: 9; Speed: 400g; Time: 5 min at room temperature. Thereafter, 
the supernatant was discarded and the pellet was washed with PBS. After 
passing through cell strainers to remove remaining fat aggregates, the cells 
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were resuspended in 15 mL of PBS for Ficoll gradient separation (274, 275)  
and carefully laid over 15 mL of Histopaque (Sigma-Aldrich, #11191) in a 50 
mL Falcon tube. The tube was then centrifuged using the following settings - 
Acceleration: 1; Decceleration: 0; Speed: 450g; Time: 20 min at RT. The 
interphase mononuclear layer was transferred to a fresh conical tube and 
washed twice with PBS. The cells were then incubated with 1 mL 
TrypleExpress (Invitrogen, #12604-013) for 5 min at 37oC and with 1 mL 
Human Erylysis Buffer (R&D Systems, WL1000) for another 5 min at room 
temperature. After washing with PBS, the cells were resuspended in a 
freezing mix containing 10% DMSO and 90% FBS and stored in liquid 
nitrogen before being thawed for IF studies. 
2.4.2. Isolation of EpCAM-positive cells from patient ascites 
samples 
First, cell number in each ascites sample was determined. Thereafter, the cell 
suspension was centrifuged and supernatant was aspirated. Cell pellet was 
then resuspended in 300 μL of buffer per 5 x 107 total cells. Next, 100 μL of 
FcR Blocking Reagent per 5 x 107 total cells was added. This was followed by 
the addition of 100 μL of CD326 (EpCAM) Microbeads (#130-061-101) per 
5x107 total cells. The mixture was then incubated at 4oC for 30 min. Cells 
were then washed and resuspended in 500 μL of buffer. Cell suspensions 
were applied to prerinsed MS columns were placed in the magnetic field of 
the MACS separator. Unlabeled cells which passed through were collected 
and the column was washed thrice with buffer. Finally the column was 
removed from the separator and placed on a suitable collection tube. 1 mL of 
buffer was pipette onto the column and the magnetically labeled cells were 
immediately flushed out by firmly pushing the plunger into the column.  
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2.4.3. Cytospinning of ascites onto slides for IF studies 
Ascites were thawed and washed twice with cold 2% FBS-PBS. Samples 
were then diluted to 1 x 106 cells/mL in 1% cold BSA-PBS. Thereafter, slides 
and filters were placed into appropriate slots in the cytospin with the 
cardboard filters facing the center of the Thermo Shannon CytoSpin machine 
(Thermo Scientific, UK).  100 μL of cold 1% BSA-PBS was first aliquoted into 
each of the wells and spun for 1 min to pre-wet the filters before 100 μL of 
each sample was added into the wells.  The samples were spun at maximum 
speed for another 3 min. Finally, filters were removed from their slides and 
slides were stored at -80oC for subsequent IF studies.  
2.4.4. IF studies on patient samples 
Ascites samples on cytospun slides were incubated with purified mAb774 at a 
dilution of 1:80 in 0.1% gelatin/PBS and incubated for 1 hr at room 
temperature in a humidified chamber. Subsequently the slides were washed 
and incubated in 1:500 HRP goat anti-mouse IgM (Invitrogen #62-6820) in 
0.1% gelatin/PBS for 45 minutes at room temperature. From this point the 
slides were protected from direct light exposure whenever possible. After the 
incubation, the slides were washed with PBS 5 x 10 min and mounted with 5 
μL of VECTASHIELD mounting medium with DAPI (Vector Laboratories 
#H1200). The edges of the coverslips were sealed with a transparent nail 
polish and the cells were visualised with a confocal microscope. 
Patient tissue sections were first deparaffinized and rehydrated before being 
placed in 0.3M glycine/PBS solution at pH7.4 to quench autofluorescence. 
Following washes in PBS, the sections were microwaved for 20 min in DAKO 
retrieval solution (DAKO, #S1700) as an antigen retrieval procedure. Slides 
were then incubated for 30 min at room temperature with 0.3% hydrogen 
peroxide to quench endogenous peroxidise activity. Subsequently, to block 
non-specific protein binding, slides were incubated for 30 min at room 
temperature in 10% normal horse serum. The appropriate dilution of primary 
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antibody in 0.1% gelatin/PBS (1:500 ABCB1; 1:400 purified mAb774) was 
applied to the sections overnight at 4°C. After washes with PBS, the slides 
were incubated with anti-mouse IgG2b 647 in 0.1% gelatin/PBS (1:400, 
Sigma #F9887) for 1 hr at room temperature, followed by incubation with anti- 
ALDH1A1 in 0.1%/PBS-Triton (1:500 dilution) overnight at 4°C. From this 
point, the slides were protected from direct light exposure whenever possible.  
Following washes with PBS, the samples were incubated with goat anti-rabbit 
IgG HRP in 0.1%/PBS-Triton (1:500). Slides were then incubated with FITC 
TSA working solution (1:50 in 1x Plus Amplification Diluent) for 7 min at room 
temperature. This was followed by further washes with PBS-Triton and 
incubation of the slides in 1% hydrogen peroxide for 15 min at room 
temperature. Afterwhich, slides were incubated with HRP goat anti-mouse 
IgM secondary antibody (Invitrogen, #62-6820) in 0.1% gelatin/PBS for 1 hr at 
room temperature. Following washes with PBS, the slides were incubated 
with Cy3 TSA working solution (1:40 in 1x Plus Amplification Diluent) for 7 min 
at room temperature. Finally, the staining was visualised and mounted with 
DAPI hard set medium (Vectashield). The edges of the coverslips were 
sealed with a transparent nail polish and the cells were visualised with a 
confocal microscope. 
2.5. In vivo experiments  
2.5.1. In vivo grafts 
IGROV1 subpopulations detected by mAb774 were sorted by flow cytometry 
as described earlier and resuspended in ice cold 50% Matrigel (BD 
Biosciences, #356234) in RPMI1640 at 50 μL per xenograft. 100 cells were 
injected into the mammary fat pad of 10 week-old NOD/SCID mice (Charles 
River, France) and allowed to grow for up to 12 weeks. Up to 1000 unsorted 
cells were grafted as a positive control for cell viability and graft take. Tumour 
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size was monitored by caliper measurements across 2 diameters (d) at 
regular intervals to calculate tumour volume (cm3) = 4/3π [(d1+d2)/4]3. 
2.5.2. Generation of novel mAbs 
Two 6-week old female BALB/c mice received six consecutive weekly 
immunisations of 1x106 sorted IGROV1 Aldefluor-positive cells suspended in 
monophosphoryl-lipid A + trehalose dicorynomycolate (MPL+TDM) adjuvant 
(Sigma- Genosys, #S6322) in the intraperitoneal cavity. Splenocytes from the 
mice were fused with SP2/0 mouse myeloma cells using the ClonalCell-HY 
Hybridoma Cloning Kit (Stem Cell Technologies Inc., #03800). 10–14 days 
after plating, hybridomas were isolated and cultured in 96-well followed by 24- 
well tissue culture plates containing Medium E. Culture supernatant from each 
hybridoma was then collected and reactivity to a panel of cell lines was 
assessed by flow cytometry. Isotyping was performed using the ClonalCell-
InstantCHEK Isotyping Kit (Stem Cell Technologies). Finally, 34 clones which 
exhibited specificity to ovarian TSCs were identified and kept for further 
characterisation experiments. Animal experiments were performed in 
accordance with The National Advisory Committee for Laboratory Animal 
Research guidelines (Biopolis Institutional Animal Care and Use Committee 
approval 050,049).  
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2.6. Buffers, media and reagents 
Phosphate buffered saline pH=7.4 (PBS) 
Per 1 litre: 
Na2HPO4     1.15 g 
KaH2PO4        0.2 g 
NaCl         8.0 g 
KCl         0.2 g 
 
PBS-Tween (PBS/T) 
0.1% Tween 20 PBS 
 
PBS-Triton  
0.5% Triton PBS 
 
PBS-glycine 
0.3M glycine PBS 
 
Tris Buffered Saline pH=7.6 (TBS) 
Per 1 litre: 
Tris Base      2.42 g 
NaCl         8.0 g 
 
TBS-Tween (TBS/T) 
0.1% Tween 20 TBS 
 
LB (Lauria- Bertani) media (pH=7.5) 
Per 1 litre: 
Bacto-tryptone       10 g 
Yeast extract         5 g 
NaCl         10 g 
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TAE (Tris-acetate-EDTA) buffer (pH=8.0) 
Per 1 litre: 
Tris Base     4.84 g 
Acetic acid     1.09 g 
EDTA             0.292 g 
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3.1. Monoclonal antibodies in ovarian cancer 
3.1.1. Introduction 
With various monoclonal antibodies (mAbs) against cancer-associated 
antigens being developed, these molecules have become one of the biggest 
classes of new drugs approved for the treatment of cancer. MAbs to the 
cancer antigen (CA) 125, epidermal growth factor receptor (EGFR), folate 
receptor alpha (FRA), mucin1 (MUC1) antigen, tumour associated 
glycoprotein (TAG) 72, vascular endothelial growth factor (VEGF), and tumour 
necrosis factor (TNF)-α receptor are currently undergoing evaluation in 
ovarian cancer clinical trials and results of these studies are awaited to 
confirm whether any of the mAbs may be useful in the treatment of ovarian 
cancer.  
3.1.2. Clinical trials: a review 
3.1.2.1.  CA125 
Bast & colleagues first described CA125, a 200 kD glycoprotein 
surface antigen, as a marker for epithelial malignancies in 1981 after they 
observed a raised level of the antigen in the serum of 82% of women with 
epithelial ovarian cancer but in only 1% of healthy blood donors (276). The 
potential therapeutic efficacy of the anti-CA125 mAb, Oregovomab, and the 
anti-idiotype antibody, ACA125, has since been extensively studied in 
antibody-based treatment of ovarian cancer (277).  
Oregovomab binds strongly to circulating CA125 antigens, forming 
complexes that the immune system recognises as foreign, thereby leading to 
enhanced processing of the autologous antigen-mAb complex.  In a mouse 
model of ovarian cancer, treatment with oregovomab resulted in a signiﬁcant 
reduction in tumour development in both intraperitoneal and subcutaneous 
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tumour xenografts, decreased ascites formation, and prolonged the survival of 
mice compared to untreated controls (278).  
Ehlen and colleagues evaluated the efficacy of single agent 
oregovomab in a phase II trial of 13 heavily pretreated patients with recurrent 
ovarian cancer. Immune responses to oregovomab and CA125, and 
stabilization of the disease, were observed in 58% and 23% of patients, 
respectively (279). In a separate single-arm phase II study comprising of 20 
patients with recurrent ovarian cancer, Gordon and colleagues studied the 
combination of chemotherapy and immunotherapy with oregovomab (280). It 
was found that patients who had measurable antigen speciﬁc immune 
responses demonstrated signiﬁcantly longer survival compared to patients 
who did not. In both phase II studies, oregovomab was observed to be well 
tolerated.  
However, despite these promising data, a large randomised, double-
blind, placebo-controlled trial of 145 stage III/IV epithelial ovarian cancer 
patients with a complete clinical response following chemotherapy showed 
that maintenance treatment with oregovomab did not improve outcomes in 
this patient population and no signiﬁcant difference was observed in the 
median disease-free survival between oregovomab and placebo patients 
(281). The inability of single agent oregovomab to induce a substantial 
immune response in the maintenance setting could possibly have contributed 
to the failure of this trial. This was demonstrated in another study by Braly and 
colleagues where the magnitude of the immune response with maintenance 
immunotherapy was much lower when compared to that achieved with 
combination chemoimmunotherapy (282).  
A murine anti-idiotypic antibody, ACA125, which mimics the epitope of 
the CA125 antigen, has also been developed. Vaccination with this antibody 
has been shown to induce humoral and T-cell responses to CA125 in patients 
with ovarian cancer (283, 284). In a phase I/II clinical trial, an average of 9.7 
104 
 
 
doses of ACA125 was given intramuscularly to 119 patients with ovarian 
cancer. In 68% of the patients, antigen specific immune responses were 
detected and in these patients there was a survival advantage compared to 
the patients who did not mount an immune response (285). However, a phase 
I trial performed a couple of years later involving 36 recurrent ovarian cancer 
patients to investigate the effect of subcutaneous administration of ACA125 
was prematurely terminated due to patient withdrawal or disease progression 
(286).  
3.1.2.2.  EGFR  
The EGFR is a family of four structurally similar tyrosine kinase 
receptors: ErbB1/HER1 (EGFR1), ErbB2/HER2 (HER2), ErbB3/HER3, and 
ErbB4/HER4. EGFR receptors play an important role in supporting the growth 
of ovarian cancer and interruption of receptor signaling through these 
receptors leads to inhibition of tumour growth or tumour regression as shown 
by extensive preclinical studies (287). Moreover, it has been observed that an 
estimated 30-98% of all epithelial ovarian cancers express high levels of the 
EGFR (288) and studies have shown that overexpression of EGFR is an 
independent prognostic factor for poor outcome (289). Therefore, these 
receptors have been recognised as promising targets for cancer therapy. 
Several mAbs against the extracellular domain of EGFR1 have been 
developed and evaluated in patients with ovarian cancer. Of these, the most 
advanced in clinical development is a chimeric mAb, cetuximab. In 
combination with conventional cytotoxic chemotherapeutic agents and 
radiotherapy, cetuximab had earlier demonstrated clinical activity in patients 
with EGFR-expressing solid tumours, including lung, head and neck, and 
colorectal cancers (290-292). A phase II study investigating the effects of 
cetuximab in combination with carboplatin and paclitaxel as first line therapy 
in advanced ovarian cancer also demonstrated that the combination was well 
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tolerated. However, in some cases, side effects such as anaphylactic 
reactions were observed (293).  
A humanised version of cetuximab, matuzumab, was later developed 
to counter the side effects which were observed with the chimeric mAb. 
Unfortunately, despite demonstrating efficacy as a single agent in phase I 
trials (294), there was no evidence of significant clinical activity when 
matuzumab was administered as monotherapy to a 37 platinum-resistant 
ovarian cancer patients during a phase II trial (295). 
MAbs directed against HER2, such as trastuzumab and pertuzumab, 
have also been tested in ovarian cancer clinical trials. Trastuzumab is a 
humanized antibody which recognises an epitope on the extracellular domain 
of HER2. In a mouse model of ovarian cancer, treatment with single agent 
trastuzumab significantly inhibited the growth of subcutaneous tumours 
compared to their growth in untreated controls (296). 
Given its encouraging results in breast cancer and data from preclinical 
studies of ovarian cancer, a phase II study was initiated to evaluate the single-
agent efficacy of trastuzumab in patients with advanced ovarian cancers 
overexpressing HER2 (297). It was found that only 11.4% of the 41 patients 
with recurrent ovarian cancer had tumours which overexpressed HER2. 
Moreover, although trastuzumab was well tolerated, the overall response rate 
was only 7.3% with a median progression free interval of 2 months.  
Pertuzumab is a humanized recombinant mAb which inhibits the 
dimerization of HER2 with other EGFR receptors. As several preclinical 
studies showed that pertuzumab inhibited the growth of cancer cells that do 
not overexpress HER2, it was initially thought to be more effective than 
trastuzumab in ovarian cancer therapy (298).  
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Unfortunately, in independent ovarian cancer clinical trials, it was 
observed that pertuzumab as a single agent demonstrated only modest 
responses (299, 300). A separate phase II study evaluating pertuzumab as a 
single agent in 123 platinum-refractory and -resistant patients with advanced 
ovarian cancer revealed a similarly disappointing low response rate of 4.3% 
(301).  
3.1.2.3.  FRA 
Folate Receptor α (FRA) represents an attractive target as it is 
overexpressed in at least 90% of nonmucinous ovarian cancers, including 
primary peritoneal and fallopian tube malignancies, but is largely absent in 
normal tissues (302). Increased expression of the FRA has also been 
reported in other tumour tissues, including endometrial and breast cancer, 
with the degree of FRA expression correlating with the malignant potential of 
the cancer. Moreover, in vitro studies showed that its overexpression 
conferred growth advantages to tumourigenic cells (303).  
Previous clinical studies of a FRA binding antibody, MOv18, suggested 
therapeutic benefit with no overt toxicity in ovarian cancer patients (304-306). 
More recently, Farletuzumab, a humanized mAb with high affinity for FRA, 
has undergone extensive preclinical testing to demonstrate potential efficacy 
and safety as a therapeutic agent for ovarian cancer. In vitro studies have 
demonstrated a growth-inhibitory effect of Farletuzumab on ovarian cancer 
cells expressing FRA. In addition, this mAb was found to inhibit 
phosphorylation of proteins by Lyn kinase, a member of the src family of 
kinases, thereby blocking a FRA-mediated signaling pathway important in 
tumour cell proliferation (307).  
In a Phase II trial of 54 patients with platinum-sensitive relapsed 
disease, patients who received weekly farletuzumab either as single agent or 
in combination with carboplatin and taxane, followed by farletuzumab 
maintenance, exhibited a prolonged remission when compared to their 
107 
 
 
previous remission (308). Moreover, of the 44 patients evaluable, CA125 
levels were normal in 89% of treated patients. Farletuzumab as a single agent 
and in combination was also generally well tolerated.  
The OC/TR bispecific mAb, which reacts with the FRA on ovarian 
cancer cells as well as the CD3 antigen on T-lymphocytes, was developed by 
Mezzanzanica and colleagues (309). Preclinical studies indicated that this 
bispecific mAb was able to redirect the cytolytic activity of T cells towards 
tumour cells expressing the FRA, resulting in efficient tumour-cell lysis (310). 
Phase I/II clinical trials have shown antitumour activity of up to 50% in ovarian 
cancer patients (311, 312) and this antibody has been used for intraperitoneal 
treatment with similar results and little systemic effect (313). 
3.1.2.4.  MUC1  
MUC1 is a high molecular weight transmembrane surface glycoprotein 
that is overexpressed in 90% of epithelial ovarian tumours. Due to significant 
differences in the glycosylation pattern of MUC1 in tumour cells and normal 
cells, differences in the exposed epitopes between malignant and normal cells 
are observed (314). Thus, MUC1 has been recognised as a promising 
molecular target for immunotherapy in patients with ovarian cancer. 
The murine IgG1 monoclonal human milk fat globule 1 (HMFG1) 
antibody exhibits speciﬁcity to an epitope on the protein backbone of MUC1. 
In a mouse model of ovarian cancer, intraperitoneal administration of 
radiolabeled HMFG1 significantly inhibited the growth of intraperitoneally 
inoculated tumours and the production of ascites, and prolonged the survival 
of these mice (315). The therapeutic efficacy of radiolabeled HMFG1 in the 
treatment of ovarian cancer has also been evaluated in several phase I/II 
trials. In one phase II study, 25 patients with epithelial ovarian cancer who had 
achieved a clinical complete response to standard primary treatment received 
adjuvant intraperitoneal radioimmunotherapy with 90Yttrium labeled HMFG1 
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(90Y-HMFG1). Nicholson and colleagues reported that the disease free 
survival of these patients who received 90Y-HMFG1 intraperitoneally was 
prolonged compared to matched historical controls with a 5-year survival of 
respectively 70 vs. 32% (316). Similarly, Epenetos and colleagues found an 
increased survival rate of 78% after more than 10 years of follow-up in 21 
ovarian cancer patients in complete clinical remission (CCR) who had 
received a single injection of 90Y-HMFG1 (317). Both studies revealed that 
90Y-HMFG1 was generally well tolerated in patients. 
Based on these promising results, two phase III trials were undertaken.  
The first was a randomized study by Nicholson and colleagues involving 107 
ovarian cancer patients in CCR (318). However, with a median follow-up of 40 
months, a survival advantage in patients treated intraperitoneally with 90Y-
HMFG1 could not be detected. In the second study, the Study of Monoclonal 
Antibody Radioimmunotherapy, the efficacy of 90Y-HMFG1 in the setting of 
maintenance therapy was evaluated. In this trial, 447 ovarian cancer patients 
in CCR were randomly assigned to receive intraperitoneally administered 90Y-
HMFG1 plus standard treatment or standard treatment alone. Again, with a 
median follow-up of 41 months, there was no significant difference in terms of 
time to relapse or overall survival between the two treatment groups (319). 
Furthermore, several side effects were observed, including nausea, fatigue, 
arthralgia, myalgia, thrombocytopenia and neutropenia.  
3.1.2.5.  TAG 72 
TAG 72, a pancarcinoma antigen, was initially identified in cancer 
tissues by its immunoreactivity to the mAb, B72.3 (320). TAG 72 has since 
been found to be expressed heterogeneously on most adenocarcinomas 
including gastrointestinal and ovarian cancers, but is rarely expressed in most 
normal tissues, therefore rendering it a potential target for diagnosis and 
therapy of several cancers (321).  
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Further research on the development of new antibodies directed 
against TAG 72 resulted in a series of second generation antibodies, including 
CC49. CC49 recognises a different epitope on TAG72 compared to mAb 
B72.3 and has a 10-fold higher affinity for TAG 72. CC49 has also been 
shown to exhibit high reactivity against tumour cells in most adenocarcinomas 
from colorectum, ovary, breast, stomach, and pancreas, with very little 
reactivity against normal tissues (322).  
A phase I trial involving 12 refractory ovarian cancer patients who 
received lutetium-177-labeled CC49 (177Lu-CC49) demonstrated good 
tolerability and even antitumour activity (323). Subsequently, Alvarez and 
colleagues performed a phase I/II trial of 177Lu-CC49 administered 
intraperitoneally in 27 patients with recurrent ovarian cancer (324). Follow-up 
with physical examination and CT scan revealed that prolonged disease-free 
survival was observed only in patients with microscopic disease while most of 
the patients with gross disease progressed after therapy. Bone marrow 
toxicity was also noted as the dose-limiting effect of 177Lu-CC49.  
In the setting of combination therapy, 177Lu-CC49 was administered 
intraperitoneally together with interferon-α (IFN-α) and paclitaxel in patients 
with recurrent or persistent ovarian cancer (325). This strategy was 
implemented based on reported findings that IFN-α enhanced the expression 
of TAG 72 tumour antigen and improved localization of radiolabeled antibody 
in the tumour (326). Results of this study revealed partial responses in 4 of 
the 17 treated patients and stable disease in 4 out of 27 patients without 
measurable disease. Another study involving a combination of intraperitoneal 
90Y-CC49, subcutaneous IFN-α2b and intraperitoneal paclitaxel in 20 
persistent or recurrent ovarian cancer patients was also found to be well 
tolerated (327).  
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3.1.2.6.  VEGF  
Angiogenesis, the process of development of new blood vessels from 
pre- existing ones, plays a critical role in the growth, invasion and metastasis 
of cancers. In various malignancies, angiogenesis provides nutrients to 
tumour growth, thereby allowing the tumour cells to express their initial growth 
advantage and permitting the establishment of continuity with the host 
vasculature. VEGF is a potent mediator of angiogenesis and has been found 
to be overexpressed in ovarian cancer, thus the pathway serves as a 
promising target for anti-angiogenesis therapy (328). VEGF-targeted agents 
inhibit neo-vascularization and normalise intratumoural blood vessels, 
resulting in a decrease in interstitial pressure and improved delivery of 
oxygen, nutrients, and cytotoxic agents (329).  
In 2002, Paley and colleagues found that an increased level of 
expression of VEGF was the most important prognostic risk factor for 
recurrence in patients with early stage ovarian cancer whilst intratumoural 
overexpression of VEGF and its receptor and VEGF gene polymorphisms 
associated with increased VEGF excretion have been demonstrated to be 
poor prognostic factors in ovarian cancer (330). Significantly, mAbs to VEGF 
in murine models of ovarian cancer have shown efficacy in inducing tumour 
regression as well as reversing and preventing malignant ascites (331). 
Subsequently, Bevacizumab, a 149-kDa recombinant humanized 
monoclonal IgG1 antibody directed against human VEGF, was developed. 
Binding of bevacizumab inhibits formation of new blood vessels and a 
decrease in vessel diameter, density and permeability, thus resulting in 
normalization of tumour vasculature (328, 332). In ovarian cancer preclinical 
studies, the inhibition of VEGF activity by bevacizumab inhibited growth of the 
tumour and ascites formation, as well as enhanced the efficacy of cisplatin in 
vivo (333).  
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The anti-tumour activity of bevacizumab as a single agent has been 
extensively evaluated in the treatment of patients with recurrent ovarian 
carcinoma. In 2 prospective phase II clinical trials, single-agent bevacizumab 
demonstrated clinically significant activity. The first trial consisted of patients 
with platinum-resistant heavily pretreated ovarian cancer. Of the 44 patients, 
there were no complete responders, but 7 partial responders were observed 
as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines with a progression-free survival (PFS) at 4.3 months for all patients 
(334).  
The second trial by the Gynecologic Oncology Group (GOG 170-D 
trial) assessed the response rates and 6-month PFS of intravenous 
bevacizumab in a cohort of 62 refractory or recurrent ovarian cancer patients 
with both platinum-sensitive and platinum-resistant disease (40). Data from 
this study revealed that 3 patients were in CCR, 8 patients had partial 
remission and 17 patients had progressive disease. Importantly, it was noted 
that an additional 34 patients  showed disease stabilization (335). However, 
although bevacizumab demonstrated significant single-agent activity in 
ovarian cancer, as demonstrated by the low percentage of patients who 
progressed on treatment, serious gastro-intestinal perforations in a minority of 
cases were observed.  
The effect of bevacizumab has also been examined in the setting of 
combination therapy in several phase II studies. Garcia and colleagues 
evaluated the activity of a combination of bevacizumab and oral 
cyclophosphamide in patients with recurrent ovarian cancer. Of the 70 
patients enrolled, 17 patients demonstrated a partial response while 44 
patients showed disease stabilization (336). Penson and colleagues also 
reported the activity of bevacizumab in combination with carboplatin and 
paclitaxel as a first line chemotherapy in patients with advanced Mullerian 
tumours, most of which were ovarian cancers. Of a total of 28 patients with 
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measurable disease, 11 patients demonstrated a complete response, and 10 
patients showed a partial response (337).  
More recently, two large randomized Phase III trials evaluating the 
benefit of adding bevacizumab to carboplatin and paclitaxel as a first-line 
agent and in disease recurrence have recently completed accrual. The first 
trial, GOG 218, involved a total of 1873 patients with newly diagnosed stage 
III and IV epithelial ovarian and peritoneal primary cancer (338). Of all the 
patients, 34% were optimally cytoreduced, 40% suboptimally debulked, and 
26% being stage 4. In this study, the impact on overall survival of 5 concurrent 
cycles of bevacizumab (15 mg/kg every 3 weeks) with 6 cycles of carboplatin 
and paclitaxel, when compared with 6 cycles of carboplatin and paclitaxel was 
investigated. Bevacizumab was omitted with the first cycle of chemotherapy 
as it increased the risk of wound healing complications. Furthermore, whether 
maintenance bevacizumab for 16 cycles beyond the 6 cycles of standard 
carboplatin and paclitaxel improved survival when compared with 6 cycles of 
carboplatin and paclitaxel was also evaluated. 
Preliminary data of this study presented at the 2010 meeting for the 
American Society of Clinical Oncology (ASCO) showed that patients treated 
with concurrent and maintenance bevacizumab had a median PFS of 14.1 
months compared to 10.3 months in women who received chemotherapy 
alone.  
The second phase III trial, ICON7, involved a total of 1528 patients, 
and included patients with high risk early stage ovarian cancer as well as 
advanced stage patients (339). This study had a similar design to GOG 218, 
investigating the impact on overall survival of 6 concurrent cycles of 
bevacizumab (7.5 mg/kg every 3 weeks) with 6 cycles of carboplatin and 
paclitaxel, when compared with 6 cycles of carboplatin and paclitaxel. This 
study also evaluated if maintenance bevacizumab for 12 cycles beyond the 6 
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cycles of standard carboplatin and paclitaxel improves survival when 
compared with 6 cycles of carboplatin and paclitaxel.  
Preliminary results of this study presented at the 2010 meeting of the 
European Society of Medical Oncology (ESMO) showed that median PFS 
increased from 17.3 months with chemotherapy alone to 19 months with the 
addition of bevacizumab.  
3.1.2.7.  TNF- α 
TNF-α is a 17-kDa polypeptide that binds as a homotrimer to two 
receptors, TNF-α  receptors TNFR1 (p55) and TNFR2 (p75) (340). Although 
usually undetectable in the plasma of healthy individuals, picogram 
concentrations of TNF-α protein have been detected in plasma of patients 
with advanced cancer (341). It has also been observed that both tumour and 
stromal cells in the tumour microenvironment of a variety of solid and 
haematological malignancies exhibit increased TNF-α expression (342, 343). 
Moreover, an increasing number of clinical and translational studies provide 
evidence that this inflammatory cytokine is a key regulator of the interactions 
between the tumour and stromal cells, resulting in upregulation of TNF-α-
regulated genes which stimulate tumour cell growth, survival, invasion and 
metastasis, inflammatory cell trafficking to the tumour site, and 
neoangiogenesis (344). 
Infliximab is a recombinant murine chimeric mAb that binds with high 
affinity to soluble and membrane TNF-α, thus inhibiting the binding of TNF-α 
to its receptors (345). Neutralisation of TNF-α in turn results in the reduction of 
TNF-α regulated cytokines, proteases and other growth factors at the 
inflammatory site, causing improvements in clinical symptoms and reversal of 
clinical disease. However, despite the success of infliximab treatment in 
chronic inflammatory diseases such as Crohn’s disease and rheumatoid 
arthritis (346, 347), there have been concerns over its safety profile as 
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infliximab may possibly increase the risk of serious infection, including re-
activation of latent tuberculosis (348, 349). 
Brown and colleagues sought to establish the safety profile and 
biological response to infliximab in patients with advanced cancer and to 
determine clinical response so as to identify suitable tumour types or patient 
characteristics that may be selected for phase II trials (350). In this study, 41 
patients received infliximab and post-treatment samples were measured for 
changes in plasma and serum TNF-α, CCL2, IL-6 and C-reactive protein. 
Infliximab was found to be well tolerated with no dose-limiting toxic effects. 7 
patients experienced disease stablisation and there was no evidence of 
disease acceleration in any patient. However, data obtained from this study 
also suggested that in the non-responding patients, higher circulating 
concentrations of TNF-α may result in less antibody reaching cell membrane-
bound TNF-α due to the quicker clearance from the microenvironment and 
thus limit the biological efficacy of infliximab.  
Similarly, a phase I study carried out by Charles and colleagues to 
investigate the clinical benefit of infliximab in patients with advanced epithelial 
ovarian cancer and ascites accumulation showed that infliximab therapy was 
well tolerated with no toxicities reported (351). 11 out of 17 patients showed 
decreased percentage of tumour cells in the ascitic fluid 24 hours following the 
first infliximab infusion and the proportion of tumour cells continued to 
decrease at 48 hours in 6 out of the 17 patients. These results suggest that 
infliximab-mediated cytotoxicity of ovarian cancer cells may be occurring in the 
ascites. Furthermore, gene expression profiles of drained ascitic cells 
revealed downregulation in many inflammatory genes and signaling pathways 
following the first infliximab infusion.  
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3.1.3. Clinical trials: discussion 
To date, ovarian cancer clinical trials have included the evaluation of 
mAbs against tumour-associated, anti-angiogenesis, and anti-inflammatory 
antigens. However, the only successful trials reported have been the recent 
GOG218 and ICON7 studies which achieved their primary endpoints of 
extending PFS with the anti-angiogenic mAb, bevacizumab. The Swiss 
pharmaceutical company, Roche, has since submitted a European Union 
(EU) marketing authorization application for the use of bevacizumab in the 
front-line setting, based on the results from these 2 trials. Another major drug 
company, Genentech, also has plans to submit applications in the US for the 
use of bevacizumab in ovarian cancer sometime this year. 
Despite the promising advances in immune-based therapies for the 
treatment of ovarian cancer, issues including unwanted side effects remain.  
For example, although both the GOG218 and ICON7 studies achieved their 
primary endpoints, adverse events were present, as observed with previous 
bevacizumab trials. Adjuvant bevacizumab approximately doubled the risk of 
perforation, fistulae, necrosis, or hemorrhage in women with newly diagnosed 
epithelial ovarian, primary peritoneal, or fallopian tube cancers (338, 339). 
Moreover, another caveat of such conventional antibody therapies is their 
limited efficacy against solid tumours as a monotherapy. Many of these 
antibodies, such as the ones mentioned earlier, are therefore typically used in 
combination with cytotoxic chemotherapy regimens.  
Perhaps most importantly, present antibody-based therapies do not 
target antigens on ovarian TSCs which initiate and maintain tumours, thus 
explaining the eventual recurrence of ovarian cancer. Therefore, successful 
identification and subsequent eradication of ovarian TSCs by targeting of TSC 
antigens could therefore be crucial in the elimination of ovarian cancer. 
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In our study, we sought to generate novel mAbs targeting surface 
antigens specific to ovarian TSCs by immunizing mice with subpopulations of 
ovarian cancer cells which possessed characteristics consistent with those of 
TSCs. We first employed two established functional methods- the Hoechst 
dye efflux and the Aldefluor activity assay, to detect putative stem cells with 
drug resistant and self-renewal properties in a series of cancer cell lines. 
Thereafter, we injected isolated subpopulations from the IGROV1 ovarian 
cancer cell line into mice for the generation of novel mAbs specific to ovarian 
TSCs.  
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3.2. Results 
3.2.1. Detection of cell subpopulations using functional 
methods  
3.2.1.1.  Detection of cell subpopulations by the Hoechst dye method  
Stem cells efficiently pump out DNA-binding dyes such as Hoechst 
33342 via an ATP-binding cassette (ABC) membrane pump-dependent 
mechanism, whereas more differentiated cells retain the dye (4, 352). By 
exploiting this principle, the SP assay was developed by Margaret Goodell to 
identify the presence of putative stem cells and to isolate these cells from 
other cells in the haematopoietic system based on the exclusion of Hoechst 
dye (210). When analysed by flow cytometry, putative stem cells appeared as 
a low-fluorescence "tail" of cells relative to the much larger bulk of Hoechst-
bright cells. This "tail" is now known as the SP which disappears upon addition 
of export pump inhibitors such as verapamil. 
SP cells have since been identified in various established cancer cell 
lines including rat C6 glioma, U87MG human glioblastoma, MCF7 human 
breast carcinoma, HuH7 human hepatoma, and HeLa human 
adenocarcinoma cell lines (212-214, 353). There are also numerous reports of 
SPs in other tissue types and their respective tumours such as the mammary 
gland, prostate, brain, as well as ovary (190, 191, 201, 218, 354, 355).  
Similarly, our group had earlier reported the successful identification of 
SP cells from ovarian cell lines as well as in patient ascites (356). These cells 
possessed an increased aggressive phenotype, as defined by anchorage- 
independent growth and tumour formation in NOD/SCID mice, and were also 
resistant to carboplatin and paclitaxel. In addition, consistent with our in vitro 
observation of a survival advantage of SP following exposure to carboplatin 
and hence potential drug selection, we observed increased SP in tumour cells 
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isolated from patient ascites following chemotherapy and at relapse compared 
to chemo-naive patients. Recent data from Hosonuma and colleagues 
corroborate our findings, where they suggested that SP from ovarian clinical 
samples were linked to chemoresistance or prognosis (357). 
In the present study, we investigated the efficiency of the Hoechst dye 
method in detecting SP cells within a panel of ovarian as well as breast and 
cervical cancer cell lines. Figure 3.1 shows representative data from the 
IGROV1 ovarian cancer cell line where a ‘tail’ of SP cells (5.60%, n=6) with 
Hoechst efflux characteristics reminiscent of those previously defined in 
haematopoietic stem cells was observed (Figure 3.1, left). The presence of 
this SP population was completely abolished by the transporter blocker, 
verapamil (Figure 3.1, right).  
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Figure 3.1. FACS analysis using the Hoechst dye 33342 to detect 
subpopulations.  
Hoechst “blue” represents the 450 BP filter, the standard analysis wavelength 
for Hoechst 33342 analysis for DNA content. Hoechst “red” was detected at 
675 nm. A live gate was defined on the flow cytometer using Hoechst red and 
blue axes to exclude dead cells (Hoechst red, very bright), red cells (no 
Hoechst stain), and debris. Flow cytometry analysis displaying a 
representative diagram of detected SP cells in the IGROV1 ovarian cancer 
cell line, following staining with Hoechst 33342 dye (left). Effect of the 
transporter blocker, verapamil, on the SP subset (right). 
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3.2.1.2.  Detection of cell subpopulations by the Aldefluor activity assay 
method  
An alternative assay for detecting TSCs is the Aldefluor activity assay, 
which has gained recognition in the past few years for detecting stem cells by 
their increased aldehyde dehydrogenase (ALDH) activity (232, 358, 359). 
ALDH is a detoxifying enzyme responsible for the oxidation of a variety of 
intracellular aldehydes and has been suggested to be involved in stem cell 
differentiation through metabolism of retinal to retinoic acid (231). It is 
expressed at high levels in haematopoietic stem cells (HSCs), conferring 
resistance to certain alkylating agents such as cyclophosphamide and 
4αhydroxyperoxycyclophosphamide. Fluorescent substrates for ALDH such 
as BODIPY-aminoacetaldehyde (BAAA) have been developed and shown to 
be successful in the isolation of mouse and human HSCs (232).  
In 2004, Dontu and colleagues first published the use of the Aldefluor 
activity assay in isolating a subpopulation of cells which displayed stem cell 
properties in normal human breast tissue and breast carcinomas (360). This 
was followed by a report which revealed that a majority of breast cancer cell 
lines were found to contain an Aldefluor-positive population with a distinct 
molecular profile that displayed TSC properties (361).  
Similarly, as mentioned earlier, Ginestier and colleagues utilized in vitro 
and in vivo experimental systems to show that normal and cancer human 
mammary epithelial cells with increased ALDH possessed stem/progenitor 
properties. Moreover, in their series of 577 breast carcinomas, they observed 
that expression of ALDH correlated with poor prognosis (233). Their data was 
supported by another study where expression of ALDH was positively 
correlated with the stage and grade of lung tumours and related to a poor 
prognosis for the patients with early-stage lung cancer (234).  
 A study on ALDH in ovarian cancer patient samples revealed that the 
ALDH-positive population possessed tumour-initiating properties. 
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Furthermore, the percentage of ALDH-positive cells correlated negatively with 
PFS (6.05 vs. 13.81 months; p<0.035). The ALDH-positive subpopulation was 
also associated with chemoresistance and targeting ALDH sensitised 
resistant cells to chemotherapy (238). Another report by Deng and colleagues 
supported these findings where a higher percentage of ALDH-positive tumour 
cells were found to be significantly associated with poor clinical outcome in 
serous ovarian cancer. These cells were also resistant to chemotherapeutic 
drugs and treatment with platinum led to an enrichment of the ALDH-positive 
tumour cell population (237).  
The use of Aldefluor has since been extended to various other solid 
tumours such as in the colorectal and liver (207, 235), thus rendering it an 
important new tool to facilitate the clinical application of stem cell concepts, 
and provide a potential prognostic factor and therapeutic target for treatment.  
In view of these findings, we sought to investigate the efficiency of the 
Aldefluor activity assay in detecting Aldefluor-positive cell populations in our 
panel of cancer cell lines. The Aldefluor activity assay was performed 
separately by incubating cells with the Aldefluor substrate, BAAA. As shown in 
Figure 3.2, Aldefluor-positive populations showed up distinctively on flow 
cytometry plots. Incubation of cells with BAAA in the absence of the enzyme 
inhibitor, diethylaminobenzaldehyde (DEAB), induced a shift in BAAA 
fluorescence, defining the Aldefluor-positive population (3.18%, n=6) (Figure 
3.2, left), while addition of DEAB abolished this effect (Figure 3.2, right).  
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Figure 3.2. FACS analysis using the Aldefluor activity assay method to 
detect subpopulations. 
Flow cytometry analysis displaying a representative diagram of Aldefluor- 
positive cells (A+) in the IGROV1 ovarian cancer cell line, following incubation 
with the Aldefluor substrate, BAAA (left). The specific inhibitor of ALDH, 
DEAB, was used to establish the baseline fluorescence of the cells. Effect of 
the ALDH inhibitor, DEAB, on the Aldefluor-positive subset (right). 
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Further flow cytometry analyses showed that both the differential 
Hoechst dye efflux method and the Aldefluor activity assay were successful in 
detecting SP and Aldefluor-positive cells respectively in our panel of ovarian, 
breast, and cervical cancer cell lines. Results obtained are summarized in the 
following table (Table 3.1).  
Cell line 
SP cells, 
n=6 
SP cells, 
median 
Aldefluor- 
positive cells 
, n=6 
Aldefluor- 
positive cells, 
median 
IGROV1 3-8% 5.6% 2-4% 3.2% 
PEA1 <0.01-1% 0.7% <0.01-2% 1.7% 
PEO14 <0.01-7% 0.3% 25-30% 29.1% 
MCF7 <0.01-2.1% 0.9% <0.01-3% 0.5% 
MDA-MB-231 <0.01-3% 1.1% <0.01-4% 0.4% 
HeLa <0.01-1.5% 0.5% 4-12% 9.0% 
 
Table 3.1. FACS analysis data showing percentages of detected 
subpopulations using the Hoechst dye and Aldefluor 
activity assay.  
Both methods were successful in detecting subpopulations across our panel 
of cancer cell lines. Flow cytometry analyses showed that SP percentages 
ranged from a median of 0.3% in the PEO14 cell line to 5.6% in the IGROV1 
cell line while Aldefluor- positive percentages ranged from a median of 0.4% 
in the MDA-MB-231 cell line to 29.1% in the PEO14 cell line. Within each cell 
line, differences in percentages of cells detected by the two methods of 
identification were also observed. 
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In view of differences in percentages of cells detected by the two 
methods of identification, a double labeling experiment involving both 
methods was carried out to investigate whether an overlap existed between 
SP and Aldefluor-positive cells. As shown in Fig. 3.3, SP cells displayed a 
high Aldefluor intensity while NSP cells exhibited a low Aldefluor intensity. 
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Figure 3.3. Co-labeling of IGROV1 cells with the Hoechst efflux dye and 
Aldefluor activity assay reagent, BAAA.  
Flow cytometry analysis displaying a representative diagram of SP in the 
IGROV1 ovarian cancer cell line (left). Cells were then gated according to low 
SP, high SP, G0/G1 and late G1/S phase. These subpopulations were further 
analysed for their Aldefluor expression levels. The SP cells (low SP, high SP) 
displayed a high intensity of Aldefluor expression while the NSP cells (G0/G1, 
late G1/S) exhibited a low intensity of Aldefluor expression (right), thereby 
demonstrating a significant overlap between the SP and Aldefluor-positive 
fractions in the IGROV1 ovarian cancer cell line. 
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3.2.2. Characterisation of detected subpopulations in the 
IGROV1 ovarian cancer cell line  
After successfully identifying subpopulations with both the differential 
Hoechst dye method and Aldefluor activity assay, we proceeded to isolate 
these detected subpopulations from the IGROV1 cell line which provided us 
with sufficient numbers of cells for further characterisation experiments. 
IGROV1 was also chosen as it was the focus of other work ongoing in the lab 
(362). This cell line originated from a patient with serous cell EOC. 
Characterisation studies performed earlier showed that IGROV1 cells 
exhibited highly tumourigenic properties when maintained in monolayer 
cultures. Subcutaneous injection of cultured cells into nude mice gave rise to 
fast growing tumours while the intraperitoneal route induced a peritoneal 
carcinomatosis with ascites which killed the animals (267). These 
characteristics therefore render the IGROV1 cell line a suitable experimental 
model for biological studies of human solid tumours. 
3.2.2.1.  Expression of stem cell markers  
3.2.2.1.1.  FACS & RT-qPCR analysis of stem cell gene expression: 
SP vs NSP 
SP and NSP cells were isolated and processed separately for RT-
qPCR analysis. We then investigated the expression of genes such as PIAS2 
and SOS2, which belong to the JAK/STAT pathway and are reportedly 
upregulated in TSCs (363). Other genes which were tested for included KI67, 
a proliferation antigen, BMI1, which is required for the self-renewal of stem 
cells, and the drug transporters, ABCB1 and ABCG2. In addition, gene 
expression of the CD133 antigen was investigated as this marker had earlier 
been used to isolate and enrich cell populations with in vitro clonogenicity 
and/or in vivo tumourigenicity characteristics in several human malignancies 
(191, 201). 
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As shown in Figure 3.4, RT- qPCR analysis of mean gene expression 
levels in SP relative to NSP (n=3) revealed that stem-cell related genes in SP 
cells were generally upregulated. The expression levels of PIAS2, SOS2, 
KI67, BMI1, ABCG2 and CD133 were upregulated in SP cells by 1.5-, 1.7-, 
1.9-, 2.0-, 2.0- and 4.2-fold, respectively. In particular, the ABCB1 gene 
showed a marked increase of 41.3-fold in mRNA expression level in SP cells 
when compared to NSP cells. The levels of upregulation for PIAS2 and SOS2 
were lower than levels reported in a study involving the MCF7 breast cancer 
cell line where the authors found PIAS2 and SOS2 to be upregulated in SP 
populations by 7.3-fold and 6.8-fold respectively. However, this could possibly 
be attributed to differences in inherent properties between the two cancer cell 
lines or incomplete separation in isolated cell populations.  
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Figure 3.4. RT-qPCR analysis of stem cell-related markers in isolated 
IGROV1 SP and NSP populations.  
Stem cell gene expression levels were upregulated in SP cells. Mean gene 
expression levels (n=3) of stem-cell markers in SP in relation to NSP. ■  
represents SP while ■  represents NSP. Expression of the endogenous gene, 
GAPDH, was taken as a control. Experiments were performed with the 
IGROV1 ovarian cancer cell line. Error bars represent mean ± SEM. 
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This significant upregulation of ABCB1 in the SP cells as revealed by 
RT-qPCR was further validated by FACS analysis. SP and NSP cells were 
isolated and stained separately for the ABCB1 antibody. As shown in Figure 
3.5, the expression of ABCB1 was detected in 93.7% of SP cells (left) while 
only 12.7% of NSP cells expressed the marker (right).  
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Figure 3.5. FACS analysis of ABCB1 expression level.  
Expression level of ABCB1 was markedly upregulated in SP cells. Flow 
cytometry analysis displaying a representative diagram of SP and NSP cells 
identified in the IGROV1 cell line, after the two subpopulations were stained 
separately with the ABCB1 antibody.  
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3.2.2.1.2. FACS & RT-qPCR analysis of stem cell gene expression: 
Aldefluor-positive vs. Aldefluor-negative populations  
Similarly, the Aldefluor-positive and Aldefluor-negative populations 
were isolated and processed separately for RT-qPCR analysis. Expression of 
the genes, PIAS2, SOS2, KI67, BMI1, CD133, ABCB1 and ABCG2, were then 
evaluated. As shown in Figure 3.6, RT-qPCR analysis of mean gene 
expression levels in Aldefluor-positive populations relative to Aldefluor- 
negative populations (n=3) revealed that stem-cell related genes in the 
Aldefluor-positive fraction were generally upregulated. The expression levels 
of PIAS2, SOS2, KI67, BMI1, ABCG2 and ABCB1 were upregulated by 2.4-, 
3.0-, 3.1-, 3.7-, 3.3- and 2.1-fold, respectively. In particular, the CD133 gene 
showed a marked increase of 5-fold in mRNA expression level.  
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Figure 3.6. RT-qPCR analysis of stem cell-related markers in isolated 
IGROV1 Aldefluor-positive and -negative populations.   
Stem cell gene expression levels were upregulated in Aldefluor-positive 
populations. RT-qPCR analysis. Mean gene expression levels (n=3) of stem-
cell markers in Aldefluor-positive populations in relation to Aldefluor-negative 
populations. ■  represents Aldefluor-positive populations while ■  represents 
Aldefluor-negative populations. Expression of the endogenous gene, GAPDH, 
was taken as control. All experiments were performed using the IGROV1 
ovarian cancer cell line. Error bars represent mean ± SEM.  
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This significant upregulation of CD133 in Aldefluor-positive cells as 
revealed by RT-qPCR was further validated by FACS analysis. Aldefluor-
positive and Aldefluor-negative cells were isolated and stained separately for 
the CD133 antibody. As shown in Figure 3.7, the expression of CD133 was 
detected in 10.8% of Aldefluor-positive cells while only 2.8% of Aldefluor-
negative cells expressed the marker.  
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Figure 3.7. FACS analysis of CD133 expression level.  
Expression level of CD133 was markedly upregulated in Aldefluor-positive 
cells. Flow cytometry analysis displaying a representative diagram of 
Aldefluor-positive and Aldefluor-negative populations identified in the IGROV1 
cell line, after the two subpopulations was stained separately with the CD133 
antibody.  
.  
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3.2.2.1.3. Microarray analysis of stem cell signatures: SP vs. NSP 
Furthermore, together with collaborators at the Institute of Cancer 
Research (ICR), we performed a microarray experiment where gene set 
enrichment analysis (GSEA) (263) was used to interrogate gene expression 
profiling of SP compared to NSP from the IGROV1 cell line for 15 published 
embryonic stem cell related signatures (Appendix 2). The GSEA is a powerful 
method for interpreting gene expression data and derives its power by 
focusing on gene sets - groups of genes that share common biological 
function, chromosomal location, or regulation. 
Using the average signal intensities of the probes mapped to one gene, 
four signatures with p<10-6 and false discovery rate (FDR)<10-4 were 
significantly upregulated in SP compared to NSP: Oct4 regulated genes, 
‘NOS’ signature (Nanog/Oct4/Sox2 regulated genes), E2F6 associated 
expression pattern and the polycomb repressive complex 2 (PRC2).  
Consistent with this upregulation of PRC2 genes, PRC2 target genes 
were significantly repressed in the SP (p<10-6, FDR<10-4) (Table 3.2). Also, 
consistent with upregulation of NOS signature, NOS target genes were 
significantly overexpressed in the SP (Figure 3.8). 
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Gene set name Score p-value FDR Status
oct4 0.1969 <0.0001 <0.0001 Upregulated
nos 0.1379 <0.0001 <0.0001 Upregulated
E2F6 0.7938 <0.0001 <0.0001 Upregulated
prc2 1.5184 <0.0001 <0.0001 Upregulated
nanog 0.095 0.12 0.3 Upregulated
sox2 0.0811 0.12 0.3 Upregulated
ES1 0.1085 0.242 0.5186 Upregulated
prc2_targets2 -0.2604 <0.0001 <0.0001 Downregulated
suz12 -0.0227 0.12 0.6 Downregulated
prc2_targets1 -0.0552 0.12 0.6 Downregulated
prc1 0.248 0.248 0.7 Downregulated
h3k27 0.262 0.262 0.7 Downregulated
nostf 0.28 0.28 0.7 Downregulated
eed 0.372 0.372 0.7238 Downregulated
ES2 0.386 0.386 0.7238 Downregulated  
Table 3.2. GSEA analysis of stem cell related signatures in SP and NSP 
subpopulations.  
Significant upregulation of published embryonic stem cell related signatures 
including Oct4 regulated genes, ‘NOS’ signature, E2F6 associated expression 
pattern and PRC2 was observed in SP cells. PRC2 target genes were 
significantly downregulated. Data was produced in collaboration with Dr. Wei 
Dai (Imperial College) and Dr. Sian Rizzo (ICR). 
 
Figure 3.8. Regulation of NOS target genes.  
NOS target genes were significantly upregulated. Data was produced in 
collaboration with Dr. Sian Rizzo (ICR) and Dr. Wei Dai (Imperial College). 
Venn diagrams were produced with the limma package for R which generated 
p values using the Fisher’s exact test. 
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3.2.2.1.4.  Microarray analysis of stem cell signatures: Aldefluor-positive vs. 
Aldefluor-negative populations  
Similarly, a microarray experiment was performed where GSEA was 
used to interrogate gene expression profiling of Aldefluor-positive compared 
to Aldefluor-negative populations from the IGROV1 cell line for the 15 
published embryonic stem cell related signatures (Appendix 2). However, in 
contrast to results we obtained with SP/NSP cells, upregulation of stem cell 
signatures in the Aldefluor-positive population was not observed. 
Gene set name Score p-value FDR Status
prc2_targets2 0.3782 <0.0001 <0.0001 Upregulated
prc1 0.0245 0.214 1.29 Upregulated
suz12 0.0198 0.344 1.29 Upregulated
eed 0.0307 0.344 1.29 Upregulated
nanog -0.0644 <0.0001 <0.0001 Downregulated
oct4 -0.0667 <0.0001 <0.0001 Downregulated
ES1 -0.0579 0.1 0.4425 Downregulated
prc2 -0.4101 0.118 0.4425 Downregulated
sox2 -0.0372 0.214 0.5182 Downregulated
nos -0.0636 0.244 0.5182 Downregulated
nostf -0.0982 0.244 0.5182 Downregulated
ES2 -0.0196 0.344 0.5182 Downregulated
E2F6 -0.0122 0.344 0.5182 Downregulated
h3k27 -0.0279 0.38 0.5182 Downregulated
prc2_targets1 -0.025 0.38 0.5182 Downregulated  
Table 3.3. GSEA analysis of stem cell related signatures in Aldefluor- 
positive and -negative subpopulations.  
No significant upregulation of published embryonic stem cell-related 
signatures in Aldefluor-positive populations was observed. In particular, the 
downregulation of Oct4 regulated genes and nanog was observed while 
PRC2 target genes were significantly upregulated. 
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3.2.2.1.5.  A comparison of microarray analysis results  
We then performed further bioinformatic analysis using Rank Product 
analysis (262) to investigate whether there were genes which overlapped 
between the SP and Aldefluor-positive population. As shown in Figure 3.9, 
there were 8 and 11 genes which were significantly up/down regulated 
respectively in both subpopulations. Gene names and the functions of these 
genes are provided in Tables 3.4 and 3.5 while their expression levels and log 
fold changes are further provided in Appendices 9 and 10. 
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Figure 3.9. Overlapping of genes in the SP and Aldefluor-positive 
population.  
8 genes were upregulated in both populations while 11 genes were 
downregulated in both populations. 
 
 
 
134 
 
 
Gene Gene name Function  
OLIG3 oligodendrocyte 
transcription factor 3 
May determine the distinct specification program of 
class A neurons in the dorsal part of the spinal cord 
and suppress specification of class B neurons. 
COL4A4 collagen, type IV,  
alpha 4 
The protein encoded by this gene is Type IV 
collagen, a major structural component of 
glomerular basement membranes, forming a 
meshwork together with laminins, proteoglycans 
and entactin/nidogen. 
 
SCEL sciellin May function in the assembly or regulation of 
proteins in the cornified envelope.  
KCNJ16 potassium inwardly-
rectifying channel, 
subfamily J, member 16 
The protein encoded by this gene is an integral 
membrane protein and inward-rectifier type 
potassium channel. It may be involved in the 
regulation of fluid and pH balance. 
CDC2 cell division cycle 2 
 
Plays a key role in the control of the eukaryotic cell 
cycle and is restricted to proliferating cells. It is 
required in higher cells for entry into S-phase and 
mitosis. 
ATXN1 
 
Spinocerebellar ataxia 
type 1 protein 
 
Binds ribonucleic acid (RNA) in vitro. May be 
involved in RNA metabolism. The expansion of the 
polyglutamine tract may alter this function. 
 
ANKRD1 
 
Ankyrin repeat 
domain-containing 
protein 1 
 
May play an important role in endothelial cell 
acitivation. May act as a nuclear transcription factor 
that negatively regulates the expression of ardiac 
genes. Induction seems to be correlated with 
apoptotic cell death in hepatoma cells.  
 
LIMCH1 
 
LIM and calponin 
homology domains 1 
 
The gene has been proposed to participate in 
actomyosin structure organization. Encodes a metal 
ion-binding protein which has regulatory roles in 
central cellular processes such as gene expression, 
proliferation, differentiation and survival.  
 
Table 3.4. List of upregulated genes in both populations. 
Expression levels and log fold changes of these genes are further provided in 
Appendix 9. 
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Gene Gene name Function 
MAGEA9 melanoma antigen family A, 9 Not known, though may play a role in 
embryonal development and tumor 
transformation or aspects of tumor progression. 
NTS Neurotensin The neurotensin protein may play an endocrine 
or paracrine role in the regulation of fat 
metabolism. It causes contraction of smooth 
muscle. 
ABCG1 sciellin This transporter protein is involved in 
macrophage lipid homeostasis and is an active 
component of the macrophage lipid export 
complex.  
NR5A2 Nuclear receptor subfamily 5, 
group A, member 2 
Binds to the sequence element 5'-
AACGACCGACCTTGAG-3' of the enhancer II 
of hepatitis B virus genes, a critical cis-element 
of their expression and regulation.  
KIF5A Kinesin family member 5A Kinesins are intracellular transport proteins that 
interact with microtubules.    
DOK5  Docking protein 5 
 
DOK proteins are enzymatically inert adaptor or 
scaffolding proteins. DOK5 plays a positive role 
in activation of the MAP kinase pathway.  
ID2 Inhibitor of DNA binding 2, 
dominant negative helix-loop-helix 
protein 
ID (inhibitor of DNA binding) HLH proteins lack 
a basic DNA-binding domain but are able to 
form heterodimers with other HLH proteins, 
thereby inhibiting DNA binding.  
C6orf218 Homo sapiens (human) 
chromosome 6 open reading 
frame 218 
Unknown. 
PRTFDC1 Phosphoribosyl transferase  
domain containing 1 
 
 Has low, barely detectable    
phosphoribosyltransferase activity (in vitro).  
Binds GMP, IMP and alpha-D-5-phosphoribosyl 
1-pyrophosphate (PRPP).  
C8orf47 Homo sapiens (human) 
chromosome 8 open reading 
frame 47 
 Unknown. 
CPS1 
 
carbamoyl phosphate synthetase I Involved in the urea cycle of ureotelic animals 
where the enzyme plays an important role in 
removing excess ammonia from the cell. 
Table 3.5. List of downregulated genes in both populations. 
Expression levels and log fold changes of these genes are further provided in 
Appendix 10. 
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3.2.2.2. Proliferation studies  
3.2.2.2.1.  Spheroid assay: SP vs. NSP 
Next, the proliferative properties of detected IGROV1 subpopulations 
were investigated. As shown in Figures 3.10 and 3.11, SP cells have a 
greater ability to grow in an anchorage-independent manner as spheroids 
compared to NSP cells. It was further observed that the largest colonies (>64 
cells) were more abundantly formed in the SP population. 
 
Figure 3.10. Anchorage-independent spheroid assays comparing the 
proliferative capacity of SP and NSP subpopulations.  
Anchorage-independent spheroid assays revealed larger and more numerous 
colonies in the SP cells compared to NSP cells. ■ represents SP while ■ 
represents NSP. Experiments were performed with the IGROV1 ovarian 
cancer cell line. Error bars represent mean ± SEM.              
                           
137 
 
 
 
                               SP                               NSP  
Figure 3.11. Representative microscopic images SP and NSP colonies.  
SP colonies were generally larger in size compared to NSP colonies. 
 
As these observed differences in growth properties of SP and NSP 
cells could be attributed to potential toxicity of Hoechst 33342 (364) and its 
increased accumulation in NSP cells, together with collaborators at the ICR, 
we carried out a standard adherent 2D tissue culture to observe differences in 
plating efficiency of IGROV1 SP and NSP cells. As shown in Figure 3.12, it 
was observed that, in fact, the NSP cells demonstrated significantly increased 
plating efficiency compared with SP cells in standard adherent 2D tissue 
culture assays, thereby confirming that the enhanced growth of SP was only 
observed in anchorage-independent spheroid growth conditions.  
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Figure 3.12. Standard adherent 2D tissue culture assays comparing the 
proliferative capacity of SP and NSP subpopulations.  
NSP cells demonstrated increased proliferative capacity in standard adherent 
2D tissue culture assays. Adherent 2D tissue culture assays revealed slightly 
larger and more numerous colonies in the NSP cells compared to SP cells. ■ 
represents NSP while ■ represents SP. Experiments were performed with the 
IGROV1 ovarian cancer cell line. Error bars represent mean ± SEM. Data was 
produced in collaboration with Dr. Sian Rizzo at the ICR. 
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3.2.2.2.2. Spheroid assay: Aldefluor-positive vs. Aldefluor-negative 
populations 
Similarly, Aldefluor-positive cells demonstrated greater ability to grow in 
an anchorage-independent manner as spheroids compared to Aldefluor-
negative cells (Figure 3.13) and it was also further observed that the largest 
colonies (> 64 cells) were more abundantly formed in the Aldefluor-positive 
population. 
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Figure 3.13. Anchorage-independent spheroid assays comparing the 
proliferative capacity of Aldefluor-positive and -negative 
subpopulations.  
Anchorage-independent spheroid assays revealed larger and more numerous 
colonies in the Aldefluor-positive cells compared to the Aldefluor-negative 
cells. ■ represents Aldefluor-positive cells while ■ represents Aldefluor- 
negative cells. Experiments were performed with the IGROV1 ovarian cancer 
cell line. Error bars represent mean ± SEM. 
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3.2.2.3.  Invasion studies 
3.2.2.3.1.  Invasion assay: SP vs. NSP 
Detected subpopulations in the IGROV1 cell line were also investigated 
for their invasive properties. Using a commercial invasion assay kit, it was 
revealed that there was an increase in the invasiveness of SP by 7-fold when 
compared to NSP (Figure 3.14).  
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Figure 3.14. Invasive capacities of SP and NSP subpopulations.  
A, a 7-fold increase in invasiveness of SP cells was observed when compared 
to that of NSP cells. B, percentage invasion of NSP and SP cells were 3% 
and 22% respectively. ■ represents SP cells while ■ represents NSP cells. 
Experiments were performed with the IGROV1 ovarian cancer cell line. Error 
bars represent mean ± SEM. 
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3.2.2.3.2. Invasion assay: Aldefluor- positive vs. Aldefluor negative 
populations 
The invasion assay was repeated on Aldefluor-positive and -negative 
populations. Similarly, the Aldefluor-positive cells also showed a 4-fold 
increase in invasiveness compared to the Aldefluor-negative cells (Figure 
3.15). 
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Figure 3.15. Invasive capacities of Aldefluor- positive and -negative 
subpopulations. 
A, a 4-fold increase in invasiveness of Aldefluor-positive cells was observed 
when compared to that of Aldefluor-negative cells. B, percentage invasion of 
Aldefluor-negative and Aldefluor-positive cells were 4% and 15% respectively. 
■ represents Aldefluor- positive cells while ■ represents Aldefluor-negative 
cells. Experiments were performed with the IGROV1 ovarian cancer cell line. 
Error bars represent mean ± SEM. 
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3.2.2.4. In vivo studies 
3.2.2.4.1. Differential tumour formation experiment: SP vs. NSP cells 
Finally, SP cells from ascites of ovarian cancer patients have been 
shown to form tumours more readily in mice than NSP cells (365). Similarly, 
we observed significantly increased tumourigenicity (Repeated Measures 
ANOVA: p<0.05) of SP compared to NSP cells when injecting 100 cells into 
the mammary fat pad of NOD/SCID mice (Figure 3.16). In addition to the 
differences in average tumour growth, SP cells initiated tumours more 
frequently (3/6 injections) than NSP (0/6 injections) (Fisher’s exact test: 
p=0.0145). 
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Figure 3.16. Tumourigenic potential of SP and NSP cells.  
SP and NSP (100 cells each) were injected into mice. A palpable tumour was 
first observed at Day 50 in SP cells. However, no tumour was observed in 
NSP cells. A significant increase in tumourigenicity was thus observed in the 
SP cells. Error bars represent mean ± SEM.  
Cells grafted SP NSP 
100 3/6 0/6 
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3.2.2.4.2.  Differential tumour formation experiment: Aldefluor-positive vs. 
Aldefluor-negative populations  
However, when we repeated the in vivo experiment with Aldefluor- 
positive cells, an increased tumourigenicity in mice was not observed (Figure 
3.17). Although Aldefluor-positive cells initiated tumours more frequently (4/6 
injections) than Aldefluor-negative cells (2/6 injections), the Aldefluor-negative 
cells exhibited increased tumourigenicity when compared to Aldefluor positive 
cells. 
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Figure 3.17. Tumourigenic potential of Aldefluor- positive and –negative 
cells.  
Aldefluor-positive cells and Aldefluor-negative cells (100 cells each) were 
injected into mice. No increase in tumourigenicity was observed with 
Aldefluor-positive population. Error bars represent mean ± SEM. 
Cells grafted Aldefluor- positive Aldefluor- negative 
100 4/6 2/6 
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To determine that the Aldefluor-positive cells were viable before 
transplantation into mice, we carried out a standard adherent 2D tissue 
culture simultaneously to observe the growth of both IGROV1 Aldefluor-
positive and -negative cells. As shown in Figure 3.18, it was observed that 
both the Aldefluor-positive and –negative cells were capable of growth in 
anchorage-dependent conditions.  
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Figure 3.18. Viability of Aldefluor-positive and -negative cells.  
Both Aldefluor-positive and –negative cells were capable of growth in 
adherent 2D tissue culture assays. ■ represents Aldefluor-positive cells while 
■ represents Aldefluor-negative cells. Experiments were performed with the 
IGROV1 ovarian cancer cell line. Error bars represent mean ± SEM. 
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3.2.2.5.  Summary of characteristics of detected subpopulations  
In summary, our in vitro and in vivo characterisation experiments 
showed that the Hoechst dye method was successful in detecting a 
subpopulation of cells which possessed TSC characteristics such as the 
upregulation in expression of stem cell markers as well as the embryonic stem 
cell related signature, NOS. Moreover, these detected SP cells exhibited 
increased proliferative and invasive capacities when compared to their 
counterpart NSP cells. Most importantly, differential tumour formation was 
observed when an in vivo tumour take experiment was performed by injecting 
low numbers of cells (Table 3.6). Similarly, the Aldefluor method was 
successful in detecting subpopulations which showed upregulation of stem 
cell marker expression. These Aldefluor-positive populations also exhibited 
increased proliferative and invasive capacities when compared to their 
counterpart Aldefluor-negative cells. However, upregulation of the NOS 
signature was not observed. Also, differential tumour formation was absent. 
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SP vs. NSP 
Aldefluor-positive vs. 
Aldefluor-negative 
Detection of putative TSC subpopulation in ovarian, 
breast and cervical cancer cell lines 
√ √ 
Upregulation of stem cell gene expression in 
putative TSC subpopulation 
√ √ 
Upregulation of the embryonic stem cell-related 
signature, NOS, in putative TSC subpopulation  
√ X 
Increased proliferation observed in putative TSC 
subpopulation 
√ √ 
Increased invasiveness observed in putative TSC 
subpopulation 
√ √ 
Differential in vivo tumour formation observed in 
putative TSC subpopulation 
√ X 
 
Table 3.6. Summary table showing the characteristics of subpopulations 
detected by the Hoechst dye and Aldefluor method. 
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3.2.3. Generation of novel mAbs by injecting Aldefluor-
positive cells into BALB/c mice 
 
As mentioned earlier, potential toxicity issues have been associated 
with the Hoechst dye (364) while the Aldefluor substrate, BAAA, does not 
enter the nucleus or bind DNA. Consequently, the isolation of cells by the 
Aldefluor activity assay may be safer and less toxic than the Hoechst dye 
which binds to nucleic acids and requires UV excitation. Moreover, there has 
been increasing evidence that Aldefluor-positive cells possess stem cell-like 
characteristics (238), which support data we obtained from our earlier in vitro 
experiments. 
 Therefore, before obtaining final results from our differential tumour 
formation experiment involving isolated Aldefluor-positive and Aldefluor-
negative subpopulations, we decided to first carry out the Aldefluor activity 
assay for the isolation and subsequent injection of Aldefluor-positive cells 
from the IGROV1 ovarian tumour cell line into BALB/c mice to generate a 
panel of novel in-house mAbs. This was to be followed by a similar 
experiment involving SP cells.  
3.2.3.1.  Primary screening  
Subsequently, a two-step screening process was carried out to select 
for mAbs which were specific to ovarian TSCs. In the primary phase of 
screening, generated in-house mAbs were tested by flow cytometry analysis 
for their reactivity towards isolated Aldefluor-positive cells from the IGROV1 
cell line.  As these cells were earlier injected into mice to generate our panel 
of antibodies, we expected specific clones to demonstrate positive reactivity 
towards this cell subpopulation.  
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Examples of positive screens from this primary phase are shown in 
Figure 3.18. Identified positive clones were then taken through to the 
secondary phase of screening where they were again tested by flow 
cytometry analysis for their reactivity towards unseparated cell lines. 
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Figure 3.19. Examples of positive clones from the primary phase of 
screening.  
Flow cytometry analyses showing representative positive clones from the 
primary phase of screening. Of the 1109 clones obtained, 143 clones 
exhibited reactivity towards isolated Aldefluor-positive cells. Secondary 
antibody only was used as controls in this experiment. Although we accept 
that the percentages shown could be underrepresented, we set the gates in 
relation to the negative controls to exclude possible false positive results. 
3.2.3.2.  Secondary screening 
In the secondary phase of screening, positive clones from the first 
phase of screening were tested for their reactivity towards the IGROV1 
unseparated cell line and four other unseparated cell lines – the ovarian 
cancer, PEA1, human embryonic stem cell (hESC), lung fibroblast (IMR-90) 
and human embryonic kidney (HEK293) cell lines. Specific clones towards 
ovarian TSCs were expected to demonstrate reactivity towards 
subpopulations of cells in the hESC and ovarian cell lines but not towards the 
differentiated IMR-90 and HEK293 cell lines.  
Out of the 143 clones, 34 clones which showed specificity (Figure 3.19) 
were kept and further characterised by both in vitro and in vivo experiments 
as discussed in the next chapter. 
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Figure 3.20. An example of a positive clone from the secondary phase of 
screening.  
Representative flow cytometry analyses of a specific binder, mAb774. Positive 
clones from the first phase of screening were tested for their specificity 
towards five whole cell lines – IGROV1, PEA1, hESC, IMR-90 and HEK293. 
Specific clones for ovarian TSCs were expected to demonstrate reactivity 
towards subpopulations of the hESC and ovarian cancer cell lines but not 
towards differentiated IMR-90 and HEK293 cells. Of the 143 clones, 34 clones 
showed reactivity towards PEA1 and hES cells but did not bind to IMR90 and 
HEK293 cells. Further in vitro and in vivo experiments were then performed 
with these 34 clones which demonstrated specificity towards ovarian TSCs, 
the results of which will be discussed in our next chapter. 
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3.3. Generation of novel mAbs to ovarian TSCs: 
discussion 
In our study, we performed two established functional methods, the 
differential Hoechst dye uptake (Figure 3.1) and Aldefluor activity assay 
(Figure 3.2), followed by flow cytometry analysis, to determine the presence of 
subpopulations with stem cell characteristics from a series of ovarian, breast 
and cervical cancer cell lines.  
Across our panel of six cancer cell lines, both functional methods were 
found to be successful in detecting subpopulations (Table 3.2). Percentages 
of Aldefluor-positive cells in the breast cancer cell lines, MCF7 and MB-MDA-
231, were comparable to previously published data (236). However, the 
average sort percentage of SP cells within the IGROV1 ovarian cancer cell 
line was elevated relative to that of the SP found in other somatic and 
malignant sources (212, 214). 
Strikingly, percentages of detected subpopulations differed across cell 
lines and even within the same cell line depending on the method of 
identification. We speculate that the percentages of detected subpopulations 
present in each cell line may possibly correlate with clinicopathologic features 
such as the aggressiveness of a tumour. For example, it has been reported 
that the percentage of clonogenic cells is higher in malignant pediatric 
medulloblastomas with respect to pilocytic astrocytoma which is typically 
benign (201). Wu and colleagues also observed the presence of a SP with 
tumour-initiating capacity within a broad range of benign and malignant 
untreated mesenchymal tumours, where the benign as well as the locally 
invasive low-grade tumours had a low expression of SP whereas high-grade 
malignant tumours had a high expression of SP (228).  
Despite varying percentages of subpopulations detected by the two 
different methods within cell lines, there was significant overlap of the SP and 
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Aldefluor-positive subpopulations as shown in Figure 3.3. Our findings agree 
with data published by Pearce and Bonnet where the SP cells overlapped with 
the Aldefluor-positive cell population in human cord blood and bone marrow 
cells (272). Thus, cells isolated by combination of the two methods could 
possibly represent a specific distinct subset of stem cells. 
We then performed in vitro and in vivo characterisation experiments 
with subpopulations isolated from the IGROV1 cell line to investigate whether 
detected populations possessed drug resistance and self-renewal 
characteristics. As shown by RT-qPCR, genes including PIAS2, SOS2, KI67, 
BMI1 and CD133, which had previously been associated with proliferation and 
self-renewal, were generally upregulated in both the SP (Figure 3.4) and 
Aldefluor-positive populations (Figure 3.6). The drug transporters, ABCB1 and 
ABCG2, were also elevated in detected subpopulations. In particular, the 
ABCB1 gene displayed a marked increase of 41.25-fold in mRNA expression 
level in the IGROV1 SP when compared to the NSP. This result was further 
validated by FACS analysis (Figure 3.5).  
The ABCB1 multiple drug resistance (MDR) gene belongs to a family of 
approximately 50 human ABC transporters which employ adenosine 
triphosphate (ATP) hydrolysis to actively efflux drugs from cells, thereby 
protecting them from cytotoxic agents (4, 366). For example, the ABCG2 
transporter confers the drug resistance-associated efflux of many lipophilic 
chemotherapeutic agents such as mitoxantrone, daunorubicin, doxorubicin, 
and indolcarbazole (367). Increased expression of ABCB1 in SP cells has 
also been suggested as a potential cause of drug resistance in refractory and 
relapsed neuroblastoma (225-227).  
In ovarian cancer, in vitro studies showed that resistance to the drug 
paclitaxel was attributed to an overexpression of ABCB1 (14, 368, 369). 
Similarly, our group showed in a recent publication that ABCB1 was found to 
be consistently overexpressed in SP compared to NSP from patients' tumour 
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cells (356). Futhermore, we observed a higher percentage SP in ascites from 
ovarian cancer patients that have relapsed following chemotherapy compared 
to chemonaive patients. Hence, it is possible that SP cells can exert a drug-
resistance mechanism which may in part be mediated by expression of 
various ABC transporters. 
In Aldefluor-positive populations, RT-qPCR analysis revealed that the 
CD133 marker expressed the highest level of upregulation among all the stem 
cell markers we tested for. This upregulation of CD133 was further confirmed 
by FACS analysis (Figure 3.7). The presence of CD133-expressing cells 
which possess cancer-initiating cell characteristics in ovarian tissues was first 
discovered by Ferrandina and colleagues in 2008 (8). CD133 expression in 
ovarian cancer has also been found to be directly regulated by epigenetic 
modifications and methylation of the CD133 promoter may be generally 
representative of epigenetic repression of other pluripotency-associated 
genes (370). These publications support our finding that the CD133 marker 
may demarcate Aldefluor-positive cells as a TSC population in ovarian 
cancers.  
In addition to RT-qPCR and FACS analyses, we performed a 
microarray experiment on isolated subpopulations to investigate the 
expression of stem cell-like gene signatures. Data obtained showed that Oct4 
regulated genes, ‘NOS’ signature, E2F6 associated expression pattern and 
PRC2 were significantly upregulated in IGROV1 SP cells. Consistent with 
upregulation of the PRC2 and NOS signature, the PRC2 target genes were 
significantly repressed in the SP population (p<10-6, FDR<10-4) and the NOS 
target genes were significantly overexpressed respectively (Table 3.3). 
However, stem cell signatures were not observed to be upregulated in 
IGROV1 Aldefluor- positive cells. This suggests that factors other than the 
‘NOS’ signature may be responsible for conferring stem cell-like properties 
towards these cells. 
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We then investigated genes which overlapped between the SP and 
Aldefluor-positive populations. Of the 8 genes which were upregulated in both 
the SP/AF+ fractions, several have been reported in studies associated with 
cancer and stem cells. For example, COL4A4 is a gene which encodes one of 
the six subunits of type IV collagen, the major structural component of 
basement membranes present in the ECM. The ECM in turn is a key 
component of the microenvironment which is in contact with tumour cells and 
is a critical source for growth, survival and motility factors which significantly 
affect tumour biology and progression.  
More than 10 years ago, Le Bail and colleagues reported that strong 
deposition of collagen type IV was observed in dysplastic areas and small 
hepatocarcinomas (HCC) in human cirrhotic livers indicative of early events in 
hepatocarcinogenesis (371). Recently, Lai and colleagues examined two 
mouse models to compare liver proteome changes occurring during the 
transition from fibrosis and steatohepatitis, common preneoplastic conditions 
in humans, to HCC (372). Results revealed that many ECM proteins, including 
all six subunits of type IV collagen, were upregulated in the tumours of both 
mouse models. The authors thus concluded that these identified HCC-
associated ECM and integrin components could possibly play an important 
role in the promotion of the early steps of hepatocarcinogenesis.  
The KCNJ16 gene encodes for an integral membrane protein and 
inward-rectifier type potassium channel. Although information regarding ion 
channels in TSCs is limited, a recent study by Li and colleagues reported that 
human ether-a-go-go-related potassium channels were expressed in leukemia 
stem cells but not in normal bone marrow cells (373). Another separate study 
showed the high expression of large- conductance Ca2+- activated potassium 
channels in CD133+ TSC subpopulations of SH-SY5Y neuroblastoma cells. In 
2011, Yu and colleagues investigated the relationship between Bmi-1, Snail, 
and ALDH1 in HNSCC or HNSCC-associated CSC and the involved 
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molecular mechanisms (374). The authors concluded that overexpression of 
Bmi-1 could turn HNSCC-ALDH1− into TSC-like HNSCC-ALDH1+ cells. 
Interestingly, the KCNJ16 gene was found to be upregulated in this ALDH- 
negative/Bmi1-overexpressed population when compared to ALDH1-negative 
HNSCC. 
Another gene of interest is the CDC2 gene which is a highly 
conserved protein that functions as a serine/threonine kinase, and is a key 
player in cell cycle regulation. It has been frequently reported in various 
cancers such as prostate, leukemia, colon cancer, cervical and breast cancer 
and has also been linked with the aggressiveness of tumours (375-379). 
Recently, Yang and colleagues carried out a study where culture- adapted 
HESCs (chHES-3) with abnormal karyotype were compared with 
karyotypically normal cells (380). The authors observed that karyotypically 
abnormal chHES- 3 cells exhibited increased survival and population growth. 
Moreover, upregulated genes in chHES-3 cells included those related to cell 
proliferation and apoptosis, as well as G1 to S cell cycle transformation-
related genes such as CDC2. The authors concluded that these karyotypically 
abnormal chHES-3 cells may be an excellent model for studying and 
characterizing initial stages that determine transition of embryonic stem cells 
into TSCs. Earlier on, Chen and colleagues also reported that the CDC2 gene 
served an important role in the proliferation of human gliomas where 
overexpression of CDC2 could possibly promote oncogenesis and 
progression of human gliomas whereas the downregulation of CDC2 
expression could inhibit the proliferation, induce G2/M arrest, and trigger 
apoptosis in human gliomas (381).  
Finally, Cizkova and colleagues examined the PIK3CA gene which 
encodes the PI3K catalytic subunit, the oncogene exhibiting a high frequency 
of gain-of-function mutations leading to PI3K/AKT pathway activation in breast 
cancer (382). Many reports have demonstrated that signaling through PI3K 
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pathway provokes drug resistance in ovarian cancer. It is also well 
established that AKT signaling plays a major role for cell survival. In addition, 
PI3K signaling has also been shown to be important for the etiology of ovarian 
cancer. Interestingly, results revealed that PIK3CA mutations were associated 
with overexpression of several genes involved in the Wnt signaling pathway, 
regulation of gene transcription, as well as metal ion binding, including the 
LIMCH1 gene.  
Of the 11 genes which were downregulated in both fractions, 2 genes 
are of particular interest as they are reportedly involved in tumour 
carcinogenesis. The first is PRTFDC1 where an array-based comparative 
genomic hybridisation study showed that hypermethylation of the PRTFDC1 
CpG island, which showed promoter activity, was observed in oral squamous-
cell carcinoma cell (OSCC) lines with no or reduced PRTFDC1 expression 
(383). Moreover, methylation of this CpG island was also observed in primary 
OSCC tissues (8/47, 17.0%). In addition, restoration of PRTFDC1 in OSCC 
cells lacking its expression inhibited cell growth in colony-formation assays, 
whereas knockdown of PRTFDC1 expression in OSCC cells expressing the 
gene promoted cell growth. These results led the authors to suggest that 
epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island 
leads to a loss of PRTFDC1 function, which might be involved in squamous 
cell oral carcinogenesis. 
The other gene of interest is the CPS1 gene which had earlier been 
found to be differentially methylated in the SP fraction (Dr. Wei Dai, 
unpublished data). A study carried out by Liu and colleagues to understand 
the regulation of the CPS1 gene in liver carcinogenesis showed that CPS1 
was silenced or downregulated in liver tumour tissues compared with matched 
non cancerous tissue (384). Moreover, hypermethylation of two CpG 
dinucleotides was the key mechanism of silencing CPS1 expression in human 
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HCC cells. Therefore, the authors concluded that CPS1 gene 
hypermethylation could be a potential biomarker for HCC. 
In addition, proliferative capacities of both SP (Figures 3.10, 3.11) and 
Aldefluor-positive populations (Figure 3.13) were investigated. Both 
populations exhibited increased proliferative potential (Figure 3.14, 3.15) 
compared to their respective counterparts. These observations are supported 
by a paper published in 2009 by Yao and colleagues where they reported that 
TSCs in malignant brain tumours have more proliferative capacity than 
stem/progenitor cells in benign brain tumours (385).  
Invasion assays also revealed that both the SP and Aldefluor-positive 
populations possessed increased invasiveness compared to their respective 
counterparts. The increase of invasiveness in TSCs possibly relates to 
aggressiveness in tumours. This finding is supported by data where putative 
ovarian TSCs formed more aggressive tumour xenografts at a lower inoculum 
than their non TSC-progeny (9). Moreover, this result is in line with our 
microarray data where the CDC2 gene which is associated with 
aggressiveness in tumours was upregulated in both subpopulations.  
Finally, tumour propagation remains the gold standard for identifying 
TSCs. Therefore, in vivo experiments were performed to investigate the ability 
of both the SP and Aldefluor-positive populations to generate tumours in 
NOD/SCID mice. In our study, differential tumour formation was observed 
when SP/NSP cells were injected into the mice (Figure 3.16). However, 
differential tumour formation was not observed with Aldefluor-positive cells 
(Figure 3.17). In fact, Aldefluor-negative subpopulations produced larger 
tumours than that produced by Aldefluor-positive subpopulations. Although it 
remains possible that there may be a difference in viability between the two 
subpopulations, this was not observed in parallel 2D experiments performed 
on another set of Aldefluor-positive and -negative cells as shown in Figure 
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3.18. Therefore, an alternative explanation for our results may be that 
Aldefluor-positive cells lacked the biological ability to grow in vivo.  
Although Aldefluor-positive cells from the IGROV1 cell line were unable 
to demonstrate differential tumourigenicity in vivo, an increasing number of 
publications report increased tumourigenicity of as high as 50-fold in 
Aldefluor-positive cells (238). Therefore, in view of these findings as well as 
data from our earlier in vitro experiments which suggested that Aldefluor-
positive cells indeed possessed stem cell-like characteristics, we proceeded 
to inject Aldefluor-positive cells from the IGROV1 cell line into mice to 
generate novel in-house mAbs. Due to time constraints, these experiments 
were started before we had the tumorigenicity data of the Aldefluor-positive 
cells and in retrospect, it may have been better to have used the SP cells for 
antibody generation. However, SP cells are technically more difficult to isolate 
in large numbers and therefore the decision was made to use Aldefluor 
selected cells, but screen any antibodies for cross-reactivity with SP cells (see 
later). 
Of the 1109 clones which were obtained, a primary screening process 
found that only 143 of them showed reactivity towards isolated Aldefluor-
positive cells from the IGROV1 cell line (Figure 3.19). These clones were kept 
for a secondary screening process where they were tested for their reactivity 
towards the cell lines, IGROV1, hESC, PEA1, IMR90 and HEK293. Specific 
clones which only bound to subpopulations in the ovarian cancer cell lines, 
IGROV1 and PEA1, as well as the human embryonic stem cell line, hESC, 
were kept while unspecific clones which bound to the normal cell lines, IMR90 
and HEK293, were discarded. Through this series of screening, we were able 
to successfully identify 34 mAbs which fulfilled these selection criteria (Figure 
3.20).  
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In summary, our initial experiments showed that subpopulations 
detected by both the Hoechst dye method and Aldefluor activity assay 
exhibited properties consistent with those of TSCs, such as increased 
expression of stem cell markers, high capacities for proliferation and 
invasiveness, as well as differential in vivo tumour formation in SP/NSP 
experiments. We were also successful in generating a panel of 34 novel in-
house mAbs which had potential to be specific to ovarian TSCs. The next 
section describes the characterisation of these 34 novel in-house mAbs. 
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4.1. Introduction 
After successfully generating a panel of novel mAbs which fulfilled the 
selection criteria for potentially identifying mAbs specific for ovarian TSCs, we 
first sought to determine the isotypes of all 34 antibodies within this panel. 
This isotyping process is routine in initial characterisation of mAbs and served 
to indicate the purity of the hybridoma cell lines. Knowledge of the isotype 
also allowed us to determine the purification method for the antibody as 
different isotypes vary in their biochemical activity and therefore have different 
affinities for purification columns (386). Finally, by identifying the isotype, the 
most effective type of secondary antibody in future immuno-based 
experiments could be determined, thus enhancing the sensitivity of the 
assays.  
Isotyping of the in-house mAbs was then followed by a co-labeling 
experiment where IGROV1 ovarian cancer cells were incubated with each of 
the 34 mAbs and the Hoechst dye to investigate whether there was an 
overlap between detected antibody-positive populations and SP cells. This 
enabled us to identify mAbs within the panel (earlier found to be reactive 
towards Aldefluor-positive subpopulations) which enriched for SP cells, thus 
possibly detecting a distinct subpopulation of cells which possessed 
characteristics of both SP and Aldefluor-positive TSC populations.  
While most of the 34 mAbs did not demonstrate reactivity towards SP 
cells, 2 mAbs, mAb168 and mAb774, showed enrichment of SP cells in the 
mAb-positive fractions. Thereafter, we focused on carrying out further in vitro 
and in vivo characterisation experiments with these 2 particularly interesting 
mAbs.  
We first tested for the specificity of mAb168 and mAb774 towards 
tumour cells by investigating whether the antibodies also bound to cells from 
normal ovarian and breast cell lines. In addition, in collaboration with 
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Professor Dominique Bonnet, we tested for the reactivity of both mAbs 
towards patient normal haematopoietic cell samples.  
Moreover, to confirm that both mAbs detected subpopulations with 
stem cell-like characteristics, we tested for differences between antibody 
reactivity towards pluripotent hESCs and differentiated embryoid bodies 
(EBs). We also isolated antibody-positive and -negative cell populations from 
the IGROV1 ovarian cancer cell line and investigated the expression of 3 
stem cell markers, ABCB1, ALDH1A1 and CD133, which had earlier been 
found to be upregulated in both SP and Aldefluor-positive ovarian TSC 
populations. Furthermore, a microarray experiment was performed to 
investigate the expression of embryonic stem cell-signatures in isolated 
mAb168-positive and -negative cells. This was to be followed by a similar 
experiment involving isolated mAb774-positive and -negative cell 
subpopulations. 
To investigate the presence of additional TSC characteristics such as 
increased proliferative and invasiveness in subpopulations detected by the 
mAbs, antibody-positive and -negative subpopulations from the IGROV1 cell 
line were again isolated and tested in spheroid formation and invasion assays 
respectively. As tumour propagation remains the gold standard for identifying 
TSCs, in vivo experiments were performed where IGROV1 cell 
subpopulations detected by the 2 mAbs were injected into mice to determine 
the presence of differential tumour formation.  
Finally, cytotoxicity and clonogenic assays were both carried out to 
determine whether binding of mAb168 and mAb774 to their target cells 
induced cytotoxicity and growth-inhibiting effects respectively in the IGROV1 
ovarian cancer cell line. 
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4.2. Results 
4.2.1. Isotyping of the 34 novel mAbs 
Clone Subtype  Clone Subtype 
61 IgM  588 IgM 
80 IgG  641 IgA 
95 Unknown  647 IgM 
96 IgM  672 IgM 
97 IgM  743 IgM 
99 IgM  758 IgG 
103 IgM  774 IgM 
115 IgM  781 IgM 
119 IgM  798 IgM 
168 IgM  810 IgM 
266 IgM  826 IgM 
282 IgM  835 IgM 
294 IgG  910 Unknown 
376 IgG  919 IgM 
426 IgG  1020 IgM 
516 IgM  1078 IgM 
551 IgM  1102 IgM 
Table 4.1. Isotyping of novel mAbs.  
Isotyping was performed using the ClonalCell-InstantCHEK Isotyping Kit. 26 
IgMs, 5 IgGs and 1 IgA were identified. The isotyping kit failed to identify the 
isotypes of clones 95 and 910.   
Isotyping of our 34 in-house mAbs revealed that 26 of them were IgMs, 
5 were IgGs and only 1 was an IgA. The isotypes of the remaining 2 mAb 
clones, 95 and 910, could not be successfully identified (Table 4.1).  
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4.2.2. In vitro characterisation experiments 
4.2.2.1. Co-labeling of IGROV1 ovarian cancer cells with each of the 
mAbs and Hoechst dye 33342 
Following isotyping, we investigated whether our in-house mAbs 
detected subpopulations which overlapped with SP cells by performing a co-
labeling experiment where cells from the IGROV1 ovarian cancer cell line 
were incubated with each of the 34 mAbs and the Hoechst dye. As shown in 
Figure 4.1, of the 34 mAbs which had earlier been found to react towards 
Aldefluor-positive ovarian cancer cells, most of them did not demonstrate 
reactivity towards SP cells.  
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Figure 4.1. Co-labeling of IGROV1 cells with each of the 34 mAbs and 
the Hoechst dye.  
Representative FACS analysis data showing an example of a clone, mAb798, 
which did not detect subpopulations overlapping with those detected by the 
Hoechst dye. Majority of the clones did not detect subpopulations which 
overlapped with SP cells. 
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However, it was interesting to note that 2 of the 34 mAbs, mAb168 and 
mAb774, demonstrated reactivity towards SP cells (Figure 4.2 & 4.3). 
Moreover, there was at least a 4-fold enrichment of SP cells in the mAb-
positive fractions. 
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Figure 4.2. FACS analysis of mAb168-positive and SP cells.  
Representative FACS analysis data showing overlap between subpopulations 
detected by mAb168 and the Hoechst dye. A >18- fold enrichment of SP cells 
in the mAb168-positive fraction was observed. 
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Figure 4.3. FACS analysis of mAb774-positive and SP cells.  
Representative FACS analysis data showing overlap between subpopulations 
detected by mAb774 and the Hoechst dye. A >4-fold enrichment of SP cells in 
the mAb774-positive fraction was observed. 
4.2.2.2.  Reactivity of mAbs towards normal cells 
Thereafter, we focused on carrying out further in vitro and in vivo 
characterisation experiments with these 2 potentially interesting mAbs, 
mAb168 and mAb774. We initially sought to further verify that both mAbs 
targeted stem cells in tumour samples by testing for reactivity of the 
antibodies towards the normal immortalised ovarian cell lines, OSEC2 and 
IOSE21, and the normal immortalised breast cell line, U19-BrSE.  
100,000 events were collected for each sample during flow cytometry 
experiments. As shown in Figure 4.4, results from flow cytometry analyses 
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showed that the antibodies reacted with only 0.5% (500 cells) of cells in all 
three normal cell lines.  
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Figure 4.4. Representative FACS analysis data showing reactivity of         
mAbs towards the OSEC2 normal ovarian cell line.  
Both mAb168 and mAb774 did not exhibit reactivity towards the normal cells. 
Incubation with secondary antibody only was taken as the negative control for 
this experiment. 
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An additional experiment involved testing the reactivity of both mAbs 
towards normal haematopoietic cells from patient umbilical cord blood. To 
determine binding of the mAbs towards CD34+ haematopoetic cells, co- 
labeling of the cells with a CD34 antibody and each mAb was performed. As 
shown in Figure 4.5, again, both antibodies did not demonstrate increased 
binding towards these normal cells when compared to the control.  
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Figure 4.5. Co-labeling of cells with a CD34 antibody (FITC) and each 
mAb (APC).  
Representative FACS analysis data showed no difference in binding between 
control and test samples. Therefore, reactivity of both mAbs towards normal 
haematopoetic cells in patient umbilical cord blood samples was not 
observed. Incubation with secondary antibody only was taken as the negative 
control for this experiment. Data was produced in collaboration with Professor 
Dominique Bonnet at Cancer Research UK, London Research Institute. 
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4.2.2.3. Reactivity of mAbs towards populations with stem cell-like 
characteristics 
Once both mAb168 and mAb774 were shown to recognise a greater 
subpopulation of cells in tumour than in normal cell population, we proceeded 
to determine whether both antibodies also demonstrated reactivity towards 
populations which possessed stem cell-like characteristics.  
An initial experiment involved incubating both pluripotent hESCs and 
differentiated EBs with the antibodies. Thereafter, we carried out FACS 
analysis to determine reactivity of both mAbs towards the 2 different cell 
types. While both mAbs detected a very high percentage of hESCs, reactivity 
towards EBs was largely absent. Figure 4.6 shows representative data of the 
analyses where mAb168 and mAb774 detected 87.0% and 86.2% of hESCs 
respectively. 
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Figure 4.6. Representative FACS analysis data showing reactivity of 
mAbs towards hESCs and EBs.  
Both mAb168 and mAb774 exhibited high reactivity towards hESCs, with 
87.0% and 86.2% of cells staining positive for the antibodies respectively. 
Incubation with secondary antibody only was taken as the negative control for 
this experiment. 
169 
 
 
Further immunocytochemistry experiments confirmed this high 
percentage of binding towards hESCs (Figure 4.7) where the antibodies were 
observed to stain a large proportion of the cells. 
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Figure 4.7. Representative immunocytochemistry images showing 
reactivity of both mAbs (red) towards hESCs.  
DAPI (blue) was used for nuclei staining. Cells stained with the pluripotent 
marker, Oct4, were taken as a positive control in this experiment. Scale bar: 
10 µm. 
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4.2.2.4. Expression of stem cell markers  
4.2.2.4.1.  RT-qPCR analysis: Expression of stem cell markers in the mAb-
selected IGROV1 ovarian cancer cell line 
We then performed RT-qPCR analysis on isolated mAb-positive and 
negative populations to investigate the expression of stem cell-related 
markers in both subpopulations. As shown in Figure 4.8, RT-qPCR analysis of 
mean gene expression levels in mAb-positive relative to mAb-negative 
populations (n=3) revealed that stem cell-related genes in the mAb-positive 
populations were significantly upregulated.  
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Figure 4.8. RT-qPCR analysis of stem cell-related markers in isolated   
IGROV1 mAb-positive and -negative populations.  
All 3 stem cell markers were upregulated in the mAb-positive IGROV1 
subpopulations. A, ABCB1, ALDH1A1 and CD133 were upregulated by 7.5- , 
53.7- , and 2.9-fold respectively in mAb168-positive populations when 
compared to mAb168-negative populations. B, Similarly, all 3 stem cell 
markers were upregulated in mAb774-positive populations. ABCB1, 
ALDH1A1 and CD133 were upregulated by 10.8- , 65.5- and 2.8-fold 
respectively. ■  represents mAb-positive populations while ■  represents mAb- 
negative populations. Expression of the endogenous gene, GAPDH, was 
taken as a control. Experiments were performed with the IGROV1 ovarian 
cancer cell line. Error bars represent mean ± SEM. P<0.05. 
4.2.2.4.2. RT-qPCR analysis: Expression of stem cell markers in the 
HEYA8 ovarian cancer cell line 
This upregulation of stem cell markers in the mAb-positive 
subpopulations was confirmed using another ovarian cancer cell line, HEYA8, 
as shown in Figure 4.9. 
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Figure 4.9. RT-qPCR analysis of stem cell-related markers in isolated 
HEYA8 mAb-positive and negative populations.  
All 3 stem cell markers were upregulated in the mAb-positive HEYA8 
subpopulations. A, ABCB1, ALDH1A1 and CD133 were upregulated by 1.8- , 
3.1- , and 2.0-fold respectively in mAb168-positive populations when 
compared to mAb168-negative populations. B, Similarly, all 3 stem cell 
markers were upregulated in mAb774-positive populations. ABCB1, 
ALDH1A1 and CD133 were upregulated by 2.4- , 2.1- and 1.6-fold 
respectively. ■  represents mAb- positive populations while ■  represents 
mAb-negative populations. Expression of the endogenous gene, GAPDH, was 
taken as a control. Experiments were performed with the HEYA8 ovarian 
cancer cell line. Error bars represent mean ± SEM. P<0.05. 
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4.2.2.4.3.  Microarray analysis of stem cell signatures: mAb168-positive vs. 
mAb168-negative cell subpopulations 
Similar to microarray experiments performed earlier with SP/NSP and 
Aldefluor-positive/negative populations, GSEA (263) was used to interrogate 
gene expression profiling of mAb168-positive compared to mAb168-negative 
from the IGROV1 cell line for 15 published embryonic stem cell related 
signatures (Table 2.1, Materials & Methods Section).  
Using the average signal intensities of the probes mapped to one gene, 
PRC2 target genes were significantly upregulated in mAb168-positive 
compared to mAb168-negative IGROV1 cells (p<10-6 and FDR<10-4). (Table 
4.2).  
Gene set name Score p-value FDR Status
prc2_targets2 0.3236 <0.0001 <0.0001 Upregulated
prc1 0.0278 0.27 0.6567 Upregulated
suz12 0.0158 0.36 0.6567 Upregulated
eed 0.0334 0.36 0.6567 Upregulated
h3k27 0.025 0.36 0.6567 Upregulated
E2F6 0.0055 0.394 0.6567 Upregulated
oct4 0.0664 0.394 0.6567 Upregulated
nos 0.042 0.394 0.6567 Upregulated
nostf 0.0369 0.394 0.6567 Upregulated
ES1 -0.0781 0.236 0.985 Downregulated
prc2 -0.0695 0.236 0.985 Downregulated
nanog -0.0474 0.36 0.985 Downregulated
sox2 -8.00E-04 3.60E-01 0.985 Downregulated
ES2 -0.06 0.36 0.985 Downregulated
prc2_targets1 -0.0098 0.394 0.985 Downregulated  
Table 4.2. GSEA analysis of stem cell related signatures in mAb168- 
positive and -negative subpopulations.  
No significant upregulation of stem cell-related signatures in mAb168-positive 
populations was observed. Instead, PRC2 targets were significantly 
upregulated.  
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Consequently, we sought to identify pathways which were associated 
with up/down-regulated genes in the mAb168-positive subpopulation. First, 
we identified genes which were differentially expressed between mAb-positive 
and negative subsets using the Rank Product test (261). This is a non-
parametric test, which is particularly applicable for small sample sizes and 
deviation from assumed underlying probability distributions in microarray 
analyses.  
Genes were considered to be regulated between two subsets if the 
rank product showed a FDR below 0.05. Genes above this threshold were 
considered to be not significantly regulated. Top-ranking genes which were 
significantly upregulated are given in Table 4.3 while top-ranking genes which 
were significantly downregulated are given in Table 4.4. Complete lists of 
significantly upregulated and downregulated genes are provided in 
Appendices 8 and 9 respectively. 
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ProbeID Gene symbol Log fold-change 
1552715_a_at ALDH1A1 5.03 
1554921_a_at NNMT 4.61 
201131_s_at ADAMTS1 4.57 
201430_s_at RAI2 4.35 
202237_at SCEL 4.22 
202238_s_at IGFBP1 4.21 
202508_s_at PLA2G4A 4.15 
203065_s_at IGFBP3 4.10 
203232_s_at NNMT 4.01 
203887_s_at SCEL 3.96 
Table 4.3. Top-ranking genes which were significantly upregulated in 
mAb168-positive subpopulations. 
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ProbeID Gene symbol Log fold-change 
224997_x_at H19 3.05 
224646_x_at H19 3.00 
230896_at BEND4 2.97 
236262_at MMRN2 2.80 
229700_at ZNF738 2.82 
206291_at NTS 3.01 
212912_at RPS6KA2 2.64 
204570_at COX7A1 3.28 
233092_s_at LOC100271840 2.59 
225817_at CGNL1 2.56 
Table 4.4. Top-ranking genes which were significantly downregulated in 
mAb168-positive subpopulations. 
We then used the online DAVID bioinformatics resources which 
consists of an integrated biological knowledgebase and analytic tools aimed 
at systematically extracting biological meaning from large gene/protein lists 
(387). By uploading lists of genes which were found to be significantly 
up/down regulated in the mAb168-positive cells, we were able to identify 
significant terms representing gene product properties which were associated 
with these gene lists.  
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As shown in Table 4.5, genes coding for extracellular matrix (ECM) 
components was found to be significantly upregulated in the mAb168-positive 
population. Conversely, cell cycle-related genes were significantly 
downregulated (Table 4.6). 
Term p-value FDR 
GO:0031012~extracellular 
matrix 
7.44E-11 9.70E-8 
GO:0044421~extracellular 
region part 
2.71E-10 3.53E-7 
GO:0005578~proteinaceous 
extracellular matrix 
4.67E-10 6.08E-7 
GO:0005576~extracellular 
region 
4.03E-8 5.25E-5 
GO:0044420~extracellular 
matrix part 
5.71E-8 7.44E-5 
GO:0005604~basement 
membrane 
4.83E-6 0.006 
GO:0005615~extracellular 
space 
1.38E-4 0.180 
Table 4.5. Terms which were significantly upregulated in the mAb168-
positive population.  
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Term p-value FDR 
GO:0015718~monocarboxylic acid 
transport 
1.58E-5 0.03 
 
GO:0031497~chromatin assembly 2.82E-5 0.05 
 
GO:0065004~protein-DNA complex 
assembly 
4.18E-5 0.07 
 
GO:0055085~transmembrane 
transport 
4.57E-5 0.08 
 
GO:0005886~plasma membrane 6.28E-5 0.08 
 
GO:0000786~nucleosome 7.05E-5 0.09 
 
GO:0044459~plasma membrane part 9.19E-5 0.12 
GO:0006323~DNA packaging 7.46E-5 0.13 
 
GO:0006334~nucleosome assembly 1.23E-4 0.21 
 
Table 4.6. Terms which were significantly downregulated in the mAb168-
positive population.  
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Finally, again using DAVID, functional analysis of pathways which the 
upregulated genes were involved in was performed. As shown in Table 4.7, 
there seemed to be a trend for upregulated genes to be associated with 
pathways involved in cancer. These included pathways involved in ECM-
receptor interaction, proliferation, tissue invasion and metastasis, evasion of 
apoptosis and cytokine-cytokine receptor interaction 
(www.david.abcc.ncifcrf.gov/home.jsp). Other signaling pathways involved 
included the Wnt and PI3K pathways. 
 
Term p- value  FDR 
Focal adhesion <0.001 0.12 
Pathways in cancer <0.001 0.08 
Small cell lung cancer <0.008 0.29 
NOD- like receptor signaling pathway <0.04 0.72 
Complement and coagulation cascades <0.06 0.76 
Table 4.7. Functional analysis of pathways which upregulated genes 
were involved in.  
Therefore, in view of data obtained from our microarray analyses, as 
well as to investigate the presence of additional TSC characteristics such as 
increased proliferative and invasiveness in subpopulations detected by the 
mAbs, subsequent spheroid formation and invasion experiments were 
performed.  
180 
 
 
4.2.2.5.  Proliferation studies 
4.2.2.5.1. Spheroid formation assay: mAb168-positive subpopulations vs. 
mAb168-negative subpopulations 
As shown in Figure 4.10, mAb168-positive cells possessed a greater 
ability to grow in an anchorage-independent manner as spheroids compared 
to mAb168-negative cells. It was further observed that the largest colonies 
(>64 cells) were more abundantly formed in the mAb168-positive population. 
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Figure 4.10. Anchorage-independent spheroid assays comparing the 
proliferative capacity of mAb168-positive and -negative 
subpopulations.  
Larger and more numerous colonies in the mAb168-positive populations were 
observed compared to that in mAb168-negative populations. ■ represents 
mAb168-positive cells while ■ represents mAb168-negative cells. 
Experiments were performed with the IGROV1 ovarian cancer cell line. Error 
bars represent mean ± SEM. 
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4.2.2.5.2.  Spheroid formation assay: mAb774-positive subpopulations vs. 
mAb774-negative subpopulations 
Similarly, mAb774-positive cells possessed a greater ability to grow in 
an anchorage-independent manner as spheroids compared to mAb774-
negative cells. It was further observed that the largest colonies (>64 cells) 
were more abundantly formed in the mAb774-positive population (Figure 
4.11). 
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Figure 4.11. Anchorage-independent spheroid assays comparing the 
proliferative capacity of mAb774-positive and -negative 
subpopulations.  
Anchorage-independent spheroid assays revealed larger and more numerous 
colonies in the mAb774-positive populations compared to mAb774-negative 
populations. ■ represents mAb774-positive cells while ■ represents mAb774-
negative cells. Experiments were performed with the IGROV1 ovarian cancer 
cell line. Error bars represent mean ± SEM. 
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Figure 4.12 shows microscopic images of the mAb-positive and 
negative subpopulations from spheroid formation experiments at Day 12 of 
the 3D phase. 
 (A) 
Live unselected mAb168- negative mAb168- positive
 
(B) 
Live unselected mAb774- negative mAb774- positive
 
Figure 4.12. Microscopic images of mAb- positive and negative 
subpopulations from spheroid formation experiments at 
Day 12 of the 3D phase.  
Antibody-positive cells demonstrated increased proliferative capacity with 
larger colonies being formed in the mAb-positive subpopulations when 
compared to that in the mAb-negative subpopulations. A, formation of larger 
colonies was observed in the mAb168-positive subpopulations when 
compared to the mAb168-negative subpopulations. B, similarly, formation of 
larger colonies was observed in the mAb774-positive subpopulations when 
compared to the mAb774-negative subpopulations. 
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4.2.2.6.  Invasion assays: mAb-positive subpopulations vs. mAb-
negative subpopulations 
Detected subpopulations in the IGROV1 cell line were also investigated 
for their invasive capacities. Using a commercial invasion assay kit, an 
increase in the invasiveness of mAb-positive cells when compared to mAb-
negative cells was observed (Figure 4.13).  
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Figure 4.13. Invasive capacities of antibody-positive and -negative 
subpopulations.  
A, antibody-positive subpopulations demonstrated increased invasiveness 
when compared to the antibody-negative subpopulations where a 3.7-fold 
increase in invasiveness of mAb168-positive cell was observed when 
compared to that of mAb168-negative cells. Similarly, a 3.9-fold increase in 
invasiveness of mAb774-positive cells was observed when compared to that 
of mAb774-negative cells. B, percentage invasion of mAb168-negative and 
mAb168-positive cells were 5% and 18.5% respectively while percentage 
invasion of Aldefluor-negative and Aldefluor-positive cells were 4.5% and 
17.5% respectively. ■ represents mAb-positive populations while ■ represents 
mAb-negative populations. Experiments were performed with the IGROV1 
ovarian cancer cell line. Error bars represent mean ± SEM.  
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4.2.2.7.  In vivo studies 
4.2.2.7.1. Isolation of mAb-positive and negative subpopulations for use in 
differential tumour formation experiments 
Finally, we performed an in vivo experiment to investigate whether 
detected subpopulations possessed enhanced tumour formation capacities. 
We first isolated mAb-positive and -negative cells and confirmed the 
upregulation of the ALDH1A1 marker in the positive subpopulation. As shown 
in Figure 4.14, ALDH1A1 was upregulated by 144-fold and 162-fold in the 
mAb168-positive and mAb774-positive populations respectively. We then 
injected both mAb-positive and -negative cells into mice for subsequent 
differential tumour formation experiments. 
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Figure 4.14. Expression of ALDH1A1 in isolated mAb-positive cell 
subpopulations.  
There was a 144-fold and 162-fold increase in ALDH1A1 expression in 
mAb168-positive and mAb774-positive cells respectively. ■ represents mAb-
positive populations while ■ represents mAb-negative populations. 
Experiments were performed with the IGROV1 ovarian cancer cell line. Error 
bars represent mean ± SEM.  
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4.2.2.7.2.  Differential tumour formation experiment: mAb168-positive 
subpopulations vs. mAb168-negative subpopulations 
As shown in Figure 4.15, we observed significantly increased 
tumourigenicity (Repeated Measures ANOVA: p<0.05) of mAb168-positive 
compared to mAb168-negative cells when injecting 100 cells each into the 
mammary fat pad of NOD/SCID mice. In addition to the differences in average 
tumour growth, mAb168-positive cells initiated tumours more frequently than 
mAb168-negative cells.  
 
Cells grafted 
mAb168-positive population 
(frequency of tumour formation) 
mAb168-negative population 
(frequency of tumour formation) 
100 6/8 4/8 
 
mAb168- positive
mAb168- negative
 
Figure 4.15. Tumourigenic potential of mAb168-positive and -negative 
cells.  
MAb168-positive and -negative cells (100 cells each) were injected into mice. 
A significant increase in size and frequency of tumour formation was observed 
in the mAb168-positive cells. Experiments were performed with the cells 
isolated from the IGROV1 ovarian cancer cell line. Error bars represent mean 
± SEM. 
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4.2.2.7.3. Differential tumour formation experiment: mAb774-positive 
subpopulations vs. mAb774-negative subpopulations 
Similarly, we observed increased tumourigenicity of mAb774-positive 
compared to mAb774-negative cells when injecting 100 cells each into the 
mammary fat pad of NOD/SCID mice (Fig. 4.16). In addition to the differences 
in average tumour growth, mAb774-positive cells initiated tumours more 
frequently than mAb774-negative cells.  
 
Cells grafted 
mAb774-positive 
population (frequency 
of tumour formation) 
mAb774-negative 
population (frequency 
of tumour formation) 
100 5/8 4/8 
 
mAb774-positive
mAb774-negative
 
Figure 4.16. Tumourigenic potential of mAb774-positive and -negative 
cells.  
MAb774-positive and -negative cells (100 cells each) were injected into mice. 
An increase in tumourigenicity was observed in the mAb774-positive cells. 
Experiments were performed with cells isolated from the IGROV1 ovarian 
cancer cell line. Error bars represent mean ± SEM. 
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4.2.2.8.  Cytotoxicity assays: Effect of mAb774 on IGROV1 ovarian 
cancer cells 
Having demonstrated through performing in vitro and in vivo 
experiments that both mAb168 and mAb774 were successful in detecting 
subpopulations of cells which possessed stem cell-like characteristics, we 
carried out cytotoxicity and clonogenic assays to determine whether binding of 
the mAbs to detected IGROV1 subpopulations affected these cells. 
Unfortunately, we were unsuccessful in the purification of mAb168. We did, 
however, manage to purify mAb774 from its cell culture supernatant. 
Thereafter, we first performed cytotoxicity experiments using this purified form 
of mAb774 where IGROV1 ovarian cancer cells were incubated with varying 
concentrations of the antibody.  
Fluorescence intensity, which is directly proportional to cell number, 
was then measured at 24h, 48h and 72h. As shown in Figure 4.17, 
fluorescence intensities of the samples increased over time and were similar 
to that of control cells (buffer only) after 72h, therefore indicating that the 
ovarian cancer cells were not affected by purified mAb774 and continued to 
increase in numbers. 
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Figure 4.17. Cytotoxicity assay.  
Cells were incubated with mAb774 at 3 different concentrations – 0.2, 0.1, 
and 0.05 mg/mL. Increasing fluorescence intensities measured at 24h, 48h, 
and 72h indicated that cell numbers continued to increase over time, showing 
that purified mAb774 did not confer cytotoxicity towards ovarian cancer cells. 
Buffer only (0 mg/mL) was used as a control. Experiments were performed 
with the IGROV1 ovarian cancer cell line. Error bars represent mean ± SEM.   
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4.2.2.9. Clonogenic assays 
Clonogenic assays which essentially tests every cell in the population 
for its ability to undergo “unlimited” division were also performed (388). The 
final size and number of colonies formed were determined using a IX70 
Olympus microscope (Olympus, USA) and a commercially available image- 
analysis software package, Image-Pro (Media Cybernetics, USA).  
Interestingly, there was a significant decrease in colony numbers of 
larger- sized colonies containing 33-64 cells when 0.05 mg/mL of purified 
mAb774 was added (Fig.4.18). 
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Figure 4.18. Clonogenic assay. 
Cells were incubated with mAb774 at 3 different concentrations – 0.2, 0.1, 
and 0.05 mg/mL. Colony numbers and sizes were significantly decreased in 
colony numbers of larger-sized colonies containing 33-64 cells when 0.05 
mg/mL of purified mAb774 was added. Buffer only (0 mg/mL) was used as a 
control. Experiments were performed with the IGROV1 ovarian cancer cell 
line. Error bars represent mean ± SEM and statistical analysis was performed 
using Student’s two- tailed t test; *, difference over control (p<0.05). 
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4.2.2.10. Summary of characteristics of detected subpopulations  
In summary, our in vitro and in vivo characterisation experiments 
showed that both mAb168 and mAb774 were successful in detecting a 
subpopulation of cells which possessed stem cell-like characteristics such as 
the upregulation of stem cell markers – ABCB1, ALDH1A1 and CD133. Flow 
cytometry and immunocytochemistry experiments revealed that both 
antibodies demonstrated specific reactivity towards pluripotent hESCs but this 
reactivity was absent in differentiated EBs. Interestingly, reactivity was also 
absent when both mAbs were tested on cells from normal ovarian, breast and 
haematopoietic cell lines in further flow cytometry experiments. 
Although microarray analyses did not detect significant upregulation of 
embryonic stem cell signatures in isolated mAb168-positive cells, subsequent 
gene ontology analyses revealed upregulation of genes related to the ECM 
and downregulation of cell cycle-related genes. In addition, further functional 
analyses showed that upregulated genes were involved in pathways 
associated with cellular growth and proliferation, development, movement and 
cell death. 
Microarray analyses results were confirmed by spheroid formation and 
invasion assays where antibody-positive cells exhibited increased proliferative 
and invasive capacities when compared to their counterpart mAb-negative 
cells. Most importantly, in vivo differential tumour formation was observed with 
both mAbs. Finally, although purified mAb774 did not induce cytotoxicity in 
IGROV1 ovarian cancer cells, clonogenic experiments revealed that low 
concentrations of the antibody (0.05 mg/mL) caused a significant decrease in 
colony numbers of larger-sized colonies (33-64 cells per colony). 
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 mAb168 mAb774 
Detection of putative TSC subpopulation in 
ovarian, breast and cervical cancer cell lines 
√ √ 
Absence of reactivity towards cells from normal 
ovarian, breast and haematopoietic cell lines 
√ √ 
Specific reactivity towards pluripotent cells √ √ 
Upregulation of stem cell gene expression in 
putative TSC subpopulation 
√ √ 
Upregulation of embryonic stem cell signatures 
in putative TSC subpopulation 
X X 
Increased proliferation observed in putative 
TSC subpopulation 
√ √ 
Increased invasiveness observed in putative 
TSC subpopulation 
√ √ 
Differential in vivo tumour formation observed 
in putative TSC subpopulation 
√ √ 
Cytotoxicity observed towards ovarian cancer 
cells  
N/A X 
Cytostatic effects observed towards ovarian 
cancer cells 
N/A √ 
Table 4.8. Summary table showing the characteristics of mAb168 and 
mAb774 
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4.3. Characterisation of novel mAbs to  ovarian TSCs: 
discussion 
As mentioned in our previous chapter, among 1109 mAbs which were 
generated, 34 of these were found to be potentially specific towards ovarian 
TSCs. Subsequent isotyping of these 34 mAbs revealed that 26 of them were 
IgMs, 5 were IgGs and 1 was IgA (Table 4.1). The isotypes of the 2 remaining 
mAbs could not be successfully identified. It is possible that the low 
productivity of this 2 clones, mAb95 and mAb910, resulted in concentrations 
which were below the threshold of detection of the isotyping kit.   
While our panel of novel mAbs included mostly IgMs, clinically 
approved therapeutic mAbs are usually of the IgG isotype. However, recent 
cancer trials testing potentially therapeutic IgM mAbs have shown promising 
anticancer activity including the regression of tumours in vivo (389-392). For 
example, mAb216, a naturally occurring human IgM, was found to efficiently 
bind and kill acute lymphoblastic leukemia B-progenitor lymphoblasts. It has 
also been shown to exhibit an enhanced degree of cytotoxicity when 
introduced in combination with vincristine, a chemotherapeutic agent (389). 
These clinical responses could be attributed to the ability of IgM to strongly 
activate the complement pathway to effectively kill tumour cells. Therefore, 
the 26 IgMs in our panel represented promising candidates for specific 
targeting and eradication of ovarian tumour cells. 
After isotyping of the mAbs, we proceeded with an in vitro co-labeling 
experiment where IGROV1 ovarian cancer cells were incubated with each of 
the 34 mAbs and the Hoechst dye to determine whether there was an overlap 
between detected antibody-positive populations and SP cells. This enabled us 
to identify 2 of the 34 mAbs within the panel (earlier found to be reactive 
towards Aldefluor-positive subpopulations) which enriched for SP cells (Fig. 
4.2 & 4.3).  
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Pierre-Louis and colleagues previously reported that the coexpression 
of SP and ALDH markers refined the Lin-CD34+CD38- haematopoietic 
compartment and identified an SP/ALDH cell subset enriched in quiescent 
primitive HSCs/HPCs (393). Similarly, the overlap between SP and 
subpopulations detected by these 2 mAbs could represent the identification of 
a cell subset enriched in primitive TSCs. We therefore focused on testing 
these 2 mAbs, mAb168 and mAb774, in further in vitro and in vivo 
experiments.  
As shown in Figure 4.4, FACS analysis data from normal immortalised 
ovarian and breast cell lines showed that both mAb168 and mAb774 did not 
demonstrate detectable reactivity towards normal cells.  Similarly, normal 
haematopoeitic cells from human umbilical cord blood samples were not 
detected by both mAbs (Fig. 4.5). This set of data suggests that there is 
perhaps a much smaller percentage of stem cells in normal compared to 
tumour samples and that our mAbs could possibly be useful in distinguishing 
between normal and disease states.  
Further experiments revealed that both mAbs were specific in detecting 
cells with stem cell-like characteristics. For example, both mAb168 and 
mAb774 demonstrated high reactivity towards pluripotent hESCs while 
reactivity was absent in differentiated EBs (Fig. 4.6). Immunocytochemistry 
experiments confirmed this high level of binding to the hESC whole cell line, 
where majority of the cells were detected by the mAbs (Fig. 4.7). Moreover, all 
3 stem cell markers, ABCB1, CD133, and ALDH1A1, were found to be 
upregulated in mAb-positive populations when compared to their mAb-
negative counterparts (Fig. 4.8 & 4.9). 
Although microarray experiments did not show the upregulation of 
embryonic stem cell-related signatures (Table 4.2), gene ontology analyses 
revealed that ECM components were highly upregulated (Table 4.5). While 
ECM has been seen as mere scaffolding for many years, its role in tumor 
194 
 
 
resistance, progression and invasion through ECM remodeling and stiffening 
of the tissue stroma has become evident in recent years. Bifunctional, 
heterodimeric cell surface receptors, known as integrins, can physically link 
cells to the ECM, enabling these integrin receptors to transduce signals into 
the cytoplasm that influence cell behavior. Moreover, cancer cells are able to 
switch the types of integrins they express, favoring ones that transmit 
progrowth signals (394, 395). 
Several publications have also highlighted the role of the ECM in 
tumour initiation and progression. For example, Emery and colleagues 
reported the overrepresentation of the ECM-receptor interaction in the 
progression from simple ductal hyperplasia to atypical ductal hyperplasia and 
further to ductal carcinoma in situ in ER+ sporadic breast cancer (396). Their 
data also suggested that in breast cancer progression, dysregulation of the 
ECM-epithelial cell interactions was an early event, even before any evidence 
of invasion became visible. Similarly, Birnie and colleagues reported 
dysregulated cell adhesion and ECM receptor interactions pathway when 
comparing prostate TSCs (CD133+/α2β1
high) to their normal and differentiated 
counterparts (CD133-/α2β1
low) (397).  
Interestingly, when Jazaeri and colleagues performed a study to 
determine whether distinct gene expression profiles were associated with 
intrinsic and/or acquired chemoresistance in EOC (398), they observed a 
significant overrepresentation of genes encoding ECM-related proteins in the 
gene expression profile of postchemotherapy ovarian tumours compared with 
that of primary tumours. This finding is consistent with an earlier study of 
ovarian cancer chemoresistance in vitro where a group of several ECM 
components was upregulated in platinum-resistant cells (399). 
Gene ontology analyses also revealed that cell cycle-related genes 
were significantly downregulated (Table 4.6). Deregulated cell-cycle control is 
a fundamental aspect of cancer. A direct molecular link between the two was 
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first discovered when it was reported that the genes which encoded 
retinoblastoma protein (RB) and p53, both of which restrain cell-cycle 
progression, were frequently mutated or deleted in human cancers (400). In 
ovarian cancer, several cell cycle-related genes play crucial roles in tumour 
tumorigenesis and development. For example, Cyclin D1 has been reported 
to be underexpressed mainly in high-grade tumours, in contrast with 
borderline and low-grade ovarian tumours (401). In addition, the loss of p27, 
was found to confer a more aggressive phenotype to tumour cells (402). This 
was supported by immunohistochemistry results from Sui and colleagues 
which showed that the expression of p27 decreased from benign to borderline 
to malignant tumors (403). Furthermore, low expression of both p27 and p57 
expression has also been significantly associated with high tumor grade, and 
patients have a lower overall survival (404). 
Subsequent functional analyses showed that pathways which the 
upregulated genes were involved in included cellular growth and proliferation, 
cellular development, movement and cell death, processes which are known 
to be hallmarks of cancer (Table 4.7)(166). These results were validated by 
spheroid formation experiments which revealed that both mAb168- and 774- 
positive cells demonstrated increased proliferative capacity when compared to 
their counterparts (Fig. 4.10- 4.12). Antibody-positive cells also possessed 
increased invasiveness when compared to their counterpart antibody-negative 
populations (Fig. 4.13). These in vitro experiments also served to confirm that 
both mAb168 and mAb774 detected subpopulations possessing TSC 
characteristics similar to those displayed by SP and Aldefluor-positive cells as 
described earlier. 
Finally, in the in vivo experiment, we isolated mAb-positive and 
negative cells, and confirmed that the stem cell marker, ALDH1A1, was 
indeed upregulated in the mAb-positive cells before injecting both 
subpopulations into mice (Fig. 4.14). As would have been expected for a TSC 
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population, it was observed that antibody-positive cells demonstrated 
increased tumorigenicity when compared to the antibody-negative cells (Fig 
4.15 & 4.16).  
While cytotoxicity experiments revealed that purified mAb774 did not 
confer cytotoxic effects towards ovarian cancer cells (Fig 4.17), conjugation of 
the antibody with cytotoxic agents in future experiments could possibly 
combine mAb specificity with the potency of cytotoxic molecules, thus 
enabling the mAb to target and effectively kill ovarian TSCs. We propose that 
the lack of cytotoxicity may be due to the inability of mAb774 to exert a direct 
effect on the IGROV1 cells as observed in other mAbs (405). Furthermore, we 
were unable to examine the effect of complement-mediated cytotoxicity in our 
in vitro setting.  However, it is possible that mAb774 may activate complement 
pathways to induce complement-mediated cytotoxicity in vivo. 
Interestingly, clonogenic experiments showed a significant decrease in 
colony numbers of larger-sized colonies when 0.05 mg/mL of purified mAb774 
was added (Fig 4.18). This data suggests that at this concentration, mAb774 
confers a cytostatic effect towards ovarian cancer cells, thus reducing the 
survival and regenerative capacity of these cells.  It is possible that at higher 
concentrations, antibodies form self-aggregates instead of binding to target 
antigens to exert their effects (406). This therefore could be a likely reason for 
our observation where higher concentrations of mAb774 failed to decrease 
colony formation. 
In conclusion, among the 34 mAbs which were earlier found to detect 
ovarian TSCs, we identified 2 interesting novel mAbs, mAb168 and mAb774, 
which detected TSC populations with stem cell-like characteristics as shown 
by in vitro as well as in vivo studies (Table 4.2). The identification of the target 
antigen of these 2 antibodies will be discussed in our next chapter. 
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Chapter 5.   
Identification and 
characterisation of 
target antigen 
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5.1. Introduction 
Following extensive characterisation of both mAb168 and mAb774, we 
sought to identify the target antigen(s) which the 2 novel mAbs detected. We 
first carried out immunoprecipitation (IP) with commercially available Phytip 
columns to purify the target antigen of both mAbs. As our mAbs detected cell 
surface antigens, whole membrane protein extracts from the IGROV1 cell line 
were obtained before undergoing IP experiments. The columns were 
functionalized with rabbit anti-mouse IgM antibodies which were conjugated 
with biotin, followed by either mAb168 or mAb774, before passing membrane 
protein extracts through.  
Thereafter, Western blotting was performed where both the IP eluates 
and whole membrane protein extracts were resolved on reducing sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and probed 
with the respective mAbs. This enabled identification of the putative target 
antigen band by comparing bands detected in both the IP eluates and whole 
membrane protein extracts. We then repeated the same loading setup on 
reducing SDS-PAGE, followed by a silver staining step. The target antigen 
bands were identified by comparing the bands from previous Western blot 
results with those present on the silver stained gels. Subsequently, the 
putative target antigen bands on the silver stained gels were excised and 
subjected to further mass spectrometry (MS) analyses.  
After successful identification of the putative target antigen by MS 
analyses, this result was verified by RT-qPCR on isolated mAb-positive and 
mAb-negative subpopulations using primers which targeted the putative target 
gene. Finally, a comparison of the 2 novel in-house mAbs with commercially 
available antibodies for the target antigen was carried out through performing 
FACS analyses and immunocytochemistry experiments. 
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5.2. Results 
5.2.1. Identification of target antigen  
5.2.1.1.  IP assays followed by Western blotting 
We were able to identify the antigen band by detecting bands of 
identical sizes present on both IP eluate (IP/MP) and membrane protein 
extract (MP) lanes. As shown in Figure 5.1, an antigen band corresponding to 
a molecular weight of ~180kDa was detected for both mAbs. The lower bands 
observed on all lanes corresponded to the reduced chain of the mAbs. 
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Figure 5.1. Identification of target antigens using IP followed by Western 
blotting.  
IP was carried out on IGROV1 membrane protein extracts using either 
mAb168 or mAb774. The IP eluate (IP/MP) and whole membrane protein 
extract (MP), were then resolved on reducing, gradient SDS-PAGE and 
probed with the appropriate mAb. Antigen band was identified by comparing 
bands between IP/MP lane and MP lane. Left, an antigen band with a 
molecular weight of ~180kDa (black arrows) was observed in both the IP/MP 
lane and MP lane for mAb168. Right, similarly, an antigen band with a 
molecular weight of ~180kDa was observed for mAb774. IP without 
membrane protein extract (IP/-ve) and non-purified mAb supernatant (mAb 
s/n) served as negative controls in this experiment. 
M 
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5.2.1.2.  IP assays followed by silver staining 
The loading setup was then duplicated on SDS-PAGE gels, probed 
with either mAb168 or mAb774, and stained with silver. Silver staining 
analysis of the gel revealed antigen bands possessing a molecular weight 
similar to that of the bands detected on the earlier Western blotting 
experiments shown in Fig 5.1. As shown in Figure 5.2, bands corresponding 
to a molecular weight of ~180kDa were detected for both mAbs. Thereafter, 
the antigen bands from the silver-stained gels were excised, reduced, 
alkylated and tryptic digested before being subjected to MS analyses.  
 
M MP -ve
IP
168
s/nMP
MW (kDa)
97-
64-
51-
39-
28-
MW (kDa)
97-
64-
51-
39-
28-
M MP -ve
IP 774
s/nMP
180-
180-
 
Figure 5.2. Identification of target antigens using IP followed by silver 
staining.  
IP was carried out on IGROV1 membrane protein extracts using either 
mAb168 or mAb774. The IP eluate (IP/MP) and whole membrane protein 
extract (MP), were then resolved on reducing, gradient SDS-PAGE and 
probed with the appropriate mAb. Antigen bands were identified by comparing 
bands present on the IP(MP) lane with those which were identified on earlier 
Western blotting results. Left, the antigen band with a molecular weight of 
~180kDa (black arrows) was observed in the IP(MP) lane for mAb168. Right, 
similarly, the antigen band with a molecular weight of ~180kDa was observed 
for mAb774.  
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5.2.1.3.  Mass spectrometry analyses 
5.2.1.3.1. Identifying the putative target antigen of mAb168 
We used mass spectrometry, an important method for the 
characterisation of proteins, to identify the antigen band of mAb168 (407). 
First, proteins were enzymatically digested into smaller peptides using trypsin.    
Subsequently these peptides were introduced into the mass spectrometer and 
identified by tandem mass spectrometry where collision-induced dissociation 
generated a set of fragments from a specific peptide ion. The observed 
fragment masses were then matched with a database of predicted masses for 
one of many given peptide sequences in order to identify the target antigen. 
In our study, although several keratin types were revealed as the 
putative antigen target (Table 5.1), discrepancy between molecular weights 
suggested that these were highly unlikely to be our target antigen and was 
most possibly due to contamination of the sample by keratin. This issue is 
further analysed in our discussion section. Therefore, we concluded that the 
antigen band of mAb168 could not be successfully identified by comparing the 
peptides data obtained with our protein database. 
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Protein name 
Protein 
accession 
numbers 
Protein 
molecular 
weight 
(Da) 
Protein 
identification 
probability 
Number 
of unique 
peptides 
Percentage 
sequence 
coverage 
Keratin, type II 
cytoskeletal 1 
K2C1_HUMAN 66,022.30 100.00% 21 34.00% 
Keratin, type I 
cytoskeletal 10 
K1C10_HUMAN 58,810.80 100.00% 10 42.00% 
Keratin, type I 
cytoskeletal 9 
K1C9_HUMAN 62,047.80 100.00% 15 41.40% 
Keratin, type II 
cytoskeletal 2 
K22E_HUMAN 65,415.90 100.00% 14 30.70% 
Keratin, type II 
cytoskeletal 5 
K2C5_HUMAN 62,361.60 100.00% 4 12.40% 
Keratin, type I 
cytoskeletal 14 
K1C14_HUMAN 51,544.50 100.00% 4 13.30% 
Table 5.1. MS analyses identifying putative antigen target of mAb168.  
Several types of keratin were identified as the putative antigen target of 
mAb168. The keratin types revealed were of molecular weights between 55 
kDa and 65 kDa with high sequence coverages and very high identification 
probabilities.  
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5.2.1.3.2. Identifying the putative target antigen of mAb774 
We were, however, successful in identifying the putative antigen target 
of mAb774 where the match comparison of amino acid sequences showed 
that the protein target was likely to be clathrin heavy chain 1 (CHC1). 
Protein name 
Protein 
accession 
numbers 
Protein 
molecular 
weight 
(Da) 
Protein 
identification 
probability 
Number 
of unique 
peptides 
Percentage 
sequence 
coverage 
Clathrin heavy 
chain 1 
CHC1 HUMAN 191,600.90 100.00% 28 23.50% 
Keratin, type II 
cytoskeletal 1 
K1C10_HUMAN 66,022.30 100.00% 18 23.10% 
Keratin, type II 
cytoskeletal 2 
epidermal 
K1C9_HUMAN 65,415.90 100.00% 16 29.70% 
Keratin, type I 
cytoskeletal 10 
K22E_HUMAN 58,810.80 100.00% 15 32.00% 
Keratin, type I 
cytoskeletal 9 
K2C5_HUMAN 62,047.80 100.00% 4 10.90% 
Eukaryotic 
translation 
initiation factor 3 
subunit A 
K1C14_HUMAN 166,556.90 100.00% 2 1.45% 
Table 5.2. MS analyses identifying putative antigen target of mAb774.  
CHC1 was identified as the putative antigen target of mAb774. This molecule 
possessed a molecular weight of close to 191kDa. A high sequence coverage 
and a protein identification probability of 100% was also obtained through the 
analyses. 
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5.2.2. Validating putative target antigen identity of mAb774 
5.2.2.1.  Western blotting with commercial CHC1 antibody 
Subsequently, we sought to validate our MS results which revealed 
that the target antigen of mAb774 was CHC1. Western blotting analysis was 
performed where the IP eluates of mAb774 resolved by SDS-PAGE and then 
probed with a commercially available antibody against CHC1. Conversely, IP 
eluates of the commercial CHC1 antibody were resolved by SDS-PAGE and 
then probed with mAb774. As shown in Fig. 5.3, target antigen bands of 
identical sizes (~180kDa) were detected in both IP/MP and MP lanes, thereby 
confirming CHC1 as the target antigen of mAb774. 
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Figure 5.3. IP and Western blotting experiments confirming antigen 
target of mAb774.  
IP was carried out on IGROV1 membrane protein extracts using either mAb774 or 
the commercial CHC1 antibody. The IP eluate (IP/MP) and whole membrane protein 
extract (MP), were then resolved on reducing, gradient SDS-PAGE and probed with 
the appropriate mAb. Left, the antigen band with a molecular weight of ~180kDa 
(black arrows) was observed in the IP/MP and MP lanes for commercial CHC1 
antibody (mAb-CHC1). Right, similarly, the antigen band with a molecular weight of 
~180kDa was observed for mAb774.  
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5.2.3. Sequencing analyses of mAb168 and mAb774 
In view of highly similar results observed during earlier in vitro and in 
vivo characterisation experiments involving both mAb168 and mAb774, as 
well as Western blotting results which showed a target antigen of similar 
sizes, we sought to verify whether the 2 mAbs were identical by sequencing 
the variable region of the heavy chains of both mAbs. As shown in Figure 5.4, 
subsequent sequencing analyses revealed that both mAbs were indeed 
identical at the cDNA level for the variable region of the heavy chain.  
 
    40168-2R
    40774-15-F
Consensus
AGGTCAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCC
AGGTCAAGCTGCAGCAGTCTGGACCTGGCCTGGTGGCGCC
aggtcaa ctgcag agtc ggacctggcctggtggcgcc
    80168-2R
    80774-15-F
Consensus
CTCACAGAGCCTGTCCATCACTTGCACTGTCTCTGGATTT
CTCACAGAGCCTGTCCATCACTTGCACTGTCTCTGGATTT
ctcacagagcctgtccatcacttgcactgtctctggattt
   120168-2R
   120774-15-F
Consensus
TCATTAAGCAGATATGGTGTATATTGGGTTCGCCAGCCTC
TCATTAAGCAGATATGGTGTATATTGGGTTCGCCAGCCTC
tcattaagcagatatggtgtatattgggttcgccagcctc
   160168-2R
   160774-15-F
Consensus
CAGGAAAGGGTCTGGAGTGGCTGGGAGTAATATGGGCGGT
CAGGAAAGGGTCTGGAGTGGCTGGGAGTAATATGGGCGGT
caggaaagggtctggagtggctgggagtaatatgggcggt
   200168-2R
   200774-15-F
Consensus
TGGAAGCACAAATTATAATTCGGCTCTCATGTCCAGACTG
TGGAAGCACAAATTATAATTCGGCTCTCATGTCCAGACTG
tggaagcacaaattataattcggctctcatgtccagactg
   240168-2R
   240774-15-F
Consensus
AGCATCAGCAAAGACAAGTCCAAGAGTCAAGTTTTCTTAA
AGCATCAGCAAAGACAAGTCCAAGAGTCAAGTTTTCTTAA
agcatcagcaaagacaagtccaagagtcaagttttcttaa
   280168-2R
   280774-15-F
Consensus
AAATGAACAGTCTGCAAACTGATGACACAGCCATGTACTA
AAATGAACAGTCTGCAAACTGATGACACAGCCATGTACTA
aaatgaacagtctgcaaactgatgacacagccatgtacta
   320168-2R
   320774-15-F
Consensus
CTGTGCCCGAGATAGAGAGTACGGCTACGGGCTTGCTTAC
CTGTGCCCGAGATAGAGAGTACGGCTACGGGCTTGCTTAC
ctgtgcccgagatagagagtacggctacgggcttgcttac
   352168-2R
   352774-15-F
Consensus
TGGGGCCAAGGGACCACGGTCACCGTCTCCTC
TGGGGCCAAGGGACCACGGTCACCGTCTCCTC
tggggccaagggaccacggtcaccgtctcctc
  
Figure 5.4. Sequencing analyses comparing mAb168 and mAb774.  
Both mAbs were identical at the cDNA level for the variable region of the 
heavy chain. Differences near the 5’ end (highlighted in blue) were due to the 
degenerate primers used in this experiment.  
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5.2.4. Further validation: putative target antigen identity of 
mAb168 and mAb774 
5.2.4.1.  RT-qPCR with CHC1 primers 
Although microarray data was not sensitive enough to reveal an 
upregulation of the CHC1 gene in mAb168- and mAb774-positive 
subpopulations, RT-qPCR experiments using primers targeting the CHC1 
gene showed that CHC1 was upregulated in the mAb-positive populations of 
2 ovarian cancer cell lines. As shown in Figure 5.5, CHC1 was upregulated by 
7.2- fold and 2.5-fold in the IGROV1 and PEA1 mAb168-positive 
subpopulations respectively. CHC1 was also upregulated by 6.9-fold and 2.9-
fold in the IGROV1 and PEA1 mAb774-positive subpopulations respectively. 
These experiments further confirmed that the target antigen of both mAbs was 
CHC1. 
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Figure 5.5. Validation of target antigen by RT-qPCR analysis of CHC1 
gene expression in isolated mAb-positive cell 
subpopulations.  
There was a 7.2-fold and 2.5-fold increase in CHC1 expression in IGROV1 
and PEA1 mAb168-positive cells respectively. Similarly, there was a 6.9-fold 
and 2.9-fold increase in CHC1 expression in IGROV1 and PEA1 mAb774- 
positive cells respectively. ■ represents mAb-positive populations while ■ 
represents mAb-negative populations. Error bars represent mean ± SEM.  
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5.2.5. Characterisation experiments 
5.2.5.1.  FACS analysis using commercial CHC1 antibodies 
Since both mAbs were identical, we selected mAb774 for subsequent 
characterisation experiments. We first carried out FACS analyses to compare 
binding of mAb774 and commercially available CHC1 antibodies towards 
IGROV1 cells. As shown in Figure 5.6, these commercial CHC1 antibodies 
detected less than 5% of the whole population of IGROV1 cells. These 
percentages were also much smaller than that detected by mAb774 as shown 
in our earlier chapter (Fig 3.18). Thus, we speculated that mAb774 could 
possibly be targeting an epitope different from those targeted by currently 
available commercial CHC1 antibodies.  
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Figure 5.6. FACS analysis data comparing commercial CHC1 mAbs and 
mAb774.  
Commercial mAbs towards the CHC1 antigen do not recognise the same 
epitope as in-house mAb774. The commercial antibodies from BD Bioscience, 
Thermos and Lifespan Bioscience, detected 4.7%, 1.5%, and 2.8% of total 
population of IGROV1 cells respectively. Secondary antibody only was used 
as controls in this experiment. 
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5.2.5.2.  Immunocytochemistry experiments  
We confirmed our previous results with immunocytochemistry 
experiments where IGROV1 cells were stained separately with either the 
commercial CHC1 antibody (Lifespan Bioscience) or mAb774. As shown in 
Figure 5.7, the commercial antibody stained intracellularly (top right) while 
mAb774 showed cell surface antigen staining (bottom right). 
 
10 µm
 
10 µm
 
Figure 5.7. Immunocytochemistry experiments comparing a commercial 
CHC1 mAb and mAb774.  
This experiment revealed different patterns of staining for the commercial 
CHC1 antibody and in-house mAb774. IGROV1 cells were stained with 
antibodies followed by secondary staining with Alexafluor 647 (red). Top right, 
commercial antibody showed intracellular cytoplasmic staining. Bottom right, 
mAb774 showed cell surface antigen staining. 
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5.2.6. Statistical analysis of CHC1 in gene expression profiling 
studies 
Following characterisation experiments, statistical analysis of CHC1 
was performed in several gene expression profiling studies to investigate the 
significance of CHC1 in EOC.  
The first dataset was obtained from a study which was earlier 
published by Tothill and colleagues in 2008. In this study where gene 
expression profiling was performed on 285 serous and endometrioid tumours 
of the ovary, peritoneum, and fallopian tube, the authors aimed to identify 
novel molecular subtypes of ovarian cancer by gene expression profiling with 
linkage to clinical and pathologic features.  
Using this dataset, we first investigated the expression of CHC1 across 
3 histological subtypes – serous, endometrial and adenocarcinoma. As shown 
in Figure 5.8, there was no significant differential expression of CHC1 
between the 3 subtypes of EOC in this dataset. 
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Figure 5.8. Investigating expression of CHC1 in 3 histological subtypes 
of EOC in the Tothill dataset.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. There was 
no significant differential expression of CHC1 between the 3 subtypes of EOC 
(p>0.05) where Ser, Endo and Adeno represent serous, endometrial and 
adenocarcinoma tumours respectively. Error bars represent mean ± standard 
deviation. 
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We then restricted the analysis to 2 types of tumours – those exhibiting 
low malignant potential and those exhibiting malignant potential. As shown in 
Figure 5.9, there was no differential expression of CHC1 observed between 
the 2 groups in this dataset. 
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Figure 5.9. Investigating expression of CHC1 in tumours with low 
malignant potential compared to those with malignant 
potential in the Tothill dataset.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. No 
differential expression of CHC1 was observed (p>0.05). Error bars represent 
mean ± standard deviation. 
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Finally, we investigated the expression of CHC1 across the stages of 
EOC. As shown in Figure 5.10, there was no differential expression of CHC1 
across the different stages of EOC in this dataset. 
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Figure 5.10. Investigating expression of CHC1 across the stages of EOC 
in the Tothill dataset.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. No 
differential expression of CHC1 was observed (p>0.05). Error bars represent 
mean ± standard deviation. 
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The next dataset we investigated was from The Cancer Genome Atlas 
project (TCGA) which analysed messenger RNA expression, microRNA 
expression, promoter methylation and DNA copy number in 489 high-grade 
serous ovarian adenocarcinomas and the DNA sequences of exons from 
coding genes in 316 of these tumours. This dataset also contained 16 early 
stage tumours and 320 late stage tumours. Again, we investigated the 
expression of CHC1 across the stages of EOC. As shown in Figure 5.11, 
there was no differential expression of CHC1 across the different stages of 
EOC in this dataset. 
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Figure 5.11. Investigating expression of CHC1 across the stages of EOC 
in the TCGA dataset.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. No 
differential expression of CHC1 was observed (p>0.05). Error bars represent 
mean ± standard deviation. 
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We also investigated a dataset from the Genome Institute of Singapore 
(unpublished data) which included 12 borderline, 8 benign, and 79 malignant 
EOC samples. Of these, 8 were early stage tumours while 70 were late stage 
tumours. As shown in Figures 5.12-14, again, there was no correlation 
between CHC1 expression and histological subtypes of the tumours. There 
was also no correlation observed between CHC1 expression and malignancy 
or stages of EOC.  
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Figure 5.12. Investigating expression of CHC1 in 3 histological subtypes 
of EOC in the GIS dataset.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot  displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. There was 
no significant differential expression of CHC1 between the subtypes of EOC 
(p>0.05) where Ser, Endo, CC and Muc represent serous, endometrial, clear 
cell and mucinous tumours respectively. Error bars represent mean ± 
standard deviation. 
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Figure 5.13. Investigating expression of CHC1 in benign, borderline and 
malignant tumours in the GIS dataset.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. No 
differential expression of CHC1 was observed (p>0.05). Error bars represent 
mean ± standard deviation. 
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Figure 5.14. Investigating expression of CHC1 across the stages of EOC 
in the GIS dataset.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. No 
differential expression of CHC1 was observed (p>0.05). Error bars represent 
mean ± standard deviation. 
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5.3.Discussion 
As shown in our Western blotting and silver staining results, the 
putative target antigen of both mAb168 and mAb774 possessed a molecular 
weight of between 97kDa and 191kDa (Fig. 5.1 & 5.2). We speculate that both 
our in-house mAbs targeted linear rather than conformational epitopes, taking 
into account that the IP eluates and whole membrane protein extracts 
underwent reduction before undergoing Western blotting and silver staining 
experiments. Subsequently, antigen bands from the silver-stained gels were 
excised, reduced, alkylated and tryptic digested before being subjected to MS 
analyses.  
MS analyses revealed several keratin types possessing molecular 
weights of between 50kDa and 70kDa were identified following mAb168 IP 
(Table 5.1). Unfortunately, due to the discrepancy in sizes of keratin and our 
target molecule, as well as keratin proteins being frequently reported to be 
common contaminants of MS studies (408), we conclude that it is highly likely 
that our samples were contaminated with keratin, thus hindering the 
identification of our main protein component in the gel bands. Our data 
reflects the sensitivity of MS to background noise, and the stringent 
requirement for cleanliness during the upstream sample preparation before 
MS analysis.  
The MS method was, however, successful in identifying the putative 
target antigen of mAb774 as CHC1, which possessed a calculated molecular 
weight of 191kDa (Table 5.2). This difference in molecular weight when 
compared to its observed size on SDS-PAGE can be explained by earlier 
reports where CHC1 displayed variable migration by SDS-PAGE, such that 
mammalian CHC1 appeared to be 180kDa in size (409). MS analyses also 
identified 28 unique peptides covering 23.5% of the whole CHC1 sequence 
and revealed that the probability of protein identification was 100%, therefore 
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providing us with a high confidence level that this data was not obtained 
through a random chance event. 
We then proceeded to validate our MS data by loading IP eluates and 
whole membrane protein extracts onto SDS-PAGE gels as described earlier 
and performed subsequent Western blotting with commercial CHC1 
antibodies. As expected, probing with commercial CHC1 antibodies revealed 
antigen bands with molecular weights of between 97kDa and 191kDa, thus 
corresponding to the size of CHC1 (Fig. 5.4).  
As previous in vitro and in vivo characterisation results revealed certain 
similarities between mAb168 and mAb774, we decided to sequence both 
mAbs to determine whether they were identical. As shown in Figure 5.5, both 
mAbs were indeed identical at the cDNA/amino acid level for the variable 
region of the heavy chain.  
Although both clones were identical at the cDNA level, differences in 
experimental variation may have led to slightly different biological effects 
which were observed between mAb168 and mAb774 in earlier experiments. 
Furthermore, in many of the in vitro experiments, antibody supernatants were 
used instead of purified versions of the antibodies. Therefore, it is possible 
that differences in concentrations of the two mAbs resulted in slightly different 
biological endpoints. Finally, clonal variation in mAb clones may explain 
slightly different characteristics observed in the 2 mAbs.  
However, simultaneous RT-qPCR experiments carried out using 
primers targeting the CHC1 gene showed the upregulation of CHC1 by 7.2- 
fold and 2.5-fold in IGROV1 and PEA1 mAb168-positive subpopulations 
respectively. Simliarly, there was a 6.9-fold and 2.9-fold upregulation of the 
CHC1 gene in IGROV1 and PEA1 mAb774-positive subpopulations 
respectively (Fig. 5.6). The Western blotting data and RT-qPCR results are 
consistent with CHC1 being the target antigen of mAb774. 
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As CHC1 had only been detected in the cytoplasm and nucleus 
previously (410, 411), we speculated that our in-house mAbs was detecting a 
novel epitope on the CHC1 molecule which was present on the cell surface. In 
order to verify this, we carried out staining of IGROV1 cells using 
commercially available CHC1 mAbs from 3 different companies and 
performed subsequent FACS analyses on these samples. These results were 
then compared with those obtained earlier with mAb774. As shown in Figure 
5.6, commercial antibodies from BD Bioscience, Thermos and Lifespan 
Bioscience detected 4.7%, 1.5%, and 2.8% of the IGROV1 whole population 
respectively. These percentages were much smaller compared to the 15% of 
the whole cell line detected by mAb774 (Figure 3.18). Therefore, it was likely 
that these commercial antibodies were detecting an epitope on the CHC1 
molecule which was different from that detected by mAb774.  
We further confirmed this result through performing 
immunocytochemistry experiments with mAb774 and the commercial CHC1 
antibody from Lifespan Bioscience. As shown in Figure 5.7, the commercial 
antibodies appeared to stain intracellular antigens whereas mAb774 detected 
cell surface CHC1 (Fig. 5.7). Taken together with earlier findings that cell 
subpopulations detected by mAb774 demonstrate stem cell-like 
characteristics, it is highly possible that mAb774 detects a novel epitope of 
CHC1 which is expressed on the cell surface of ovarian TSCs. 
Further statistical analyses showed no correlation of CHC1 with 
histological subtypes, malignancy and stages of EOC in 3 different datasets 
(Fig. 5.8- 5.14). However, the few early stage ovarian tumour cases present in 
each dataset may have contributed to the failure to reliably demonstrate the 
statistical significance of CHC1 across the stages of ovarian cancer.  
The remainder of this chapter focuses on an overview of the CHC1 
molecule and further explores how this molecule could be intricately linked to 
cancer, stem cells, and ultimately, ovarian TSCs. 
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5.3.1. History of CHC1 
Roth & Porter first discovered clathrin over 40 years ago while studying 
the uptake of yolk protein in insect oocytes (410). Using electron microscopy, 
they observed characteristic bristle-like coats at the borders of invaginations 
of the plasma membrane and of vesicles in the cytosol. Further investigation 
revealed that the bristle-like coat was composed of a lattice-like polygonal 
array, the geometry of which resembled that of seams on a soccer ball (412). 
However, it was more than 10 years later that a biochemical analysis of these 
coated vesicles was undertaken by Pearse, who purified coats and coated 
vesicles from bovine brain and identified their major protein component as 
CHC1 (413). When analysed by SDS-PAGE, CHC1 appeared as a band with 
an an apparent molecular mass of 180-190 kDa. 
5.3.2. Molecular model of CHC1 
It is now known that clathrin is a three-legged molecule, or triskelion, 
which consists of three ~190 kDa CHC1s each with an associated ~25 kDa 
light chain (414-416). The triskelion is in turn the assembly unit of a clathrin 
coat where its structural backbone is provided by the three CHC1s.  
Figure 5.15 shows the organization of a triskelion where the units 
interact via their proximal and distal leg regions to form the polyhedral outer 
cage of clathrin. A single polygonal edge is made up of four clathrin leg 
sections from different triskelia: an anti-parallel pair of proximal regions from 
triskelia with vertices at opposite ends of the edge and an anti-parallel pair of 
distal regions from triskelia with vertices one edge away. Therefore, a 
triskelion leg runs from one vertex along two neighbouring polygonal edges 
and then turns inward, with its terminal domain extending into an inner 
network (417). 
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Figure 5.15. Three triskelions are highlighted to show how triskelia 
interact in the cage.  
The top layer of the lattice is made up by two proximal legs from the 
red and green triskelia. The yellow distal legs of two triskelia centered at 
adjacent vertices in the lattice can be seen curving underneath the proximal 
legs to form a deeper layer of the lattice. The terminal domains (not included 
in this image) curve into the center of the polyhedron, under the vertices. 
Figure taken from Brodsky et al. (418). 
CHC1 has multiple subdomains, starting with the N-terminal domain 
consisting of a seven-bladed β-propeller structure with binding sites for 
various clathrin-interacting proteins (419). This is followed by a short linker, 8 
CHC1 repeat motifs (CHC1R0 –7), a final α-zigzag hairpin and a ‘tripod’ 
region which mediates trimerisation (Fig. 5.16)(420). 
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Figure 5.16. Molecular model of CHC1 showing the structural features of 
the triskelion.  
Figure taken from Fotin et al. (420). 
5.3.3. CHC1 genes  
Only one single-copy gene for CHC has been identified in mammals 
(421-423), yeast (424),Dictyostelium (425), Caenorhabditis elegans (426) 
and Drosophila (427). However, in humans, two isoforms of CHC exist and 
are 85% similar at the amino acid level (428). The major form of the heavy 
chain, as detected in our studies, is CHC17 (CHC1). This is a ubiquitous 
1675-residue protein that is involved in membrane trafficking and mitosis, 
whereas CHC22 is a 1640-residue protein expressed at relatively low levels in 
cardiac and skeletal muscle and in testis tissue. CHC22 has not been found to 
be involved in endocytosis, but may play a role in the organisation of 
membranes (429). Recently, Wakeham and colleagues performed a 
comparative analysis of clathrin genes from genomes sequenced so far and 
suggested that the reason we have two genes for CHC may be the result of 
independent gene duplication which occurred somewhere between 510 and 
600 million years ago in our evolution (430).  
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The sequence of CHC1 is highly conserved from yeasts to humans, 
with human CHC1 sharing 70% amino acid similarity to the heavy chain from 
yeast (431).  The strong pressure to preserve the primary structure has been 
suggested to reflect the highly extended interleg contacts required for 
assembly, as well as the large number of interactions with other proteins 
involved in cargo sorting and regulation of coat formation (414). 
5.3.4.Localisation of CHC1 
CHC1 is known to be localised in the plasma membrane and the 
cytoplasmic face of intracellular organelles in the plasma membrane, called 
coated vesicles and coated pits (410). Furthermore, in 2006, Enari and 
colleagues discovered that clathrin exists not only in the cytosol but also in 
nuclei (411).  
5.3.5. Functions of CHC1 
The role of clathrin in endocytosis has been extensively characterised.  
During interphase, clathrin plays a key role in membrane trafficking (414) 
where it removes proteins and lipids from the plasma membrane and 
transports them to an internal compartment (the endosome). Electron 
microscopy and biochemical studies have shown that endocytosis begins with 
the nucleation of a clathrin-coated pit involving cargo capture and 
multimerisation of clathrin. This is followed by propagation of the coated pit 
involving membrane invagination and budding of the clathrin-coated vesicle 
(CCV). The coat disassembles once the CCV is inside the cell and the 
uncoated vesicle is trafficked to its destination (Fig. 5.17). Clathrin is also 
involved in coating membranes that are transported between the trans-Golgi 
network (TGN) and endosomes (414). When coating membranes, clathrin 
links to the membranes via adaptor proteins. The main class of adaptors are 
the adaptor protein (AP) complexes (432). AP-2 mediates endocytosis at the 
plasma membrane while AP-1 mediates traffic from the TGN to endosomes.  
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Although the formation of CCVs occurs continuously in non-dividing 
cells (433), this process is ceased during mitosis (434), when clathrin 
concentrates at the spindle apparatus (435, 436). clathrin stabilizes fibres of 
the mitotic spindle to aid congression of chromosomes.  
 
 
Figure 5.17. Schematic diagram of clathrin-mediated endocytosis (CME).  
CME proceeds in four stages: initiation, propagation, vesicle budding and 
uncoating. Figure taken from Kirchhausen et al.(414) 
In addition to fundamental roles in receptor-mediated endocytosis and 
in mitosis, CCVs play a number of specialised roles in different tissues. These 
include the maintenance of polarity in epithelial cell lines (437) and 
recapturing of synaptic vesicle proteins in neurons (438). CCVs also play an 
important role in cells that undergo regulated secretion (439). Finally, in the 
immune system, CCVs are involved in regulation of the cell surface 
expression of antigen receptors and signaling molecules and in sorting 
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molecules to the pathway of antigen processing and presentation by class II 
histocompatibility molecules (440, 441). 
5.3.6. CHC1 knockouts 
To investigate consequences related to the deletion of clathrin, clathrin 
knockouts have been generated in a number of organisms. In one study, the 
CHC1 homologue gene from yeast was disrupted. Although the cells survived, 
slowed growth and limited endocytosis was observed (442, 443). Similarly, 
deletion of clathrin in the soil-living amoeba, Dictyostelium discoideum, by 
antisense RNA or gene replacement resulted in slow growth and decreased 
endocytosis (444, 445). Moreover, clathrin-null D. discoideum cells which 
were placed in suspension were observed to exhibit defects in cytokinesis 
(446, 447). In the parasite, Trypanosoma brucei, depletion of clathrin by RNA 
interference (RNAi) dramatically reduced endocytosis and resulted in a 
‘bigeye’ phenotype due to the coalescence of many intracellular vesicles 
(448).  
In higher organisms such as roundworms, depletion of clathrin by RNAi 
resulted in decreased yolk uptake by endocytosis in oocytes and dead 
progeny (449). Similarly, deletion of the CHC1 homologue in the fruit fly, 
Drosophila melanogaster, by ethylmethane sulphonate mutagenesis (EMS) 
resulted in embryonic lethality (427). These results, together with the 
observation that deletion of two of the other hubs in the network, AP1 and 
AP2, are embryonic lethal in the mouse (450, 451), suggest that deletion of 
CHC1 in mammals would also be incompatible with life. Taken together, the 
above studies largely underline the importance of clathrin in endocytosis and 
show that clathrin is essential in higher organisms.  
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5.3.7. CHC1 in cancer and stem cells 
Factors involved in endocytosis have long been recognised to be 
crucial targets of the processes driving cancer initiation and progression 
(452). For example, enhanced internalisation and unbalanced partitioning of 
junctional proteins between the lysosomal pathway and the recycling route 
result in dissolution of cell–cell junctions and loss of morphological polarity. 
Consequently, this leads to full malignant transformation. Tumourigenesis 
may also occur when the role of endocytosis in signal transduction is 
disrupted. As described by Blitzer and Nusse, endocytosis plays a critical role 
in Wnt signaling, a pathway which is upregulated in numerous cancers (453). 
In their study, blockade of clathrin-mediated endocytosis resulted in loss of β-
catenin accumulation and its target gene expression, which are downstream 
of Wnt signaling. Conversely, it is possible that an increase in clathrin-
mediated endocytosis could result in the amplification of the Wnt signal 
strength, thus contributing to tumorigenesis.  
There is also growing evidence which suggests that tumours are able 
to gain self-sufficiency in growth signals by delaying endocytosis-mediated 
inactivation of growth factor receptors. This delay is achieved via multiple 
oncogenic mechanisms which intercept receptor endocytosis such as defects 
in key endosomal proteins, evasion of ubiquitylation-mediated sorting to 
degradation, and malfunctioning of collaborative processes including actin 
remodelling. In addition, tumour cells dynamically disintegrate cell-to-matrix 
adhesion sites and re-assemble them at the front of invading protrusions in 
order to conquer tissue barriers and colonize distant organs. This re-
distribution process involves enhanced recycling of adhesion molecules of the 
integrin family, which in turn results in the increased invasiveness and 
metastasis of tumours (454). 
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Although there have been no reports of the CHC1 gene being amplified 
in either ovarian cancer or other cancers to date, two different gene fusions 
involving CHC1 have been described in human tumours. 
Gene fusions occur in euchromatin regions and a recent paper by 
Robinson and colleagues (455) suggested that fusion genes are not only 
present but abundant in epithelial cancers such as carcinomas of the breast, 
ovary, and prostate (456). These fusion genes are thought to arise 
predominantly from double stranded DNA breakages followed by a DNA 
repair error (457). For example, fusion genes may be formed when a 
structural rearrangement of the genome, such as a deletion, inversion, 
tandem duplication, or translocation, resulting in the joining of two unrelated 
genes. Several gene fusions also involve cancer-relevant genes such as 
chromatin modifiers and signaling proteins. These fusions create genes and 
proteins that are tumour-unique and may therefore serve as drug targets and 
markers for diagnosis and monitoring (458). Finally, fusions may also result in 
inactivated genes (459).  
 
Two classes of gene fusions have been described. The first involves 
promoter exchanges which are characterized by the replacement of an 
oncogene's regulatory regions with those of another gene, resulting in 
deregulation of transcription of the oncogene. For example, in prostate 
cancer, the androgen-responsive regulatory elements of TMPRSS2 drive the 
expression of the ETS family member to whichTMPRSS2 is fused (460). The 
second class of gene fusions leads to the creation of a chimeric protein with 
biological function distinct from either of the partner genes from which it 
originated. One example is BCR-ABL1, a chimeric protein which is the 
defining lesion in chronic myelogenous leukaemia (CML), and which induces 
growth factor independence and the inhibition of apoptosis (461). 
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In the case of fusions involving clathrin, fusion of CHC1 and the 
anaplastic lymphoma kinase (ALK) protein results in the fusion protein, CHC1-
ALK. This fusion protein has been reported in anaplastic null/T-cell lymphoma, 
ALK+ diffuse large B- cell lymphoma and a rare non-lymphoid neoplasm, 
inflammatory myofibroblastic tumour(462, 463). Moreover, fusion of the CHC1 
gene with the C-terminal region of transcription factor binding to IGHM 
enhance 3 (CHC1-TFE3) has been reported in one case of pediatric renal cell 
carcinoma (464).  
 
A publication by Royle and colleagues revealed that these fusion 
proteins could possibly impair the function of clathrin during mitosis by 
disrupting trimerisation while allowing binding to the mitotic spindle, thus 
leading to tumourigenesis. In this 2005 paper, the authors discovered that 
clathrin stabilized fibers of the mitotic spindle to aid the congression of 
chromosomes (465). Furthermore, when cells were depleted of clathrin, an 
increased frequency of misaligned chromosomes was observed. The mis-
segregation of chromosomes during mitosis is a potential source of 
aneuploidy, a form of genetic instability that may lead to cancer or birth 
defects (466). For example, research had previously shown that kinetochore 
proteins, CENP-A and CENP-H, were upregulated in human primary colon 
cancer, and their overexpression induced aneuploidy (467).   
In another report by Enari and colleagues, nuclear CHC1 was found to 
be necessary for the transactivation of the p53 target genes (411). Moreover, 
CHC1 bound to the p53-responsive promoter in vivo and stabilized p53–p300 
interaction to promote p53-mediated transcription.  The p53 gene encodes a 
protein that plays an important role in preventing tumorigenesis and mutations 
of this gene have been found in >50% of human cancers (468-471). The 
function of p53 as a regulator of various phenomena including transcriptional 
activation for cell cycle arrest and apoptosis (470, 471), centrosome 
duplication (472), homologous recombination (473), nucleotide excision repair 
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(474), and transcription-independent apoptosis (475), is also tightly 
associated with tumor progression. Consequently, altered levels of CHC1 
could affect p53 activity, thus resulting in possible tumourigenesis. 
Furthermore, as mentioned earlier, gene fusions occurring at the C terminus 
of CHC1 have been observed in various human tumours. Therefore, the 
authors speculated that binding of p53 to CHC1 at the C terminus of CHC1 
may similarly result in fusion proteins which lead to impaired function of p53- 
mediated transcription.  
A separate report published by Endo and colleagues two years later 
showed that the association of p53 with CHC1 was also present in the 
cytosol. Furthermore, in response to EGF stimulation, p53 co-localized with 
CHC1 at the plasma membrane in normal human fibroblast and human 
cancer cells (476). In cells with ablated p53 expression by RNAi, EGFR 
internalisation was delayed and intracellular signaling from EGFR was altered. 
Thus, these findings provided evidence that cytosolic p53 and CHC1 fusion 
proteins may participate in the regulation of clathrin-mediated endocytosis to 
control the correct signaling from EGFR. The dysregulation of this system 
could presumably result in various diseases including cancer (477).  
Finally, it has been reported that the transformation of chicken embryo 
fibroblasts by the Rous sarcoma virus (RSV) resulted in phosphorylated 
CHC1s (478). This phosphorylation of CHC1 was not detected in normal cells. 
Moreover, while clathrin was present in the perinuclear region of normal cells, 
the antigen was primarily found at peripheral regions of transformed cells. 
This set of data, coupled with earlier literature reporting that cellular 
transformation by RSV causes a loss of dependence on the presence of 
ligand for receptor-mediated endocytosis of both EGF and thrombin (479-
481), suggests that the phosphorylation and redistribution of CHC1 could be 
implicated in the internalisation of growth factor receptors in the absence of 
their ligand. Therefore, the transformed cell becomes more independent of 
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external stimuli, a phenomenon which represents yet another hallmark of 
cancer (166). 
Although research investigating the role of CHC1 in stem cells has not 
been extensively carried out, a couple of interesting reports have highlighted a 
possible relationship between the two. The first is a publication by Prowse and 
colleagues where they sought to identify factors secreted by feeder cells into 
conditioned media which may be required to support pluripotent, 
undifferentiated growth of hESCs (482). To elucidate these factors, proteomic 
analyses were performed to isolate and identify proteins in the conditioned 
media of three mitotically inactivated fibroblast lines (human fetal, human 
neonatal, and mouse embryonic fibroblasts). Results showed that CHC1 was 
secreted only in conditioned media from human fetal fibroblast. Interestingly, 
an earlier study evaluating a panel of 11 different human adult, fetal, and 
neonatal feeders for hES cell support revealed that fetal feeders were typically 
superior to the others (483). Therefore, CHC1 could perhaps be a key factor 
in human fetal fibroblast which contributes to the maintenance and 
proliferation of hESCs.  
A second publication by Scholer and colleagues reported the use of 
electron microscopy studies to compare induced pluripotent stem cells (iPS) 
cells derived from mouse embryonic fibroblasts (MEFs) with embryonic stem 
cells (484). Their data revealed that these two pluripotent stem cell 
populations were highly similar, with both cell types exhibiting clathrin- 
mediated endocytosis. Conversely, MEFs exhibited caveolae-mediated 
endocytosis. Therefore, this suggests that clathin-mediated endocytosis may 
be a characteristic specific to pluripotent stem cells in certain cell types. 
5.3.8. CHC1 in ovarian TSCs 
The overexpression of CHC1 had been observed in hepatocarcinoma 
where evaluation of the staining intensity of CHC1 together with another 
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molecule, formiminotransferase cyclodeaminase (FTCD), in hepatocarcinoma 
tumour tissues enabled Seimiya and colleagues to distinguish non tumour and 
tumour tissues with high accuracy (485). Moreover, combination of the 2 
markers increased sensitivity and specificity towards early diagnosis of liver 
cancer. Therefore, similarly, CHC1 could very likely be a marker of ovarian 
TSCs which could improve diagnostic accuracy of early ovarian cancer. 
In another study by Pandey and colleagues, a large scale quantitative 
proteomic analysis of ESCs and its malignant counterpart, embryonal 
carcinoma cells (ECCs), was carried out in order to identify potential 
candidates which might affect the regulation of pluripotency and malignancy 
(486). Subsequent bioinformatics analyses revealed shared features of their 
pluripotent nature as well as distinguished the expression of key factors which 
could possibly contribute to the oncogenetic nature of ECCs. Interestingly, 
CHC1 was found to be overexpressed in ECCs when compared to ESCs. 
This result therefore supports our data where CHC1 was also observed to be 
upregulated in malignant ovarian stem cell subpopulations. 
In addition, CHC1 has been found to be upregulated in various drug 
resistant cancer cell lines (487). For example, a study investigating differential 
protein expression between paclitaxel sensitive and resistant ovarian cancer 
cell lines showed that most of these proteins were related to the category of 
stress response (24%), metabolism (22%), protein biosynthesis (15%) and 
cell cycle and apoptosis (11%) (488). This led the authors to suggest that 
alterations of those processes might be involved in paclitaxel resistance 
mechanisms. Interestingly, the CHC1 molecule was also found to be 
upregulated in paclitaxel resistant ovarian cancer cells. This therefore 
indicated a putative role for CHC1 in drug resistance, a well-known 
characteristic of TSCs. 
Furthermore, involvement of CHC1 in chemoresistance of paclitaxel-
resistant head and neck cancer cells has been reported (489). The authors 
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established a paclitaxel-resistant subline originating from the larynx carcinoma 
cell line, HLaC79, and identified genes differentially expressed in the taxol-
resistant cell clone. Subsequently analyses revealed increased expression of 
6 genes, including CHC1. Overexpression of MDR-1 was also observed in the 
taxol-resistant clone. As surface P-glycoprotein undergoes constitutive 
clathrin-mediated endocytosis and recycling (490), this led the authors to 
suggest that it was plausible that clathrin polypeptides are overexpressed in 
the taxol-resistant clone expressing MDR-1 at a very high level. This study 
corroborates our data where isolated ovarian TSCs possessing CHC1 
overexpressed ABCB1 when compared to their counterparts.   
In conclusion, data from our study taken together with previous 
literature prove that CHC1 present on ovarian TSCs could serve as a 
biomarker of early ovarian cancer. More importantly, our novel in-house mAbs 
which target a novel epitope of CHC1 on cell surfaces could prove to be 
useful in the detection and eradication of this disease. In our next chapter, we 
sought to further assess the usefulness of both novel mAbs and the CHC1 
marker in EOC. 
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Chapter 6.                  
Applications of our 
novel in-house 
antibodies and the 
CHC1 marker in 
EOC  
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6.1. Introduction 
Besides identifying ovarian TSCs in cell lines, we sought to investigate 
whether both novel mAbs could also be potentially useful in detecting TSCs 
subpopulations in patient samples such as ascites. We also carried out 
experiments with mAb168 and mAb774 in combination with commercially 
available ALDH1A1 antibodies to assess their usefulness in the detection of 
distinct double-positive TSC subpopulations on paraffin-embedded tissue 
sections. 
Furthermore, as chemotherapy resistance remains a major obstacle in 
the treatment of women with ovarian cancer, we briefly investigated whether 
differential expression of the CHC1 marker was present between platinum-
sensitive and -resistant ovarian cancer cell lines. The finding of a predictive 
marker of chemoresponse could in turn help individualise therapy and 
improve survival of ovarian cancer patients. 
Finally, although the potential prognostic value of individual biomarkers 
in ovarian cancer has been investigated in many studies (491-493), the 
independent prognostic significance of most of these proposed markers is 
unclear and none have been approved for clinical use (494). In our study, we 
briefly investigated the role of CHC1 in progression free and overall survival of 
ovarian cancer patients using a publicly available online Kaplan-Meyer plotter. 
As earlier publications have identified genes which are associated with both 
ovarian and breast cancer (495, 496), we again used the same online Kaplan-
Meyer plotter to determine the role of CHC1 in relapse free survival and 
distant metastasis free survival of these patients (497). 
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6.2. Results 
6.2.1. MAb168 and mAb774 as tools for the identification and 
isolation of TSCs in primary patient samples 
As shown in Figure 6.1, preliminary immunofluorescence (IF) data 
revealed that mAb774 successfully detected subpopulations of cells in a 
sample of EpCAM-positive patient ascites.  
20 µm 20 µm 20 µm
 
Figure 6.1. Detection of mAb774-positive subpopulations in a patient 
ascites sample by IF.  
Left, nuclei staining by DAPI (blue). Middle, mAb774-positive cells (green). 
Right, overlay of DAPI and mAb774. 
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6.2.2. Identification of TSCs in EOC using expression of CHC1 
in combination with other markers 
In addition to being a single agent, we speculated that mAb168 and 
mAb774 may be useful in combination with other antibodies such as 
commercially available ALDH1A1 antibodies for the detection of distinct TSC 
subpopulations. As shown in Figure 6.2, preliminary data from IF studies 
revealed that mAb774 was successful in staining paraffin-embedded patient 
tumour sections where colocalisation of CHC1 and ALDH1A1 was detected in 
subpopulations of ovarian tumour cells.  
 
10 µm 10 µm 10 µm
 
Figure 6.2. Confocal microscopy and Z-stack analysis of images to 
investigate colocalisation of CHC1 and ALDH1A1.  
Confocal microscopy allows us to focus at various depths of the section where 
CHC1 (red) is first seen at the surface membrane. As the focus is moved 
deeper into the cytoplasm, ALDH1A1 (green) is detected. Left, CHC1 (red) 
localizes on the surface membrane while ALDH1A1 (green) is detected in the 
cytoplasm (middle). Right, image showing colocalisation of CHC1 and 
ALDH1A1 (yellow). 
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6.2.3. CHC1 as a potential predictive marker in early stage 
EOC patients 
As mentioned earlier, chemotherapy resistance remains a major 
obstacle in the treatment of women with ovarian cancer. However, at present, 
there is no predictive marker of chemoresponse available clinically to help 
individualise therapy and improve survival of ovarian cancer patients.  
Therefore, we briefly investigated whether differential expression of 
CHC1 was present between platinum-sensitive and -resistant ovarian cancer 
cell lines. Gene expression data was obtained from Dr. Euan Stronach who 
earlier performed microarray experiments on the cisplatin-sensitive ovarian 
cancer cell line PEO1 and -resistant PEO4, established from the same patient 
before treatment and after developing resistance to platinum-based 
chemotherapy. Dr. Ed Curry subsequently assisted in comparing the 
expression levels of CHC1 between both cell lines. As shown in Figure 6.3, 
CHC1 was significantly upregulated in the PEO4 resistant cell line when 
compared to the sensitive PEO1 cell line. We speculate that while this could 
be attributed to an increase in expression of CHC1, this result could also 
indicate an enrichment for a stem cell population, whereby the number of cells 
which express CHC1 is increased in the resistant ovarian cancer cell line.   
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Gene  Probe_ID Fold- change p- value 
CHC1 200614_at 2.5 2.96x10-8 
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Figure 6.3. Investigating expression of CHC1 in platinum-sensitive and   
-resistant ovarian cancer cell lines.  
Expression values obtained from HGU133-Plus array data were first 
normalised using RMA. The box plot  displaying the mean of log2-transformed 
CHC1 expression levels was then generated using the R software. The 
expression of CHC1 was significantly upregulated in the platinum- resistant 
PEO4 cell line by 2.5-fold when compared to the platinum-sensitive PEO1 cell 
line. Error bars represent mean ± standard deviation. Data was produced in 
collaboration with Dr. Euan Stronach and Dr. Ed Curry.  
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6.2.4. CHC1 as a potential prognostic marker in early stage 
EOC patients 
To investigate the potential prognostic value of the CHC1 marker in 
progression free and overall survival of ovarian cancer patients, we used an 
online Kaplan- Meyer plotter (http://kmplot.com/analysis/index.php?p=service) 
which was capable of assessing the effect of 22,277 genes on survival in 
1,287 ovarian cancer patients.  
This database was established using gene expression data and 
survival information downloaded from the gene expression omnibus (GEO) 
database at NCBI. This included data from both Affymetrix HGU133A and 
HGU133Plus2 microarrays. After quality control and normalization, only 
probes present on both Affymetrix platforms were retained (n=22,277). 
Thereafter, the background database was handled by a PostgreSQL server, 
which integrates gene expression and clinical data simultaneously. 
In the first instance, 142 patients were identified upon restricting the 
analysis to stage 1 or 2 serous EOC patients with available PFS data. As 
shown in Figure 6.4, high expression of CHC1 (in red) was found to be 
significantly associated with a shortened PFS period in early stage patients.    
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Figure 6.4. Investigating the correlation between CHC1 expression and 
PFS in early stage serous EOC patients. 
High CHC1 expression was significantly associated with shortened PFS in 
early stage serous EOC patients (p<0.05). 
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We then identified 102 patients upon restricting the analysis to stage 1 
or 2 serous EOC patients, grade 3 tumours with available PFS data. As 
shown in Figure 6.5, high expression of CHC1 (in red) was found to be 
significantly associated with a shortened PFS period in early stage, high 
grade ovarian cancer patients.    
 
Figure 6.5. Investigating the correlation between CHC1 expression and 
PFS in early stage, high grade, serous EOC patients. 
High CHC1 expression was significantly associated with shortened PFS in 
early stage, high grade, serous EOC patients (p<0.05). 
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142 patients were also identified upon restricting the analysis to stage 
1 and 2 serous EOC patients with available overall survival data. As shown in 
Figure 6.6, high expression of CHC1 (in red) was found to be significantly 
associated with a shortened overall survival period in early stage patients.    
 
Figure 6.6. Investigating the correlation between CHC1 expression and 
overall survival in early stage serous EOC patients. 
High CHC1 expression was significantly associated with shortened overall 
survival in early stage serous EOC patients (p<0.05). 
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Again, 102 patients were identified after restricting the analysis to stage 
1 and 2, grade 3 serous EOC patients with available overall survival data. 
However, as shown in Figure 6.7, expression of CHC1 (in red) was not 
significantly associated with shortened overall survival in this group of 
patients.    
 
Figure 6.7. Investigating the correlation between CHC1 expression and 
overall survival in early stage, high grade, serous EOC 
patients.  
CHC1 expression was not significantly associated with overall survival in early 
stage, high grade, serous EOC patients (p>0.05). 
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Next, we restricted the analysis to stage 3 and 4 serous EOC patients, 
grade 3, with available progression free and overall free survival data which 
resulted in the identification of 653 patients. As shown in Figures 6.8 & 6.9, 
the association with progression free and overall survival in this group of 
patients was not significant. 
 
Figure 6.8. Investigating the correlation between CHC1 expression and 
PFS in late stage serous EOC patients. 
CHC1 expression was not significantly associated with PFS in late stage 
serous EOC patients (p>0.05). 
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Figure 6.9. Investigating the correlation between CHC1 expression and 
overall survival in late stage serous EOC patients. 
CHC1 expression was not significantly associated with overall survival in late 
stage serous EOC patients (p>0.05). 
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As earlier publications have identified genes which are associated with 
both ovarian and breast cancer (495, 496), we used the same online Kaplan-
Meyer plotter which was capable of assessing the effect of 22,277 genes on 
survival in 2472 breast cancer patients to determine the role of CHC1 in 
relapse free survival and distant metastasis free survival of these patients 
(497).  
First, we investigated whether differential expression of CHC1 was 
associated with relapse free survival in breast cancer. As shown in Figure 
6.10, high expression of CHC1 was significantly associated with shortened 
relapse free survival in breast cancer patients. 
 
Figure 6.10. Investigating the correlation between CHC1 expression and 
relapse free survival in breast cancer patients. 
High CHC1 expression was significantly associated with shortened relapse 
free survival in breast cancer patients (p<0.05). 
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We also investigated whether differential expression of CHC1 was 
associated with distant metastasis free survival in breast cancer. As shown in 
Figure 6.11, high expression of CHC1 was significantly associated with 
shortened distant metastasis free survival in breast cancer patients. 
 
Figure 6.11. Investigating the correlation of CHC1 expression and 
distant metastasis free survival in breast cancer patients. 
High CHC1 expression was significantly associated with shortened distant 
metastasis free survival in breast cancer patients (p<0.05). 
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6.3. Applications of our novel in-house antibodies and 
the CHC1 marker in EOC: discussion 
As shown in Figure 6.1, mAb774 successfully detected subpopulations 
of cells in a sample of EpCAM-positive patient ascites. Furthermore, together 
with a commercially available ALDH1A1 antibody, mAb774 was successful in 
detecting double-positive TSC subpopulations in paraffin-embedded patient 
tissue (Figure 6.2). Therefore, we propose that in future, both mAb168 and 
mAb774 may represent novel tools for identification and isolation of ovarian 
TSCs in primary patient samples. This would replace currently-used methods 
which suffer from several disadvantages.  
For example, the sphere assay is very sensitive to the culturing method 
used including its media composition and seeding technique, therefore it is 
difficult to consolidate experimental findings from different research groups. 
Also, instead of through clonal expansion, individual spheres often develop as 
a result of aggregation of cells. Furthermore, as spheroid bodies display 
marked cellular heterogeneity, experiments using spheres should be 
interpreted with caution as studies of mixed cell populations. Although in vivo 
transplantation experiments are useful in assaying TSCs, it takes long periods 
for such assays to be conclusive, they are often very time consuming, 
cumbersome and costly. Finally, antibody labelling methods are usually more 
straightforward to perform than functional assays such as the Hoechst dye 
and Aldefluor activity assay methods. 
Future studies could therefore include further staining using our novel 
mAbs singly as well as in combination with other stem cell markers such as 
ABCB1 and ALDH1A1 across a larger number of ascites and paraffin-
embedded ovarian tumour samples with known clinical parameters. 
Thereafter, statistical analyses may be performed to investigate the 
correlation of detected subpopulations with relevant clinical parameters. 
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In view of data we obtained from platinum-sensitive and -resistant cell 
lines where CHC1 was overexpressed in the platinum-resistant PEO4 cell line 
(Figure 6.3), we propose that ovarian TSCs which overexpress CHC1 may 
contribute to drug-resistance in patients. Therefore, future studies could be 
designed to investigate the role of CHC1 in drug resistance. This could then 
translate clinically where administering mAb774 to EOC patients 
before/together with chemotherapy may perhaps reduce the incidence of drug 
resistant events. 
Finally, data shown in Figures 6.4-6.9 indicate that CHC1 may be a 
useful prognostic marker in early stage, high grade ovarian cancer. We 
speculate that this result is in line with the TSC hypothesis where TSCs with 
upregulated CHC1 are present to initiate tumour growth. Moreover, it is 
plausible that the presence of an increased number of stem cells in early 
tumours results in increased aggressiveness and faster recurrence of the 
tumour.  Data from figures 6.10 and 6.11 also suggest that expression of the 
CHC1 gene may also determine breast cancer patients with shortened 
relapse free survival and distant metastasis free survival. Therefore, further 
investigations into the expression of CHC1 at a protein level may be useful to 
confirm its role in breast cancer. 
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Chapter 7.                  
General 
discussion and 
conclusion 
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7.1. Synopsis of major findings 
We were successful in the detection and isolation of SP and Aldefluor-
positive cells from ovarian cancer cell lines using the Hoechst dye and 
Aldefluor activity assay methods respectively. Consistent with previous 
findings from our group, characterisation of isolated putative TSC 
subpopulations revealed that these cells possessed stem cell-like 
characteristics including the upregulation of stem cell markers, as well as 
increased proliferative and invasive capacities. However, although SP cells 
were able to give rise to differential tumour formation in vivo, Aldefluor-
positive cells were unable to demonstrate this characteristic.  
Immunisation of BALB/c mice with Aldefluor-positive cells for the 
generation of novel mAbs towards this subpopulation of cells was then carried 
out. Out of 1109 mAbs which were generated, 34 fulfilled our selection criteria 
of being an antibody which targeted subpopulations of ovarian cells. Of the 34 
mAbs, 2 were particularly interesting as they demonstrated cross-reactivity 
with ovarian SP cells. Further characterisation of these 2 mAbs, mAb168 and 
mAb774, revealed that they targeted cells which possessed stem cell-like 
characteristics. Similar to SP and Aldefluor-positive cells, the upregulation of 
stem cell markers, as well as increased proliferative and invasive capacities 
were observed in mAb-positive cell subpopulations. Interestingly, these cell 
subpopulations were able to give rise to differential tumour formation in vivo.  
Moreover, although purified mAb774 did not induce cytotoxicity in IGROV1 
ovarian cancer cells, clonogenic experiments revealed that low concentrations 
of the antibody caused a significant decrease in colony numbers of larger-
sized colonies. 
Subsequently, mass spectrometry experiments identified the target 
antigen of both mAbs as CHC1, a molecule which has been widely studied in 
the process of endocytosis. Further experiments involving commercial CHC1 
mAbs showed that our in-house mAbs recognised a different epitope 
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compared to the commercially-available ones. This is also the first report of an 
antibody capable of detecting an epitope of CHC1 which resides on the 
surface of cells. 
We then further investigated the usefulness of both novel mAbs and 
the CHC1 marker in EOC. We were successful in detecting ovarian TSC 
subpopulations in patient ascites and paraffin-embedded tissue samples 
using both mAb774 alone and in combination with a commercially-available 
ALDH1A1 antibody respectively. We were also able to establish CHC1 as a 
potential predictive marker in early stage EOC patients. Finally, our data 
showed that the CHC1 marker may be a useful prognostic marker in early 
stage, high grade ovarian cancer as well as in determining breast cancer 
patients with shortened relapse free survival and distant metastasis free 
survival. 
7.2. Considerations for successful antibody therapy in 
EOC 
Antibodies can be used effectively to target tumour-specific molecules 
and thereby modulate various major signaling pathways which are involved in 
tumour growth, survival and metastasis. However, although unique properties 
of antibodies themselves contribute to a successful therapeutic approach, the 
target proteins recognised by these antibodies are equally important and what 
constitutes a good target for therapeutic intervention in EOC may not simply 
be its association with a poor prognosis as such markers may be correlative 
rather than causative. In the sections below, we describe the qualities of an 
ideal therapeutic target and discuss the pros and cons of CHC1 as a target in 
EOC therapy. 
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7.2.1. Characteristics of an ideal target for cancer therapy 
The ideal target for therapy is a molecule which is expressed on 
tumour cells and is absent in normal, healthy human tissues, especially in vital 
organs such as the heart, brain, liver and kidneys. This ensures specificity 
where antibody therapy would affect only the tumour cells. In turn, inhibition of 
the antigen should result in clinical responses in patients whose tumours 
express the target. Conversely, patients whose tumours do not express the 
target should exhibit minimal to absent responses. Moreover, drugs which 
suppress or inhibit these antigens should not be circumvented easily by 
numerous other adaptive pathways (498). A direct correlation with prognosis 
is also ideal where the expression of the target antigen persists or increases 
in more advanced tumours and metastases (499).  
Unfortunately, targets are usually expressed in both tumour and normal 
cells, in part, because tumour cells evolve from normal cells. Therefore, the 
next best target for therapy is an antigen which is overexpressed in tumour 
cells compared to normal cells. The dose of the relevant antibody can then be 
optimised so that tumour cells are targeted more frequently and effectively 
than normal cells. It should also be noted that in some cases, certain levels of 
target antigen expression in normal tissues may be tolerable and resultant 
potential toxicities may depend on the relative ratio between tumour and 
normal expression levels. For example, although the EGF receptor and 
HER2/neu are expressed on a variety of normal tissues, minimal antibody 
toxicity has been observed (499). 
Besides overexpressed antigens, proteins which play unique roles in 
tumour cells compared with normal cells may also serve as ideal therapeutic 
targets. For example, even though a particular protein is expressed by both 
tumour and normal cells, a mutant form of the protein with a cancer-specific 
function may be found only in the tumour cells. This therefore enables 
effective targeting of tumour cells by an antibody which recognizes only the 
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mutant form of the target protein. Alternatively, proteins involved in different 
signaling pathways in tumour cells compared to normal cells may be ideal 
targets where targeting the protein on a tumour cell would lead to apoptosis 
whereas normal cells expressing the same protein remain unaffected.  
Effective and therapeutically relevant molecular targets should also 
play a defined role in malignant transformation and be crucial to the malignant 
phenotype – besides being expressed and mutated frequently in a particular 
cancer, these targets should also regulate a key aspect of the cancer 
phenotype or serve as an essential step in a mutationally activated pathway, 
such as the AKT pathway.  
Finally, upon binding with the relevant therapeutic antibody, an ideal 
target should internalise the antigen-antibody complex by endocytosis which 
facilitates the intracellular mechanism of tumour cell killing properties and 
does not affect or produce toxicity in non-tumour cells (500).  
An exception to the requirements of an ideal target may constitute of a 
cell surface antigen which can internalise with an antibody conjugate or 
alternatively serve as a docking site for an antibody which mediates antibody-
dependent cellular cytotoxicity or complement-dependent cytotoxicity as its 
primary function. In this case, the internalisation and shedding characteristics 
of the antigen, together with the specific antibody, should be investigated 
using appropriate cell types and models (499). 
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7.2.2. The use of our novel in-house antibodies and CHC1 as a 
target for cancer therapy: pros and cons 
Although intracellular CHC1 has been reported to be ubiquitously 
expressed by eukaryotic cells, our in-house antibodies recognise a novel 
epitope of CHC1 which resides on the surface of ovarian TSCs. It is probable 
that TSCs in tumour tissues express both surface and intracellular CHC1 
while normal tissues express only the intracellular version of the antigen. Our 
mAbs, mAb168 and mAb774, would therefore be useful in targeting cells 
which express CHC1 on the surface while sparing normal cells which express 
intracellular CHC1. Future experiments will include testing our in-house 
antibodies on tissue microarrays containing a large variety of both normal and 
tumour tissues to confirm binding towards tumour tissues only.  
Also, as mentioned earlier, certain levels of target antigen expression 
in normal tissues may be tolerable and resultant potential toxicities may 
depend on the relative ratio between tumour and normal expression levels. 
Therefore, another possibility is that surface CHC1 may be overexpressed in 
tumour cells and the dose of our in-house antibodies may be optimised so 
that only tumour cells which express surface CHC1 are targeted more 
frequently and effectively than normal cells. 
Earlier, our data showed that mAb774 conferred cytostatic properties 
towards ovarian cancer cells at a concentration at 0.05 mg/mL. Therefore, 
future experiments could involve injecting ovarian TSCs into mice, followed by 
the administration of mAb774. A decrease in tumour formation would indicate 
the growth-inhibiting properties of the antibodies. Moreover, although our in 
vitro experiments showed that mAb774 did not confer cytotoxicity towards 
ovarian tumour cells, it is possible that the antibody may elicit antibody-
dependent cellular cytotoxicity or complement-dependent cytotoxicity in vivo.  
Therefore, future in vivo experiments may be performed to measure antibody-
dependent and complement-dependent activity of the antibodies. 
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Finally, it is possible to conjugate the mAbs with a cytotoxic molecule, 
thus developing a novel antibody-drug conjugate. This would in turn allow for 
targeted delivery of the cytotoxic mAb towards ovarian TSCs.   
One successful example of an antibody-drug conjugate is 
Trastuzumab-DM1, which was found to decrease the size of tumours in 
women with highly advanced HER2-positive breast cancer. This open-label, 
single-arm, multicenter, phase II study of trastuzumab-DM1 (T-DM1) included 
110 patients who were previously treated with lapatinib, trastuzumab, and 
chemotherapy (501). Data obtained revealed that T-DM1 decreased the size 
of tumours in 32.7% of all patients, and 44.5% of patients demonstrated 
complete or partial response or stable disease for 6 months or more. The 
investigators concluded that single-agent T-DM1 demonstrated significant 
anti-tumour activity in this heavily pretreated patient population and was well 
tolerated with no dose-limiting cardiotoxicity. 
Therefore, similarly, conjugation of both mAb168 and mAb774 with a 
cytotoxic agent may result in anti-tumour activity of the mAbs where in vitro 
cytotoxicity experiments may be performed initially to investigate the activity of 
the antibody-drug conjugates. Furthermore, activity can also be monitored by 
injecting ovarian TSCs into mice, followed by the administration of conjugated 
mAb774. An eradication of tumour formation would indicate the cytotoxicity of 
the novel antibody-drug conjugates. Positive results from all the proposed 
experiments mentioned above may then be followed by a similar evaluation of 
the antibodies and antibody-drug conjugates in a clinical setting. 
However, we described previously in Chapter 5 that unicellular 
organisms such as yeast and Dictyostelium exhibited slower growth in the 
absence of clathrin and even the relatively simple cellular differentiation of 
these organisms required the function of clathrin. Furthermore, in multicellular 
organisms, clathrin function has been reported to be essential. There is also a 
specialized role for clathrin in certain cell differentiation processes, like 
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spermatogenesis (427). Therefore, inhibition of CHC1 with our in-house 
antibodies may be detrimental towards these cell differentiation processes. 
Moreover, toxicity may occur in patients due to antibody reactivity towards 
normal tissues such as the liver and kidneys which express CHC1.  
7.3. CHC1 as a TSC marker for EOC 
7.3.1. Characteristics of an ideal marker 
Clinical applications of tumour markers include screening and early 
detection, diagnostic confirmation, determining prognosis such as recurrence, 
metastasis and survival, as well as prediction of therapeutic response. The 
ideal marker should possess several characteristics including being clinically 
sensitive where it is detectable in premalignant or malignant tissue early in the 
progression of disease. It should also be highly specific where it is produced 
at detectable levels in all patients with a specific malignancy. Furthermore, 
levels of the marker should correlate reliably with the tumour volume and 
extent, along with a short half-life to reflect temporal changes in tumour 
burden and response to therapy. However, the marker should be non-
detectable in physiological or benign disease states (502). 
For an ideal marker to be applied in large, clinically asymptomatic 
populations, additional requisite characteristics include the presence of the 
marker in bodily fluids obtained noninvasively or in easily accessible tissue as 
well as the existence of  standardized, reproducible, and validated objective 
and quantitative assays. Finally, tests used for detection of the marker should 
be simple and cheap for screening application at mass level.  
Unfortunately, none of the tumour markers reported to date fulfills all of 
the above criteria. For example, CA125 is the only marker which has been 
accepted for clinical use in ovarian cancer. However, while CA125 detects 
peritoneally-spread disease, it has limited sensitivity for early ovarian disease, 
many of which are potentially curable. Moreover, several studies have also 
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reported that approximately 50% of patients with advanced ovarian cancer 
whose CA-125 levels return into the normal range will have persistent 
microscopic or macroscopic disease at second-look surgery (503-505).  
In the sections below, we discuss CHC1 as a TSC marker for EOC and 
describe various further experiments for validating whether CHC1 is indeed a 
TSC marker for EOC. 
7.3.2. CHC1 as an ideal TSC marker for EOC 
As described in section 6.6, at present, there is no predictive marker of 
chemoresponse available clinically to help individualise therapy and improve 
survival of ovarian cancer patients. In view of data we obtained from platinum-
sensitive and -resistant cell lines where CHC1 was overexpressed in the 
platinum-resistant PEO4 cell line (Figure 6.3), we propose that ovarian TSCs 
which overexpress CHC1 may contribute to drug-resistance in patients. 
Therefore, the CHC1 marker may be useful in predicting the success of 
chemotherapy in patients. We propose that future studies could be designed 
to further investigate the role of CHC1 in drug resistance. This could then 
translate clinically where administering mAb774 to EOC patients 
before/together with chemotherapy may perhaps reduce the incidence of drug 
resistant events. 
CHC1 marker may also be a useful prognostic marker in early stage, 
high grade ovarian cancer as well as in determining breast cancer patients 
with shortened relapse free survival and distant metastasis free survival as 
shown from our data (section 6.7). The CHC1 marker could be particularly 
useful in ovarian cancer where vast majority of cases are detected during late 
stages when prognosis is much worse for the patient. Therefore, this marker 
may aid greatly in diagnosing the cancer an early stage before the disease 
has progressed.  
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As mentioned earlier, for an ideal marker to be applied in large, 
clinically asymptomatic populations, the existence of standardized, 
reproducible, and validated objective and quantitative assays is also 
necessary. The CHC1 marker fulfills this criterion where our in-house 
antibodies detect the marker in a reliable and straightforward manner, thereby 
allowing for screening application at mass level.  
Finally, future experiments should aim to confirm the sensitivity and 
specificity of the CHC1 marker. These could include staining of tissue 
microarrays containing normal tissue as well as early and late stage disease 
with both our in-house and commercially available CHC1 antibodies. 
It should also be noted that, as attractive as the concept of a single 
marker is, it is crucial to consider what these markers really mark. These 
molecules, which often lack tumour-specific function, may help tumour cells 
maintain their characteristics in a specific niche, or they may be expressed 
because of another gene turned on in the tumour or because of altered 
adhesion. Therefore, markers such as CHC1 may not be constant, and they 
may also be present in normal tissues. A spectrum of markers which include 
CHC1 may thus be necessary for the identification of EOC. 
7.3.3. Is CHC1 a true marker of stem cells in EOC? 
The question remains as to whether CHC1 is a true marker of stem 
cells in EOC. In earlier chapters, our results showed that both mAb168 and 
mAb774 targeted CHC1 which was overexpressed in a subpopulation of 
ovarian cancer cells. These mAb-positive cells demonstrated stem cell-like 
characteristics such as the upregulation of stem cell markers, increased 
proliferation and invasiveness. Moreover, both antibodies exhibited reactivity 
towards pluripotent hESC cells while reactivity towards cells from normal 
ovarian, breast and haematopoietic cell lines was largely absent. Although 
these data provide evidence of the antibodies recognising CHC1 on ovarian 
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cancer cells which possess stem cell-like features, we noted that these mAb-
positive cells also possessed several features of a metastatic cancer cell as 
defined by Welch in his 2006 publication (506). 
These characteristics include increased invasive and proliferative 
properties which we have shown to be exhibited by our mAb-positive cells. 
Another characteristic involves the modulation of the secondary site where 
metastatic cells reorganise the ECM to create a more favourable environment 
for survival. In our study, genes coding for ECM components were found to be 
significantly upregulated in our mAb-positive population (Table 4.5).  
There has since been increasing evidence to suggest that ECM 
components play an active role in tumour progression and are important 
determinants for the growth and progression of solid tumours. For example, 
peritoneal cells are known to express and secrete ECM proteins, adhesion 
molecules and many other factors that provide an important microenvironment 
to aid the implantation of ovarian cancer cells (507, 508). It has further been 
demonstrated that peritoneal cells can promote ovarian cancer motility by 
increasing production of the ECM molecule, hyaluronan (HA).  
Increased survival was also suggested as a characteristic of metastatic 
cells. This property was again observed in our mAb-positive cells where 
upregulated genes were found to be associated with pathways involved in 
evasion of apoptosis. Moreover, as mentioned earlier, ECM-integrin 
interactions have previously been shown to control cell survival and ECM has 
been implicated in ovarian cancer drug resistance (398). Therefore, it is 
plausible that the upregulation of ECM-related components (Table 4.5) in 
mAb-positive cells contributes to cell survival through interacting with integrins 
as well as by promoting drug resistance. 
Another characteristic is the presence of dysregulated adhesion which 
enables metastatic cells to detach and migrate away from the primary tumour. 
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We propose that our antibody-positive cells which overexpress CHC1 allow 
enhanced recycling of adhesion molecules of the integrin family. This in turn 
results in tumour cells dynamically disintegrating cell-to-matrix adhesion sites 
and re-assemble them at the front of invading protrusions in order to conquer 
tissue barriers and colonise distant organs, thus increasing the metastasis of 
tumours. 
Besides the characteristics which Welch describes in his paper, the key 
roles of the Wnt, Notch and PI3K pathways in metastatic progression has 
become increasingly evident in recent years, as is the nature of the molecules 
that metastasis-initiating cells resort to in order to maximize the activity of 
these pathways in difficult microenvironments (509, 510). Interestingly, 
upregulated genes in antibody-positive cells were found to be associated with 
the Wnt and PI3K pathways (Table 4.7). 
Finally, it has been proposed that distinct TSC subsets exist, one 
stationary and one migratory (511). In 2007, Hermann and colleagues showed 
that while both CD133+CXCR4-  and CD133+CXCR4+ cells from a human 
pancreatic cancer cell line was capable of sustaining tumour growth, depletion 
of the CD133+CXCR4+ fraction prevented the formation of metastases (189).   
The presence of metastatic TSCs was further demonstrated in primary 
tumour tissue where Pang and colleagues where none of their 19 patients 
lacking CD26+ cells in the primary tumour developed liver metastases (512). 
However, 5 out of the 8 patients with CD26+ cells developed liver metastases 
(the remaining 3 subjects were followed for a much shorter time period). The 
authors then established an orthotopic xenotransplantation assay in which 
colorectal cancer subpopulations were implanted into the mouse cecal wall. 
Their findings showed that while both CD26+ and CD26- populations were 
able to initiate growth of human tumours in the cecum, only CD26+ 
populations were capable of establishing metastases.   
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Similarly, considering data from our study, we propose that CHC1 may 
possibly be a marker of a subset of ovarian TSCs with increased metastatic 
properties.  
7.3.4. Further experiments to validate CHC1 as a TSC marker 
for EOC 
To validate whether CHC1 is indeed a TSC marker for EOC, several 
experiments including serial transplantations may be performed. For example, 
using an in vivo serial transplantation model, Curley and colleagues showed 
that primary uncultured human ovarian tumours could be reliably propagated 
in NOD/SCID mice, generating heterogeneous tumors which maintained the 
histological integrity of the parental tumor. Further profiling of human ovarian 
tumours for expression of candidate TSC surface markers indicated 
consistent expression of CD133 (513). Similarly, we could perform serial 
transplantation and investigate the expression of CHC1 in the tumours. 
Consistent expression of CHC1 would in turn suggest its usefulness as a TSC 
marker in EOC. 
Furthermore, in a separate study, Szotek and colleagues performed 
BrdU incorporation and doxycycline inducible histone2B-green fluorescent 
protein pulse–chase techniques to successfully identify a label-retaining cell 
population in the coelomic epithelium of the adult mouse ovary as candidate 
somatic stem/progenitor cells (218). Similarly, isolation of the label-retaining 
fraction in ovarian cancer cell lines, ascites or tumour tissue could be 
performed. Thereafter, staining of these cells with our in-house mAb168 or 
mAb774 would enable us to determine whether these stem/progenitor cells 
also expressed the CHC1 marker. 
Another experiment would involve growing ovarian cell lines or primary 
ovarian tumours in both 2D and 3D cultures.  We could then compare the 
phenotypes of cells seeded in the self-renewal promoting suspension culture 
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conditions with that seeded in adherent conditions. To characterize the stem 
cell component of the spheres, flow cytometry may be used to measure cells 
bearing the tumour-initiating phenotype CHC1 activity. An increase in the 
percentage of cells expressing CHC1 in the 3D culture would suggest the 
reliability of CHC1 as a stem cell marker in EOC.  
Moreover, further work may be performed with ascites using 
techniques such as flow cytometry to isolate cells expressing CHC1. These 
CHC1-positive cells may then undergo a series of in vitro experiments to 
investigate for stem cell characteristics such as the upregulation of other stem 
cell markers. Staining performed on larger numbers of paraffin embedded 
tissue with mAb168 or mAb774 together with other stem cell markers may 
also help to confirm whether CHC1 is a TSC marker. In this process, the type 
of detected subcellular localisation may also help us understand whether the 
antibody is specific.  
Finally, given the universal expression and the high sequence 
conservation of CHC1 from yeast Saccharomyces cerevisiae, worm 
Caenorhabditis elegans, fly Drosophila melanogaster, various mammals to 
human and even certain plants (414), it would also be interesting to perform 
knockdown/out studies of the gene to investigate whether the properties of 
ovarian TSCs are altered by a change in CHC1 expression. For example, 
following knockdown/out of the gene, expressions of stem cell markers such 
as ABCB1 and ALDH1A1 may be measured. In vitro experiments such as 
spheroid formation and invasion assays may also be carried out. These 
experiments, coupled with in vivo studies in mice, may together convincingly 
show the importance of CHC1 expression in the maintenance of stem cell-like 
characteristics in ovarian TSCs. 
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7.4. Concluding remarks 
The TSC research field is in its early stages and further insight into the 
molecular mechanisms which govern TSC development, self-renewal, 
survival, and differentiation are required to increase our understanding of 
tumour initiation and progression. These discoveries may possibly have a 
large impact on the early diagnosis and treatment of cancer. In particular, 
therapeutics with decreased toxicity and enhanced specificity towards TSCs 
may potentially lead to a decrease in morbidity and mortality associated with 
many human cancers.  
In our study, we focused on the generation and characterisation of 
novel mAbs which targeted antigens on ovarian TSCs. We discovered 2 novel 
mAbs, mAb168 and mAb774, which targeted CHC1 in subpopulations of cells 
from ovarian cancer cell lines as well as in patient tumour tissue samples.  
Regardless of whether CHC1 is a marker of stem cells, metastasis or 
metastatic stem cells, cells which overexpressed this marker demonstrated 
increased aggressiveness when compared to other ovarian cancer cells. We 
propose that both novel antibodies may inhibit proliferation of these CHC1-
positive cells in vivo, thus decreasing tumour growth and preventing tumour 
metastasis. Furthermore, cytotoxic drug-conjugated mAb168 and mAb774 
may target and eradicate these CHC1-positive cells, therefore serving as 
potential therapeutic agents for EOC. Finally, CHC1 may serve as a 
prognostic marker in early stage EOC patients.  
Future studies focused on elucidating these functions of mAb168 and 
mAb774 as therapeutic targets or early diagnostic markers could prove to be 
beneficial in the field of EOC therapy. This promising marker will also benefit 
from further well-designed clinical studies which would support its 
effectiveness and usefulness in the clinical setting. 
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Appendix 1 
RT-qPCR primers 
 
Name Gene Code/Sequence 
CLTC F clathrin ACTTAGCCGGTGCTGAAGAA 
CLTC R  AACCGACGGATAGTGTCTGG 
     
GAPDH  
glyceraldehyde-3- phosphate 
dehydrogenase  Hs99999905_m1 
      
ACTB beta- actin  Hs99999903_m1 
      
SOS2 son of sevenless homolog 2  Hs00183311_m1 
      
PIAS2 
protein inhibitor of activated 
STAT 2 Hs00190699_m1 
      
MKI67 
antigen identified by monoclonal 
antibody Ki 67 Hs00267195_m1 
      
BMI1 
B lymphoma Mo-MLV insertion 
region 1 homolog  Hs01053787_m1 
      
ABCG2 
ATP-binding cassette, sub-
family G   Hs01053787_m1 
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ABCB1 
ATP-binding cassette, sub-
family B  Hs01053787_m1 
      
CD133 prominin-1  Hs01053787_m1 
      
ALDH1A1 aldehyde dehydrogenase 1A1  Hs01053787_m1 
      
Appendix 2  
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Appendix 3 
PCR primers 
Name Sequence 
M13F-pUC (-40) 5' GTT TTC CCA GTC ACG AC 3' 
M13R-pUC (-26) 5' CAG GAA ACA GCT ATG AC 3’ 
  
Mouse Heavy chain variable 
(VH) region F 
5' TGA GGA GAC GGT GAC CGT GGT CCC 
TTG GTT CCA G 3' 
Mouse Heavy chain variable 
(VH) region R 5' CAG GTS MAR CTG CAG SAG TCW GG 3' 
 
where: 
R = A or G 
M = A or C 
S = G or C 
W = A or T 
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Appendix 4 
Antibody Isotype Company 
Catalogue 
number 
Dilution 
factor 
CHC1 IgM Abcam Ab14401 1:20 
CHC1 
IgM Thermo 
Scientific 
MA1-20194 1:20 
CHC1 
IgM Lifespan 
Bioscience 
LS-C22242-100 1:20 
CD133/1 IgG1 Miltenyi 130-090-422 1:10 
ABCB1 IgG1 Abcam Ab3366 1:10 
ALDH1A1 IgG Abcam Ab52492 1:80 
Oct3/4 IgG Santa Cruz sc-8628 1:20 
FITC Anti-IgM Dako F0479 1:500 
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Appendix 5 
Genes upregulated at ≥ 2- fold in SP versus NSP in HGU133Plus2 microarray 
experiment 
 
Affymetrix probe Log fold change Gene symbol 
209993_at 4.78 ABCB1 
209994_s_at 3.72 ABCB1 
241703_at 3.18 RPIB9 
1557161_at 2.84 NA 
1557360_at 2.56 LRPPRC 
201110_s_at 2.56 THBS1 
201842_s_at 2.51 EFEMP1 
227478_at 2.49 SETBP1 
243951_at 2.45 ABCB1 
237462_at 2.39 FAM133B 
241983_at 2.39 PTPN2 
210807_s_at 2.26 SLC16A7 
207057_at 2.23 SLC16A7 
229288_at 2.2 NA 
236856_x_at 2.17 NA 
217659_at 2.15 WAPAL 
241079_at 2.11 PUM1 
223875_s_at 2.11 EPC1 
241472_at 2.09 DMXL1 
231087_at 2.06 RIC8B 
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232504_at 2.02 LOC285628 
225417_at 2.02 EPC1 
1557585_at 2.01 ATP6V1H 
228421_s_at 2.01 EFEMP1 
1569652_at 2 MLLT3 
234969_s_at 1.98 EPC1 
1557586_s_at 1.97 ATP6V1H 
235556_at 1.97 LOC153222 
242593_at 1.96 KIAA0143 
244455_at 1.95 KCNT2 
242230_at 1.94 ATXN1 
1560422_at 1.94 NA 
226899_at 1.93 UNC5B 
207455_at 1.93 P2RY1 
241866_at 1.92 SLC16A7 
206852_at 1.91 EPHA7 
242990_at 1.9 WDFY3 
1566897_at 1.89 UNQ1887 
1557081_at 1.88 RBM25 
240152_at 1.85 HDLBP 
201108_s_at 1.85 THBS1 
212665_at 1.85 TIPARP 
239846_at 1.84 MTHFD1 
242059_at 1.83 ETNK1 
237508_at 1.83 CPEB3 
230003_at 1.82 NA 
242431_at 1.81 ARIH1 
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223686_at 1.81 TPK1 
242931_at 1.81 NA 
244414_at 1.81 MAML2 
206884_s_at 1.8 SCEL 
236778_at 1.79 ATRX 
229779_at 1.78 COL4A4 
237459_at 1.78 PCTK2 
234233_s_at 1.77 KBTBD2 
232865_at 1.75 AFF4 
202859_x_at 1.74 IL8 
1558356_at 1.73 UACA 
237239_at 1.73 CREBBP 
239660_at 1.72 C20orf74 
243591_at 1.72 LAMC1 
224081_at 1.72 NA 
242542_at 1.72 PHACTR2 
1569674_at 1.71 BHLHB9 
233869_x_at 1.7 DKFZP586B0319 
223575_at 1.7 KIAA1549 
206625_at 1.68 PRPH2 
209446_s_at 1.68 C7orf44 
1570295_at 1.67 VPS13A 
204470_at 1.67 CXCL1 
205569_at 1.67 LAMP3 
205992_s_at 1.66 IL15 
232056_at 1.66 SCEL 
1552972_at 1.66 hCG_2032978 
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1566896_at 1.66 UNQ1887 
232356_at 1.65 KIAA0143 
241147_at 1.65 EXOC6 
236237_at 1.65 KIAA1370 
1566094_at 1.64 ARHGEF12 
206029_at 1.64 ANKRD1 
1556989_at 1.63 ADAMTS9 
241623_at 1.63 PTPN2 
201109_s_at 1.62 THBS1 
231622_at 1.62 ASB17 
207082_at 1.62 CSF1 
212365_at 1.62 MYO1B 
231534_at 1.62 CDC2 
236757_at 1.61 SGMS1 
229649_at 1.6 NRXN3 
235740_at 1.61 MCTP1 
220346_at 1.58 MTHFD2L 
225957_at 1.58 LOC153222 
1556417_a_at 1.57 BPTF 
239571_at 1.57 MEF2A 
1560153_at 1.57 FRAS1 
229530_at 1.56 GUCY1A3 
222926_at 1.53 DCDC2 
233243_at 1.53 CBFA2T2 
212531_at 1.53 LCN2 
1556371_at 1.35 OLIG3 
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Appendix 6 
Genes downregulated at ≥ 2- fold in SP versus NSP in HGU133Plus2 
microarray experiment 
 
Affymetrix probe Log fold change Gene symbols 
201667_at -4.29 GJA1 
244829_at -3.51 C6orf218 
215889_at -3.47 SKIL 
202037_s_at -3.14 SFRP1 
206291_at -3.11 NTS 
209942_x_at -3.08 MAGEA3 
238460_at -2.95 FAM83A 
202036_s_at -2.94 SFRP1 
204920_at -2.89 CPS1 
214612_x_at -2.83 MAGEA6 
242868_at -2.83 EPAS1 
214844_s_at -2.82 DOK5 
224348_s_at -2.72 NA 
231690_at -2.61 NA 
230896_at -2.53 CCDC4 
222803_at -2.5 PRTFDC1 
207429_at -2.46 SLC22A2 
230720_at -2.38 RNF182 
230315_at -2.33 KLF3 
1556499_s_at -2.3 COL1A1 
211748_x_at -2.28 PTGDS 
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226071_at -2.23 ADAMTSL4 
1570122_at -2.2 PRDM10 
232654_s_at -2.13 UGT1A6 
210437_at -2.12 MAGEA9 
204532_x_at -2.12 UGT1A9 
237112_at -2.08 FAM102B 
208343_s_at -2.02 NR5A2 
230964_at -2.02 FREM2 
206857_s_at -1.98 FKBP1B 
1560469_at -1.95 NR5A2 
239913_at -1.93 SLC10A4 
212187_x_at -1.9 PTGDS 
235607_at -1.9 NA 
1558052_at -1.89 TMED4 
203924_at -1.89 GSTA2 
203180_at -1.89 ALDH1A3 
207663_x_at -1.87 GAGE3 
232696_at -1.86 LOC648556 
1563649_at -1.86 NA 
1554863_s_at -1.84 DOK5 
224997_x_at -1.84 H19 
229641_at -1.84 NA 
237168_at -1.84 NA 
228103_s_at -1.82 NRP2 
204642_at -1.81 EDG1 
1561015_at -1.79 KLF3 
216753_at -1.79 PRKCE 
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224646_x_at -1.78 H19 
212706_at -1.78 RASA4 
1564240_at -1.77 NA 
240681_at -1.76 NA 
242904_x_at -1.77 NA 
204570_at -1.76 COX7A1 
237651_x_at -1.76 NA 
206640_x_at -1.75 GAGE7B 
207126_x_at -1.75 UGT1A1 
215125_s_at -1.75 UGT1A6 
208982_at -1.75 PECAM1 
238928_at -1.73 SPEN 
213931_at -1.73 ID2 
216151_at -1.71 NA 
214455_at -1.69 HIST1H2BC 
239586_at -1.69 FAM83A 
230410_at -1.68 NRP2 
233030_at -1.67 PNPLA3 
204567_s_at -1.67 ABCG1 
216408_at -1.67 OR2B2 
204466_s_at -1.66 SNCA 
223541_at -1.65 HAS3 
227654_at -1.65 C20orf175 
1556651_at -1.64 WHSC2 
204082_at -1.64 PBX3 
206331_at -1.63 CALCRL 
238741_at -1.62 FAM83A 
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1552439_s_at -1.61 MEGF11 
210387_at -1.62 HIST1H2BG 
237531_at -1.6 C2orf3 
206378_at -1.6 SCGB2A2 
232164_s_at -1.58 EPPK1 
210174_at -1.57 NR5A2 
236204_at -1.57 COPS8 
1554545_at -1.56 APOBEC4 
211340_s_at -1.56 MCAM 
219853_at -1.56 FKRP 
219860_at -1.54 LY6G5C 
224337_s_at -1.54 FZD4 
1562516_at -1.54 WDR60 
230521_at -1.53 C9orf100 
209877_at -1.52 SNCG 
242274_x_at -1.53 SLC25A42 
243933_at -1.53 NFIB 
1552389_at -1.52 C8orf47 
243985_at -1.52 GTF2A2 
1560963_a_at -1.51 NA 
206094_x_at -1.52 UGT1A6 
1565768_at -1.51 ZNF268 
1570251_at -1.51 HECTD1 
229921_at -1.51 KIF5A 
205389_s_at -1.51 ANK1 
1557921_s_at -1.49 NA 
216278_at -1.47 KIAA0256 
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208235_x_at -1.47 GAGE7 
207739_s_at -1.46 GAGE2 
209304_x_at -1.47 GADD45B 
1561652_at -1.46 BECN1 
205390_s_at -1.46 ANK1 
1564357_at -1.45 ABHD12B 
217564_s_at -1.45 CPS1 
239690_at -1.46 NA 
1553398_at -1.45 NA 
207574_s_at -1.44 GADD45B 
208510_s_at -1.44 PPARG 
1570371_a_at -1.44 SELI 
230642_at -1.44 C18orf19 
207267_s_at -1.43 DSCR6 
212298_at -1.43 NRP1 
216504_s_at -1.43 SLC39A8 
214774_x_at -1.42 TOX3 
241763_s_at -1.42 FBXO32 
207086_x_at -1.4 GAGE4 
232165_at -1.39 EPPK1 
241610_x_at -1.39 PACS1 
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Appendix 7 
Genes upregulated at ≥ 2- fold in AF- positive versus AF- negative in 
HGU133Plus2 microarray experiment 
 
Affymetrix 
probe Log fold change Gene symbol 
212224_at 5.02 ALDH1A1 
236979_at 3.06 BCL2L15 
215704_at 2.98 FLG 
243938_x_at 2.82 DNAH5 
236646_at 2.79 C12orf59 
202478_at 2.71 TRIB2 
205051_s_at 2.63 KIT 
202479_s_at 2.63 TRIB2 
227449_at 2.58 EPHA4 
1555486_a_at 2.57 FLJ14213 
228948_at 2.56 EPHA4 
203180_at 2.47 ALDH1A3 
202237_at 2.45 NNMT 
242626_at 2.40 SAMD5 
206354_at 2.27 SLCO1B3 
225667_s_at 2.25 FAM84A 
205626_s_at 2.25 CALB1 
242013_at 2.23 BCL2L15 
228653_at 2.22 SAMD5 
206114_at 2.18 EPHA4 
234335_s_at 2.17 FAM84A 
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1556371_at 2.13 OLIG3 
207291_at 2.13 PRRG4 
205625_s_at 2.12 CALB1 
229779_at 2.10 COL4A4 
214602_at 2.00 COL4A4 
203661_s_at 1.97 TMOD1 
222969_at 1.96 B3GALT1 
1570515_a_at 1.94 FILIP1 
213197_at 1.92 ASTN1 
229374_at 1.90 EPHA4 
223784_at 1.90 TMEM27 
238513_at 1.89 PRRG4 
220829_s_at 1.87 B3GALT1 
217248_s_at 1.86 SLC7A8 
219383_at 1.85 FLJ14213 
200953_s_at 1.83 CCND2 
1554921_a_at 1.83 SCEL 
1569433_at 1.83 SAMD5 
201278_at 1.82 DAB2 
222901_s_at 1.79 KCNJ16 
228949_at 1.78 GPR177 
203913_s_at 1.77 HPGD 
219564_at 1.75 KCNJ16 
236083_at 1.74 BCL2L15 
230047_at 1.73 FLJ32810 
206382_s_at 1.72 BDNF 
206884_s_at 1.72 SCEL 
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222449_at 1.72 PMEPA1 
1552760_at 1.68 HDAC9 
202238_s_at 1.68 NNMT 
202800_at 1.66 SLC1A3 
201340_s_at 1.65 ENC1 
228950_s_at 1.65 GPR177 
201506_at 1.65 TGFBI 
239367_at 1.64 BDNF 
221958_s_at 1.64 GPR177 
235763_at 1.64 SLC44A5 
232914_s_at 1.63 SYTL2 
204532_x_at 1.59 UGT1A9 
232654_s_at 1.59 UGT1A1 
232231_at 1.59 RUNX2 
228981_at 1.58 TMEM169 
214382_at 1.56 UNC93A 
210004_at 1.56 OLR1 
216598_s_at 1.55 CCL2 
1555253_at 1.55 COL25A1 
215125_s_at 1.54 UGT1A1 
207126_x_at 1.54 UGT1A1 
204304_s_at 1.54 PROM1 
202202_s_at 1.54 LAMA4 
219686_at 1.53 STK32B 
225496_s_at 1.53 SYTL2 
219508_at 1.53 GCNT3 
1561969_at 1.52 ZPLD1 
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204014_at 1.51 DUSP4 
203300_x_at 1.51 AP1S2 
232504_at 1.50 LOC285628 
207447_s_at 1.50 MGAT4C 
235318_at 1.49 FBN1 
202765_s_at 1.49 FBN1 
210145_at 1.47 PLA2G4A 
227155_at 1.47 LMO4 
209283_at 1.47 CRYAB 
216604_s_at 1.46 SLC7A8 
207528_s_at 1.46 SLC7A11 
232056_at 1.46 SCEL 
231559_at 1.44 NNMT 
231945_at 1.44 FILIP1 
205832_at 1.44 CPA4 
208596_s_at 1.44 UGT1A3 
201431_s_at 1.44 DPYSL3 
205123_s_at 1.43 TMEFF1 
203662_s_at 1.41 TMOD1 
206094_x_at 1.39 UGT1A6 
215646_s_at 1.39 VCAN 
210757_x_at 1.38 DAB2 
205659_at 1.37 HDAC9 
229163_at 1.37 CAMK2N1 
213895_at 1.37 EMP1 
221489_s_at 1.36 SPRY4 
231798_at 1.35 NOG 
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202609_at 1.35 EPS8 
203299_s_at 1.35 AP1S2 
230264_s_at 1.35 AP1S2 
216959_x_at 1.34 NRCAM 
225207_at 1.34 PDK4 
206429_at 1.34 F2RL1 
221667_s_at 1.33 HSPB8 
201998_at 1.32 ST6GAL1 
209921_at 1.31 SLC7A11 
204105_s_at 1.31 NRCAM 
201616_s_at 1.31 CALD1 
205348_s_at 1.30 DYNC1I1 
211571_s_at 1.30 VCAN 
208354_s_at 1.30 SLC12A3 
202018_s_at 1.30 LTF 
210617_at 1.29 PHEX 
201617_x_at 1.29 CALD1 
204619_s_at 1.29 VCAN 
213506_at 1.28 F2RL1 
1569112_at 1.28 SLC44A5 
223928_s_at 1.28 GUCA1C 
221283_at 1.27 RUNX2 
213316_at 1.27 KIAA1462 
230323_s_at 1.27 TMEM45B 
207864_at 1.27 SCN7A 
232381_s_at 1.26 DNAH5 
216277_at 1.26 BUB1 
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211124_s_at 1.26 KITLG 
201325_s_at 1.25 EMP1 
214079_at 1.25 DHRS2 
233902_at 1.25 GUCA1C 
214460_at 1.24 LSAMP 
213664_at 1.24 SLC1A1 
210559_s_at 1.24 CDC2 
211248_s_at 1.23 CHRD 
1562966_at 1.23 KIAA1217 
206132_at 1.23 MCC 
204620_s_at 1.22 VCAN 
209205_s_at 1.22 LMO4 
1558034_s_at 1.22 CP 
202954_at 1.21 UBE2C 
223595_at 1.21 TMEM133 
221731_x_at 1.21 VCAN 
209118_s_at 1.21 TUBA1A 
1553861_at 1.20 TCP11L2 
226844_at 1.20 MOBKL2B 
217678_at 1.19 SLC7A11 
234393_at 1.19 HDAC9 
240873_x_at 1.19 DAB2 
203232_s_at 1.19 ATXN1 
228415_at 1.19 AP1S2 
200952_s_at 1.18 CCND2 
227828_s_at 1.18 FAM176A 
201615_x_at 1.18 CALD1 
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204472_at 1.18 GEM 
205593_s_at 1.18 PDE9A 
202760_s_at 1.18 PALM2-AKAP2 
206765_at 1.17 KCNJ2 
202766_s_at 1.17 FBN1 
231534_at 1.17 CDC2 
215821_x_at 1.17 PSG3 
231823_s_at 1.17 SH3PXD2B 
1565162_s_at 1.16 MGST1 
219659_at 1.16 ATP8A2 
205122_at 1.16 TMEFF1 
209160_at 1.16 AKR1C3 
201341_at 1.16 ENC1 
203214_x_at 1.15 CDC2 
212599_at 1.15 AUTS2 
210605_s_at 1.15 MFGE8 
233953_at 1.15 GUCA1C 
236013_at 1.15 CACNA1E 
228150_at 1.14 SEC16B 
215324_at 1.14 SEMA3D 
219836_at 1.14 ZBED2 
205016_at 1.14 TGFA 
204750_s_at 1.14 DSC2 
1567359_at 1.13 BDNFOS 
239579_at 1.13 ABHD7 
218309_at 1.13 CAMK2N1 
211548_s_at 1.13 HPGD 
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226122_at 1.13 PLEKHG1 
206029_at 1.12 ANKRD1 
203914_x_at 1.12 HPGD 
209822_s_at 1.12 VLDLR 
226534_at 1.12 KITLG 
211518_s_at 1.12 BMP4 
205376_at 1.12 INPP4B 
207029_at 1.12 KITLG 
201324_at 1.11 EMP1 
237737_at 1.11 LOC727770 
233030_at 1.11 PNPLA3 
204595_s_at 1.10 STC1 
1561759_at 1.10 LOC645513 
210360_s_at 1.10 MTSS1 
226047_at 1.10 MRVI1 
208868_s_at 1.10 GABARAPL1 
230925_at 1.09 APBB1IP 
215342_s_at 1.09 RABGAP1L 
233555_s_at 1.09 SULF2 
205931_s_at 1.09 CREB5 
203213_at 1.09 CDC2 
226226_at 1.09 TMEM45B 
213764_s_at 1.09 MFAP5 
229245_at 1.09 PLEKHA6 
213238_at 1.08 ATP10D 
202481_at 1.08 DHRS3 
1556029_s_at 1.08 NMNAT2 
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209738_x_at 1.08 PSG6 
203231_s_at 1.08 ATXN1 
226869_at 1.07 MEGF6 
202828_s_at 1.07 MMP14 
220084_at 1.07 C14orf105 
203962_s_at 1.07 NEBL 
224724_at 1.07 SULF2 
202149_at 1.07 NEDD9 
242092_at 1.06 EPB41L2 
209937_at 1.06 TM4SF4 
1556704_s_at 1.06 LOC286297 
205032_at 1.06 ITGA2 
205619_s_at 1.06 MEOX1 
204830_x_at 1.06 PSG5 
204827_s_at 1.06 CCNF 
229909_at 1.06 B4GALNT3 
221258_s_at 1.06 KIF18A 
1553645_at 1.05 CCDC141 
211470_s_at 1.05 SULT1C2 
201667_at 1.05 GJA1 
205786_s_at 1.05 ITGAM 
204057_at 1.05 IRF8 
228221_at 1.05 SLC44A3 
202759_s_at 1.04 PALM2-AKAP2 
212311_at 1.04 KIAA0746 
226460_at 1.04 FNIP2 
209204_at 1.04 LMO4 
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210176_at 1.04 TLR1 
222857_s_at 1.04 KCNMB4 
228461_at 1.04 SH3RF3 
228252_at 1.04 PIF1 
1565525_a_at 1.04 TCP11L2 
225355_at 1.04 LOC54492 
221646_s_at 1.04 ZDHHC11 
234910_at 1.03 RASAL2 
207885_at 1.03 S100G 
212077_at 1.03 CALD1 
226694_at 1.03 PALM2-AKAP2 
205925_s_at 1.03 RAB3B 
47550_at 1.03 LZTS1 
230232_at 1.03 KIAA0746 
232116_at 1.02 GRHL3 
227123_at 1.02 RAB3B 
244235_at 1.02 IVNS1ABP 
210916_s_at 1.02 CD44 
219026_s_at 1.02 RASAL2 
206268_at 1.02 LEFTY1 
231736_x_at 1.01 MGST1 
219660_s_at 1.01 ATP8A2 
1555591_at 1.01 PIF1 
226545_at 1.01 CD109 
201279_s_at 1.01 DAB2 
201141_at 1.01 GPNMB 
210445_at 1.01 FABP6 
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219225_at 1.01 PGBD5 
204613_at 1.01 PLCG2 
202752_x_at 1.00 SLC7A8 
209949_at 1.00 NCF2 
243483_at 1.00 TRPM8 
213765_at 1.00 MFAP5 
231842_at 1.00 KIAA1462 
219195_at 1.00 PPARGC1A 
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Appendix 8 
Genes downregulated at ≥ 2- fold in AF- positive versus AF- negative in 
HGU133Plus2 microarray experiment 
 
Affymetrix probe Log fold change Gene symbol 
204988_at -2.68 FGB 
210437_at -2.01 MAGEA9 
216238_s_at -1.96 FGB 
212386_at -1.92 TCF4 
207057_at -1.90 SLC16A7 
241703_at -1.90 RUNDC3B 
209993_at -1.88 ABCB1 
206291_at -1.83 NTS 
207327_at -1.77 EYA4 
219612_s_at -1.74 FGG 
1554607_at -1.72 CNKSR2 
219985_at -1.70 HS3ST3A1 
212382_at -1.69 TCF4 
204567_s_at -1.68 ABCG1 
209994_s_at -1.64 ABCB1 
210807_s_at -1.63 SLC16A7 
241866_at -1.63 SLC16A7 
225275_at -1.62 EDIL3 
238877_at -1.58 EYA4 
209505_at -1.53 NR2F1 
241031_at -1.49 FAM148A 
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214461_at -1.49 LBP 
228915_at -1.48 DACH1 
227697_at -1.46 SOCS3 
205934_at -1.46 PLCL1 
217489_s_at -1.46 IL6R 
243213_at -1.43 STAT3 
229116_at -1.42 CNKSR2 
230075_at -1.41 RAB39B 
1558143_a_at -1.39 BCL2L11 
227856_at -1.39 C4orf32 
203753_at -1.39 TCF4 
228360_at -1.35 LYPD6B 
226982_at -1.33 ELL2 
214397_at -1.32 MBD2 
202023_at -1.31 EFNA1 
228935_at -1.28 SLC4A8 
211652_s_at -1.26 LBP 
208343_s_at -1.26 NR5A2 
227647_at -1.25 KCNE3 
213912_at -1.24 TBC1D30 
212387_at -1.21 TCF4 
204920_at -1.21 CPS1 
237116_at -1.21 LOC646903 
205945_at -1.20 IL6R 
232530_at -1.19 PLD1 
224027_at -1.18 CCL28 
210174_at -1.17 NR5A2 
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226333_at -1.17 IL6R 
235174_s_at -1.15 
LOC10012882
2 
225481_at -1.15 FRMD6 
1554057_at -1.14 LOC645676 
206548_at -1.13 hCG_1776259 
213913_s_at -1.13 TBC1D30 
208337_s_at -1.13 NR5A2 
205511_at -1.13 FLJ10038 
243951_at -1.13 ABCB1 
214022_s_at -1.12 IFITM1 
205514_at -1.12 ZNF415 
227236_at -1.12 TSPAN2 
230030_at -1.12 HS6ST2 
1557584_at -1.11 FLJ20444 
202357_s_at -1.11 CFB 
205515_at -1.11 PRSS12 
205471_s_at -1.11 DACH1 
233082_at -1.10 ZNF630 
205472_s_at -1.10 DACH1 
1569107_s_at -1.09 ZNF642 
244829_at -1.08 C6orf218 
208081_s_at -1.08 ZNF442 
222803_at -1.07 PRTFDC1 
204798_at -1.07 MYB 
244317_at -1.07 KIAA1324L 
226099_at -1.06 ELL2 
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238992_at -1.06 POLI 
225846_at -1.06 RBM35A 
1568627_at -1.06 SMEK2 
225464_at -1.06 FRMD6 
1556579_s_at -1.06 IGSF10 
241969_at -1.05 ARID5B 
1552390_a_at -1.05 C8orf47 
222146_s_at -1.05 TCF4 
231008_at -1.05 UNC5CL 
208747_s_at -1.04 C1S 
213568_at -1.04 OSR2 
228256_s_at -1.04 EPB41L4A 
226789_at -1.04 LOC647121 
206440_at -1.04 LIN7A 
220399_at -1.04 FLJ22639 
219525_at -1.03 SLC47A1 
225606_at -1.02 BCL2L11 
1552822_at -1.02 TXNDC10 
1560250_s_at -1.02 LOC284242 
207847_s_at -1.01 MUC1 
201601_x_at -1.01 IFITM1 
225996_at -1.01 LONRF2 
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Appendix 9 
Expression values and log fold changes of upregulated genes in both populations as 
obtained by HGU133Plus2 microarray experiments. 
SP vs NSP         
Probe ID IGNSP1.CEL IGNSP2.CEL IGNSP3.CEL IGSP1.CEL IGSP2.CEL IGSP3.CEL logFC geneSym 
1556371_at 5.75 3.41 5.60 8.74 6.04 4.02 1.35 OLIG3 
214602_at 6.20 6.72 5.93 7.14 7.59 7.36 1.08 COL4A4 
229779_at 3.44 5.69 5.20 6.58 6.41 6.66 1.78 COL4A4 
241565_at 4.79 4.49 4.40 4.93 4.79 4.41 0.15 COL4A4 
1554920_at 1.89 1.66 1.89 1.82 1.94 1.85 0.06 SCEL 
1554921_a_at 4.29 5.45 5.36 6.51 6.45 6.29 1.39 SCEL 
206884_s_at 5.58 5.23 4.60 7.41 6.68 6.69 1.80 SCEL 
232056_at 2.38 3.29 2.91 3.94 4.94 4.68 1.66 SCEL 
219564_at 7.65 8.57 7.78 8.99 9.52 9.97 1.49 KCNJ16 
222901_s_at 6.73 7.11 6.05 7.50 8.01 9.03 1.55 KCNJ16 
210559_s_at 6.79 6.72 6.75 7.65 7.15 7.06 0.53 CDC2 
203213_at 8.37 8.95 9.06 9.52 9.36 9.43 0.64 CDC2 
203214_x_at 6.35 6.64 6.88 7.50 7.34 6.98 0.65 CDC2 
1559249_at 2.89 3.55 2.90 3.06 3.38 3.47 0.19 ATXN1 
203231_s_at 7.17 8.26 7.17 8.21 8.19 8.53 0.78 ATXN1 
203232_s_at 6.02 7.10 6.63 6.75 8.18 7.83 1.00 ATXN1 
230507_at 5.44 5.63 5.48 6.15 5.90 6.04 0.51 ATXN1 
242230_at 4.69 5.35 5.32 6.92 7.17 7.10 1.94 ATXN1 
206029_at 5.53 7.99 4.62 5.96 8.55 8.55 1.64 ANKRD1 
212325_at 7.45 8.80 7.76 9.14 9.73 9.70 1.52 LIMCH1 
212327_at 8.39 9.55 8.54 9.54 10.51 10.05 1.21 LIMCH1 
212328_at 8.60 9.86 8.75 9.69 10.53 10.49 1.17 LIMCH1 
232457_at 5.30 5.13 4.43 5.92 5.36 4.98 0.46 LIMCH1 
241459_at 5.46 5.49 4.93 7.04 6.40 6.38 1.32 LIMCH1 
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AF+ vs AF-         
Probe ID A-_P15.CEL A-_P16.CEL A+_P17.CEL A+_P15.CEL A+_P16.CEL A+_P17.CEL logFC geneSym 
1556371_at 4.60 5.49 5.75 7.58 7.80 6.86 2.13 OLIG3 
214602_at 3.61 3.57 3.81 5.81 5.73 5.47 2.00 COL4A4 
229779_at 3.08 3.41 4.10 5.36 6.20 5.35 2.10 COL4A4 
241565_at 3.34 3.36 3.25 3.34 3.65 3.29 0.11 COL4A4 
1554920_at 1.66 1.98 2.08 1.37 1.63 1.70 -0.34 SCEL 
1554921_a_at 4.61 4.99 5.02 6.69 6.99 6.43 1.83 SCEL 
206884_s_at 3.81 5.18 5.17 6.36 6.63 6.34 1.72 SCEL 
232056_at 2.89 3.78 4.03 5.12 4.99 4.97 1.46 SCEL 
219564_at 7.51 8.04 7.83 9.61 9.75 9.27 1.75 KCNJ16 
222901_s_at 7.01 7.18 6.89 8.97 8.97 8.51 1.79 KCNJ16 
203213_at 9.02 9.32 9.43 10.38 10.28 10.38 1.09 CDC2 
203214_x_at 7.56 8.15 8.16 8.95 9.02 9.35 1.15 CDC2 
210559_s_at 7.36 7.86 8.15 8.88 8.93 9.26 1.24 CDC2 
1559249_at 2.47 2.94 2.73 2.59 4.10 2.63 0.39 ATXN1 
203231_s_at 5.34 5.64 5.49 6.64 6.67 6.39 1.08 ATXN1 
203232_s_at 6.34 6.64 6.47 7.66 7.67 7.68 1.19 ATXN1 
230507_at 4.92 4.87 4.77 5.22 5.20 4.78 0.22 ATXN1 
242230_at 3.36 3.39 4.09 4.50 4.66 4.43 0.91 ATXN1 
206029_at 6.07 6.42 6.83 7.43 7.55 7.71 1.12 ANKRD1 
212325_at 6.92 7.21 7.08 7.83 8.09 7.81 0.84 LIMCH1 
212327_at 7.69 7.96 8.10 8.66 9.08 8.54 0.84 LIMCH1 
212328_at 7.98 7.90 8.12 8.92 9.13 8.80 0.94 LIMCH1 
232457_at 4.17 4.35 4.00 4.50 4.62 4.71 0.44 LIMCH1 
241459_at 2.75 2.26 3.18 2.82 2.65 2.67 -0.02 LIMCH1 
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Appendix 10 
Expression values and log fold changes of downregulated genes in both populations as 
obtained by HGU133Plus2 microarray experiments. 
SP vs NSP         
Probe ID IGNSP1.CEL IGNSP2.CEL IGNSP3.CEL IGSP1.CEL IGSP2.CEL IGSP3.CEL logFC geneSym 
210437_at 6.23 8.36 6.96 5.21 4.88 5.11 -2.12 MAGEA9 
206291_at 7.17 4.15 7.63 4.40 2.42 2.79 -3.11 NTS 
204567_s_at 7.48 7.34 7.43 5.53 6.97 4.74 -1.67 ABCG1 
211113_s_at 5.20 5.01 5.17 4.61 4.69 4.54 -0.51 ABCG1 
1560469_at 6.32 3.02 6.05 3.58 3.17 2.80 -1.95 NR5A2 
208337_s_at 8.34 7.59 7.62 5.62 7.06 7.12 -1.25 NR5A2 
208343_s_at 6.80 7.38 6.70 4.63 6.13 4.05 -2.02 NR5A2 
210174_at 7.57 7.87 8.18 6.29 6.73 5.89 -1.57 NR5A2 
205318_at 4.16 5.18 5.20 3.91 3.09 3.43 -1.37 KIF5A 
223933_at 3.36 3.88 3.82 3.14 2.70 2.87 -0.79 KIF5A 
229921_at 6.39 5.63 6.19 4.75 4.50 4.43 -1.51 KIF5A 
1554863_s_at 7.34 7.73 8.19 6.17 6.36 5.20 -1.84 DOK5 
214844_s_at 8.63 7.68 8.31 5.44 5.59 5.13 -2.82 DOK5 
201565_s_at 9.78 9.29 9.79 8.26 8.89 8.93 -0.93 ID2 
201566_x_at 8.14 8.21 8.61 6.65 7.53 7.66 -1.04 ID2 
213931_at 7.34 7.60 7.71 5.45 6.17 5.83 -1.73 ID2 
244829_at 5.90 6.01 6.20 2.70 2.42 2.46 -3.51 C6orf218 
222803_at 8.02 8.72 8.59 6.73 5.34 5.75 -2.50 PRTFDC1 
1552389_at 6.61 4.55 5.90 4.42 4.06 4.01 -1.52 C8orf47 
1552390_a_at 7.04 7.69 6.92 5.62 5.93 6.72 -1.13 C8orf47 
204920_at 7.27 4.84 8.27 4.92 2.95 3.84 -2.89 CPS1 
217564_s_at 4.23 2.47 4.60 1.78 2.81 2.34 -1.45 CPS1 
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AF+ vs AF-         
Probe ID A-_P15.CEL A-_P16.CEL A-_P17.CEL A+_P15.CEL A+_P16.CEL A+_P17.CEL logFC geneSym 
210437_at 8.56 8.28 8.95 7.17 4.92 7.68 -2.01 MAGEA9 
206291_at 7.25 7.54 7.57 6.01 4.39 6.46 -1.83 NTS 
204567_s_at 5.60 5.05 5.33 3.97 2.86 4.09 -1.68 ABCG1 
211113_s_at 4.28 4.07 4.13 3.91 3.41 4.01 -0.38 ABCG1 
1560469_at 3.72 2.92 3.43 2.77 2.36 2.98 -0.65 NR5A2 
208337_s_at 8.24 8.01 8.17 7.17 6.29 7.57 -1.13 NR5A2 
208337_s_at 8.24 8.01 8.17 7.17 6.29 7.57 -1.13 NR5A2 
210174_at 7.93 7.71 8.09 6.86 5.80 7.54 -1.17 NR5A2 
205318_at 4.33 4.35 4.48 3.60 3.09 3.55 -0.97 KIF5A 
223933_at 3.24 3.37 3.72 2.97 3.08 3.10 -0.39 KIF5A 
229921_at 6.03 5.63 5.99 5.22 4.92 5.34 -0.72 KIF5A 
1554863_s_at 7.04 7.11 7.35 6.43 5.92 6.82 -0.77 DOK5 
214844_s_at 7.25 6.94 7.59 6.16 5.96 6.91 -0.92 DOK5 
201565_s_at 8.60 8.14 7.94 7.80 7.62 7.25 -0.67 ID2 
201566_x_at 7.64 7.28 7.30 6.61 6.52 6.59 -0.84 ID2 
213931_at 8.07 7.11 7.46 7.12 6.68 6.97 -0.63 ID2 
244829_at 6.18 6.08 6.66 5.42 4.34 5.90 -1.08 C6orf218 
222803_at 8.43 8.72 8.75 7.54 7.15 8.00 -1.07 PRTFDC1 
1552389_at 5.42 5.91 5.76 4.44 4.53 5.31 -0.94 C8orf47 
1552390_a_at 7.30 7.43 7.60 6.31 6.03 6.86 -1.05 C8orf47 
204920_at 7.01 7.13 7.76 6.03 5.37 6.87 -1.21 CPS1 
217564_s_at 4.15 4.25 4.74 3.46 2.61 4.19 -0.96 CPS1 
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Appendix 11 
Genes upregulated at ≥ 2- fold in mAb168-positive versus mAb168-negative 
in HGU133Plus2 microarray experiment 
 
Affymetrix probe Log fold change Gene symbols 
1552715_a_at 5.03 ALDH1A1 
1554921_a_at 4.61 NNMT 
201131_s_at 4.57 ADAMTS1 
201430_s_at 4.35 RAI2 
202237_at 4.22 SCEL 
202238_s_at 4.21 IGFBP1 
202508_s_at 4.15 PLA2G4A 
203065_s_at 4.10 IGFBP3 
203232_s_at 4.01 NNMT 
203887_s_at 3.96 SCEL 
203963_at 3.78 IGFBP3 
204014_at 3.61 ADAMTS1 
204105_s_at 3.60 NRCAM 
204115_at 3.50 THBD 
204475_at 3.16 DPYSL3 
204508_s_at 3.14 FOXF2 
205302_at 3.14 DSC2 
205466_s_at 3.07 COL4A4 
206377_at 2.99 RUNX2 
206884_s_at 2.96 HS3ST1 
210095_s_at 2.95 SAMD5 
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210145_at 2.93 DUSP4 
212097_at 2.92 MAML2 
212143_s_at 2.88 CA12 
212224_at 2.85 FOXA2 
215646_s_at 2.77 CAV1 
217678_at 2.77 CDK6 
219440_at 2.76 MMP1 
222162_s_at 2.75 CDK6 
222486_s_at 2.74 C6orf192 
224847_at 2.74 PARM1 
224851_at 2.73 IKZF2 
225664_at 2.73 ATXN1 
225809_at 2.73 NPNT 
225911_at 2.72 SCEL 
226301_at 2.71 COL12A1 
226817_at 2.65 VCAN 
228653_at 2.65 CDH1 
229779_at 2.60 GNG11 
231929_at 2.54 RXFP1 
232056_at 2.51 DSC2 
232231_at 2.51 SLC7A11 
235457_at 2.50 EYA4 
238877_at 2.48 FBN1 
40284_at 2.46 VCAN 
1555963_x_at 2.45 CAV1 
204446_s_at 2.43 CA12 
202800_at 2.43 PRSS23 
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201721_s_at 2.42 CA12 
213506_at 2.41 UNC93A 
221731_x_at 2.40 CA12 
207327_at 2.39 SNAP25 
226145_s_at 2.36 DPYSL3 
212190_at 2.33 SLC7A11 
231804_at 2.26 FOXQ1 
238206_at 2.24 RXFP1 
210103_s_at 2.21 VCAN 
204620_s_at 2.20 FOXA2 
1552566_at 2.18 F2RL1 
227475_at 2.18 BTBD16 
209921_at 2.17 RXFP1 
201431_s_at 2.15 CD109 
214382_at 2.15 SLC1A3 
204750_s_at 2.13 KITLG 
211571_s_at 2.10 VCAN 
226279_at 2.09 SERPINE2 
215867_x_at 2.08 FRAS1 
202765_s_at 2.07 LAPTM5 
214164_x_at 2.06 RNF144B 
204687_at 2.05 DSC2 
206029_at 2.05 EYA4 
202766_s_at 2.05 ANKRD1 
228153_at 2.03 B3GNT7 
209493_at 2.03 CTTNBP2 
241412_at 2.02 SCGB2A1 
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235350_at 2.01 ALOX5 
210735_s_at 2.00 PDZD2 
1553132_a_at 2.00 PRSS23 
226869_at 1.98 COLEC12 
224848_at 1.97 CDK6 
221019_s_at 1.96 C4orf19 
202948_at 1.96 SH3RF3 
227919_at 1.96 FBN1 
228461_at 1.96 ST6GALNAC1 
232136_s_at 1.96 PARM1 
227725_at 1.91 BCL2L15 
202458_at 1.91 C4orf19 
219450_at 1.91 IL1R1 
205659_at 1.90 UCA1 
235318_at 1.90 HDAC9 
205979_at 1.89 MEGF6 
209184_s_at 1.88 DCLK1 
215303_at 1.86 KCNJ2 
221933_at 1.85 TC2N 
236979_at 1.84 WNT5A 
209598_at 1.83 BTC 
228708_at 1.82 CA12 
204751_x_at 1.82 MGST1 
204015_s_at 1.81 FBN1 
230962_at 1.80 COL4A4 
205990_s_at 1.79 PNMA2 
206765_at 1.77 BMP4 
303 
 
 
214421_x_at 1.75 NLGN4X 
226534_at 1.75 THBD 
211518_s_at 1.75 IRS2 
235046_at 1.74 DCLK1 
209656_s_at 1.73 VCAN 
206618_at 1.72 CYP2C9 
205593_s_at 1.72 TMEM47 
209185_s_at 1.72 DUSP4 
238567_at 1.71 BASP1 
221563_at 1.71 IL18R1 
202391_at 1.71 IRS2 
215704_at 1.70 PDE9A 
203888_at 1.70 MGST1 
233587_s_at 1.70 KCTD12 
215170_s_at 1.68 SGPP2 
212192_at 1.67 NA 
205376_at 1.67 FLG 
207528_s_at 1.67 RAB27B 
204619_s_at 1.66 COL12A1 
209292_at 1.65 INPP4B 
219496_at 1.64 IRF8 
209270_at 1.63 TFPI2 
227759_at 1.62 ANKRD57 
226545_at 1.61 SIPA1L2 
227828_s_at 1.61 CEP152 
220658_s_at 1.61 ID4 
239201_at 1.61 DUSP10 
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1555962_at 1.60 F2RL2 
216025_x_at 1.59 B3GNT7 
231766_s_at 1.59 FAM176A 
203323_at 1.59 SLC7A11 
223586_at 1.58 LAMB3 
229070_at 1.56 MFAP5 
228038_at 1.55 F2RL1 
227379_at 1.54 CCL20 
220017_x_at 1.54 CYP2C9 
224918_x_at 1.53 CAV2 
209278_s_at 1.53 CP 
203355_s_at 1.53 CDK15 
234970_at 1.52 PSD3 
209758_s_at 1.52 SOX2 
205476_at 1.51 MBOAT1 
239413_at 1.51 CXCL3 
225056_at 1.51 SERPINA1 
204057_at 1.51 FAM84A 
227498_at 1.50 ARNTL2 
207018_s_at 1.50 C6orf105 
215882_at 1.50 CYP2C9 
228143_at 1.50 PCSK9 
230147_at 1.49 ANO1 
238513_at 1.48 ARNTL2 
213425_at 1.48 PRRG4 
219508_at 1.47 NRP1 
224204_x_at 1.47 TC2N 
305 
 
 
207526_s_at 1.47 CP 
207850_at 1.47 MGST1 
212298_at 1.46 SLC44A3 
218804_at 1.45 TMEM45B 
235638_at 1.45 SIPA1L2 
215501_s_at 1.45 RAB27B 
215856_at 1.44 CYP4F11 
228195_at 1.43 RASSF6 
203726_s_at 1.43 WNT5A 
202833_s_at 1.42 CEP152 
226041_at 1.42 CEP152 
206153_at 1.42 SOX6 
202831_at 1.41 IL1RL1 
228221_at 1.41 KCNJ16 
204563_at 1.41 GPX2 
205844_at 1.40 SIGLEC15 
211676_s_at 1.40 LAMA3 
203556_at 1.40 PSD3 
200762_at 1.39 PRAGMIN 
208146_s_at 1.39 TEX15 
226614_s_at 1.37 FAM167A 
214607_at 1.36 C2orf88 
203324_s_at 1.36 DPYSL2 
241014_at 1.36 ARNTL2 
204846_at 1.36 GCNT3 
231154_x_at 1.35 VNN1 
218995_s_at 1.35 DUSP10 
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204259_at 1.35 LOC339400 
219564_at 1.33 TNC 
201626_at 1.32 CP 
201720_s_at 1.31 NAPEPLD 
201752_s_at 1.30 SELL 
243179_at 1.30 ZHX2 
33736_at 1.30 MMP7 
229256_at 1.29 CP 
218613_at 1.29 CPVL 
222901_s_at 1.29 IFNGR1 
232760_at 1.29 CAV2 
225667_s_at 1.28 TINAG 
201939_at 1.28 ADD3 
219836_at 1.27 BCL2L15 
214321_at 1.27 MFAP5 
201753_s_at 1.27 PGM2L1 
209291_at 1.26 ID4 
219659_at 1.26 DCLK1 
1565162_s_at 1.26 STOML1 
1558034_s_at 1.25 PAK3 
213929_at 1.25 NAPEPLD 
204624_at 1.24 PIK3R1 
204501_at 1.24 PLK2 
231736_x_at 1.24 INSIG1 
227253_at 1.24 KCNJ16 
205822_s_at 1.23 HMGCS1 
214602_at 1.22 EDN1 
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212240_s_at 1.21 LAPTM5 
213765_at 1.21 BIRC3 
235106_at 1.21 LOC100130360 
237591_at 1.21 ZBED2 
242800_at 1.21 HLA-DMB 
206429_at 1.21 ADD3 
230323_s_at 1.20 TMEM45B 
226438_at 1.20 NOV 
231945_at 1.20 NOV 
201540_at 1.20 FHL1 
214708_at 1.19 DPYD 
228933_at 1.19 HTRA1 
204646_at 1.19 IL8 
222802_at 1.19 IL8 
228981_at 1.18 SNTB1 
226322_at 1.18 TMEM27 
201645_at 1.18 BDNF 
205399_at 1.18 SERPINA1 
219660_s_at 1.17 MFAP5 
242635_s_at 1.17 FILIP1 
210538_s_at 1.17 TMEM169 
221210_s_at 1.17 SNTB1 
224797_at 1.17 MAML2 
235085_at 1.17 EXPH5 
211429_s_at 1.16 NCRNA00173 
239871_at 1.16 CLTC 
205882_x_at 1.16 ADD3 
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1559072_a_at 1.16 ARRDC3 
242013_at 1.16 NHS 
211506_s_at 1.16 NPL 
206228_at 1.15 EDN1 
223301_s_at 1.15 TNFAIP3 
223784_at 1.15 ATP8A2 
222449_at 1.15 RNLS 
232195_at 1.15 ATP7B 
203639_s_at 1.14 FNIP2 
242229_at 1.14 ATP8A2 
221750_at 1.13 OPN3 
232893_at 1.13 DPYSL5 
228948_at 1.12 TMTC1 
235649_at 1.12 NHS 
209443_at 1.12 INSIG1 
225589_at 1.12 FGFR2 
227034_at 1.12 PAX2 
204470_at 1.11 ELFN2 
235421_at 1.11 CCDC82 
202644_s_at 1.11 CCDC82 
213577_at 1.10 FGFR2 
223300_s_at 1.10 MMP14 
201185_at 1.10 SGPP2 
202643_s_at 1.10 LMBRD2 
222797_at 1.09 NAPEPLD 
213764_s_at 1.09 SQLE 
1557094_at 1.09 HMGCS1 
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218980_at 1.09 MAP3K8 
219032_x_at 1.09 TNFAIP3 
212239_at 1.09 GPR158 
202827_s_at 1.08 STARD4 
203638_s_at 1.07 FGFR2 
203680_at 1.07 ID4 
209293_x_at 1.07 ADAMTS8 
202727_s_at 1.07 PEG10 
201627_s_at 1.07 LBH 
202018_s_at 1.06 AP1S2 
220122_at 1.06 SERPINA5 
209121_x_at 1.06 MET 
203386_at 1.05 RSPH1 
203037_s_at 1.05 SLC1A1 
244780_at 1.05 FLJ32810 
219686_at 1.05 SH3RF1 
203932_at 1.05 MTSS1 
213238_at 1.04 PIK3R1 
212703_at 1.03 PMEPA1 
41037_at 1.03 ATXN1 
212188_at 1.03 LTF 
221011_s_at 1.03 CXCL1 
242230_at 1.02 ATP10D 
208228_s_at 1.02 FHOD3 
215561_s_at 1.02 NR2F2 
209218_at 1.02 EPHA4 
207469_s_at 1.01 TBC1D4 
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224002_s_at 1.01 LOC728449 
203300_x_at 1.00 AP1S2 
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Appendix 12 
Genes downregulated at ≥ 2- fold in mAb168-positive versus mAb168- 
negative in HGU133Plus2 microarray experiment 
 
Affymetrix probe Log fold change Gene symbol 
224997_x_at -3.05 H19 
224646_x_at -3.00 H19 
230896_at -2.97 BEND4 
236262_at -2.80 MMRN2 
229700_at -2.82 ZNF738 
206291_at -3.01 NTS 
212912_at -2.64 RPS6KA2 
204570_at -3.28 COX7A1 
233092_s_at -2.59 LOC100271840 
225817_at -2.56 CGNL1 
212813_at -2.52 JAM3 
219091_s_at -2.51 MMRN2 
214844_s_at -2.62 DOK5 
219014_at -2.41 PLAC8 
226789_at -2.44 EMB 
223854_at -2.35 PCDHB10 
236892_s_at -2.45 hCG_2042068 
205876_at -2.37 LIFR 
207429_at -2.33 SLC22A2 
1552799_at -2.19 TSNARE1 
229667_s_at -2.34 HOXB8 
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202525_at -2.28 PRSS8 
244370_at -2.39 KIAA2022 
206172_at -2.26 IL13RA2 
241826_x_at -2.15 ZNF738 
219525_at -2.16 SLC47A1 
204584_at -2.42 L1CAM 
235051_at -2.25 CCDC50 
1558692_at -2.04 C1orf85 
231726_at -2.09 PCDHB14 
1552701_a_at -2.21 CARD16 
227719_at -2.12 SMAD9 
227812_at -2.09 TNFRSF19 
209505_at -2.26 NR2F1 
229485_x_at -2.13 SHISA3 
224367_at -2.04 BEX2 
202912_at -2.08 ADM 
220889_s_at -2.88 CA10 
233064_at -2.16 ZFR2 
39248_at -2.19 AQP3 
227771_at -2.08 LIFR 
205477_s_at -1.97 AMBP 
209267_s_at -1.98 SLC39A8 
219973_at -2.00 ARSJ 
210192_at -1.97 ATP8A1 
208343_s_at -2.27 NR5A2 
211368_s_at -2.03 CASP1 
202620_s_at -2.23 PLOD2 
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228988_at -2.08 ZNF711 
201667_at -2.79 GJA1 
202619_s_at -1.92 PLOD2 
213150_at -1.85 HOXA10 
227688_at -1.83 LRCH2 
228802_at -1.85 RBPMS2 
209806_at -1.84 HIST1H2BK 
225575_at -1.86 LIFR 
1569847_at -1.85 CGNL1 
1554863_s_at -1.88 DOK5 
234974_at -1.87 GALM 
210174_at -1.93 NR5A2 
235256_s_at -1.89 GALM 
222803_at -1.93 PRTFDC1 
236717_at -1.94 FAM179A 
223170_at -1.95 TMEM98 
236831_at -1.96 CCDC50 
1554384_at -1.75 PADI2 
227654_at -1.78 FAM65C 
1554127_s_at -1.77 MSRB3 
204567_s_at -1.79 ABCG1 
205428_s_at -1.98 CALB2 
213618_at -1.82 ARAP2 
224461_s_at -1.80 AIFM2 
229116_at -1.82 CNKSR2 
213913_s_at -1.83 TBC1D30 
225782_at -1.81 MSRB3 
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209726_at -1.79 CA11 
235781_at -1.72 CACNA1B 
225790_at -1.71 MSRB3 
238741_at -1.72 FAM83A 
219869_s_at -1.75 SLC39A8 
219424_at -1.74 EBI3 
205575_at -1.64 C1QL1 
209877_at -1.64 SNCG 
223687_s_at -1.74 LY6K 
212531_at -1.68 LCN2 
203874_s_at -1.71 SMARCA1 
1564158_a_at -1.71 LOC100130894 
212614_at -1.74 ARID5B 
228956_at -1.72 UGT8 
1559827_at -1.65 LOC401074 
203753_at -1.63 TCF4 
211508_s_at -1.95 GH2 
228737_at -1.61 TOX2 
213716_s_at -1.61 SECTM1 
213106_at -1.63 ATP8A1 
221232_s_at -1.72 ANKRD2 
227182_at -1.64 SUSD3 
204205_at -1.63 APOBEC3G 
238962_at -1.58 ZNF681 
208337_s_at -1.61 NR5A2 
230469_at -1.55 RTKN2 
229310_at -1.60 KLHL29 
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221523_s_at -1.58 RRAGD 
223422_s_at -1.62 ARHGAP24 
239586_at -1.60 FAM83A 
225331_at -1.56 CCDC50 
208354_s_at -1.56 SLC12A3 
34408_at -1.54 RTN2 
227641_at -1.54 FBXL16 
206070_s_at -1.55 EPHA3 
230807_at -1.54 CCDC151 
204379_s_at -1.56 FGFR3 
231982_at -1.54 C19orf77 
213891_s_at -1.55 TCF4 
205774_at -1.55 F12 
207826_s_at -1.57 ID3 
228600_x_at -1.51 C7orf46 
212386_at -1.52 TCF4 
228062_at -1.57 NAP1L5 
206277_at -1.50 P2RY2 
238460_at -1.54 FAM83A 
226461_at -1.52 HOXB9 
222582_at -1.52 PRKAG2 
215294_s_at -1.52 SMARCA1 
225571_at -1.66 LIFR 
209942_x_at -1.72 MAGEA3 
223550_s_at -1.55 CA10 
227272_at -1.46 C15orf52 
206122_at -1.46 SOX15 
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201058_s_at -1.48 MYL9 
205738_s_at -1.44 FABP3 
214285_at -1.45 FABP3 
231725_at -1.66 PCDHB2 
206307_s_at -1.50 FOXD1 
1559826_a_at -1.46 LOC401074 
210059_s_at -1.46 MAPK13 
228904_at -1.44 HOXB3 
202708_s_at -1.45 HIST2H2BE 
205880_at -1.51 PRKD1 
210058_at -1.42 MAPK13 
202920_at -1.70 ANK2 
219113_x_at -1.42 HSD17B14 
228063_s_at -1.46 NAP1L5 
1568838_at -1.45 LOC100132169 
229057_at -1.52 SCN2A 
1557771_at -1.38 FHAD1 
240312_at -1.38 LOC389895 
209118_s_at -1.46 TUBA1A 
208161_s_at -1.39 ABCC3 
208747_s_at -1.38 C1S 
1552897_a_at -1.39 KCNG3 
209904_at -1.37 TNNC1 
228693_at -1.37 CCDC50 
225019_at -1.39 CAMK2D 
216905_s_at -1.47 ST14 
208111_at -1.36 AVPR2 
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203875_at -1.38 SMARCA1 
218854_at -1.44 DSE 
214455_at -1.35 HIST1H2BC 
229331_at -1.38 SPATA18 
210448_s_at -1.34 P2RX5 
204612_at -1.33 PKIA 
238149_at -1.33 ZNF818P 
236884_at -1.32 RIMKLA 
205736_at -1.46 PGAM2 
204416_x_at -1.42 APOC1 
224839_s_at -1.33 GPT2 
210609_s_at -1.32 TP53I3 
215274_at -1.32 SLC12A3 
212646_at -1.50 RFTN1 
217028_at -1.38 CXCR4 
208373_s_at -1.33 P2RY6 
219532_at -1.36 ELOVL4 
235728_at -1.35 ZFP3 
235721_at -1.30 DTX3 
203729_at -1.39 EMP3 
222240_s_at -1.31 ISYNA1 
244829_at -1.32 C6orf218 
228618_at -1.34 PEAR1 
208108_s_at -1.30 AVPR2 
231793_s_at -1.40 CAMK2D 
224179_s_at -1.38 MIOX 
220120_s_at -1.28 EPB41L4A 
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220945_x_at -1.30 MANSC1 
228555_at -1.30 CAMK2D 
218309_at -1.34 CAMK2N1 
227506_at -1.28 SLC16A9 
203402_at -1.27 KCNAB2 
230748_at -1.31 SLC16A6 
203234_at -1.27 UPP1 
205406_s_at -1.26 SPA17 
227231_at -1.29 KIAA1211 
229014_at -1.40 FLJ42709 
222238_s_at -1.25 POLM 
231991_at -1.29 C20orf160 
204462_s_at -1.23 SLC16A2 
1562606_a_at -1.26 LOC440028 
222146_s_at -1.25 TCF4 
238791_at -1.23 ZNF100 
209639_s_at -1.24 RGS12 
202005_at -1.37 ST14 
229332_at -1.24 HPDL 
223806_s_at -1.31 NAPSA 
244076_at -1.34 KIAA2022 
210316_at -1.25 FLT4 
225968_at -1.23 PRICKLE2 
226713_at -1.26 CCDC50 
203423_at -1.22 RBP1 
212636_at -1.25 QKI 
238066_at -1.28 RBP7 
319 
 
 
212382_at -1.20 TCF4 
230082_at -1.20 LOC100133660 
209498_at -1.20 CEACAM1 
211341_at -1.20 POU4F1 
206230_at -1.20 LHX1 
226926_at -1.21 DMKN 
229337_at -1.20 USP2 
209504_s_at -1.19 PLEKHB1 
214719_at -1.19 SLC46A3 
204885_s_at -1.23 MSLN 
242162_at -1.27 WDR69 
227468_at -1.21 CPT1C 
218292_s_at -1.31 PRKAG2 
204422_s_at -1.24 FGF2 
206253_at -1.29 DLG2 
209706_at -1.21 NKX3-1 
218692_at -1.24 GOLSYN 
219594_at -1.20 NINJ2 
217975_at -1.18 WBP5 
241803_s_at -1.18 RP11-160N1.10 
208886_at -1.16 H1F0 
209970_x_at -1.20 CASP1 
219360_s_at -1.18 TRPM4 
224994_at -1.23 CAMK2D 
225671_at -1.17 SPNS2 
226264_at -1.17 SUSD1 
227674_at -1.19 ZNF585A 
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206756_at -1.21 CHST7 
220793_at -1.18 SAGE1 
226863_at -1.17 FAM110C 
237116_at -1.18 LOC646903 
209008_x_at -1.19 KRT8 
227070_at -1.22 GLT8D2 
1560620_at -1.15 KCNK15 
210324_at -1.28 C8G 
225128_at -1.18 KDELC2 
204200_s_at -1.13 PDGFB 
222217_s_at -1.12 SLC27A3 
204268_at -1.17 S100A2 
205934_at -1.21 PLCL1 
209035_at -1.14 MDK 
220540_at -1.17 KCNK15 
1553787_at -1.12 C11orf45 
205601_s_at -1.12 HOXB5 
232165_at -1.21 EPPK1 
202575_at -1.17 CRABP2 
204347_at -1.12 AK3L1 
232994_s_at -1.20 RGNEF 
206897_at -1.30 PAGE1 
236917_at -1.12 LRRC34 
212654_at -1.12 TPM2 
215071_s_at -1.15 HIST1H2AC 
214612_x_at -1.29 MAGEA6 
235521_at -1.12 HOXA3 
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213912_at -1.22 TBC1D30 
214033_at -1.09 ABCC6 
219922_s_at -1.15 LTBP3 
209409_at -1.13 GRB10 
209844_at -1.16 HOXB13 
214975_s_at -1.13 MTMR1 
224497_x_at -1.09 HSD17B14 
213547_at -1.13 CAND2 
235948_at -1.10 RIMKLA 
204906_at -1.08 RPS6KA2 
240891_at -1.08 FSTL1 
220162_s_at -1.12 CARD9 
238520_at -1.13 TRERF1 
225004_at -1.07 TMEM101 
236918_s_at -1.07 LRRC34 
225871_at -1.19 STEAP2 
233748_x_at -1.24 PRKAG2 
220119_at -1.08 EPB41L4A 
204083_s_at -1.10 TPM2 
1552390_a_at -1.11 C8orf47 
240537_s_at -1.13 LOC440356 
242517_at -1.08 KISS1R 
224814_at -1.05 DPP7 
226499_at -1.08 NRARP 
1557754_at -1.08 LOC401068 
225342_at -1.08 AK3L1 
204237_at -1.08 GULP1 
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229566_at -1.08 LOC645638 
225612_s_at -1.07 B3GNT5 
210619_s_at -1.14 HYAL1 
227053_at -1.06 PACSIN1 
204310_s_at -1.08 NPR2 
1557132_at -1.08 WDR17 
219282_s_at -1.06 TRPV2 
236893_at -1.09 hCG_2042068 
209990_s_at -1.13 GABBR2 
207213_s_at -1.11 USP2 
226629_at -1.05 SLC43A2 
235383_at -1.08 MYO7B 
209791_at -1.05 PADI2 
228256_s_at -1.05 EPB41L4A 
232415_at -1.04 PCDHB13 
228754_at -1.08 SLC6A6 
205485_at -1.08 RYR1 
224609_at -1.03 SLC44A2 
235391_at -1.09 FAM92A1 
209911_x_at -1.09 HIST1H2BD 
201117_s_at -1.05 CPE 
1557049_at -1.05 BTBD19 
228302_x_at -1.10 CAMK2N1 
204557_s_at -1.02 DZIP1 
218885_s_at -1.05 GALNT12 
213467_at -1.10 RND2 
235404_at -1.13 ARID5B 
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227856_at -1.07 C4orf32 
212494_at -1.03 TENC1 
232164_s_at -1.15 EPPK1 
228785_at -1.02 ZNF281 
227760_at -1.02 IGFBPL1 
211712_s_at -1.02 ANXA9 
1557038_s_at -1.00 LOC100289373 
228046_at -1.11 ZNF827 
228360_at -1.13 LYPD6B 
227687_at -1.00 HYLS1 
216504_s_at -1.09 SLC39A8 
231953_at -1.00 BPTF 
244385_at -1.00 KDM4C 
203407_at -1.00 PPL 
201968_s_at -1.00 PGM1 
207052_at -1.01 HAVCR1 
222361_at -0.99 TUBBP5 
209893_s_at -1.00 FUT4 
228973_at -1.10 DLG2 
236436_at -1.00 SLC25A45 
203637_s_at -1.01 MID1 
226771_at -1.00 ATP8B2 
227230_s_at -1.00 KIAA1211 
229797_at -1.00 MCOLN3 
233082_at -1.01 ZNF630 
239791_at -1.02 hCG_2042068 
204217_s_at -1.00 RTN2 
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